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Texaphyrins represent the vanguard of experimental anticancer drugs and also 
symbolize a well-known example of expanded porphyrins, a class of oligopyrrolic 
macrocycles with tumor localization properties and powerful metal chelating properties.  
Chapter 1 of this thesis describes the unique structural characteristics of this 
complex synthetic molecule along with the biological relevance and scientific 
justifications for studying its anticancer properties and powerful MRI contrast ability. 
This Chapter also serves to underscore the need to improve further and refine the efficacy 
of texaphyrins as compounds that may be applied in the struggle against cancer.  
Chapter 2 details the synthesis of bismuth(III) and lead(II)-texaphyrin complexes 
that could potentially find use as α-core emitters for radiotherapy. In principle, 
porphyrins would ostensibly appear to be ideal ligands for use in radiotherapy due to their 
 vii 
tumor-localizing ability. However, Bi(III)- and Pb(II)-porphyrin complexes are extremely 
rare, most reflecting the vastly challenging synthesis of these compounds as well as their 
general lack of stability. These limitations provided an incentive for us to use texaphyrins 
as more versatile ligands to prepare and fully characterize stable bismuth(III) and lead(II) 
complexes. To be of interest in future medical applications, we needed to prepare these 
complexes quickly as compared to the relevant time scales set by the half-lives of the 
isotopes targeted for use in radiotherapy. This goal was successfully realized. 
As mentioned above, texaphyrin is able to form stable complexes with a large 
variety of metals particularly in the lanthanide series. Gadolinium(III) complexes of 
texaphyrin have been studied in considerable detail. Chapter 3 details the synthesis and 
conjugation methods used to develop a texaphyrin conjugated dual mode nanoparticle 
contrast agent. This project has been done in collaboration with the group of Prof. Jinwoo 
Cheon (Yonsei University, Seoul, Korea), who demonstrated fascinating results with the 
texaphyrin functionalized nanoparticles. Not only do these conjugates act as improved 
magnetic resonance contrast agents displaying enhanced signals in both the T1 and T2 
MRI modes, but also serve to sensitize apoptotic hyperthermia.  It is this latter, double 
effector feature, that has been most extensively studied to date.  
Chapter 4 of this dissertation describes work done in close collaboration with Dr. 
Natalie Barkey and Dr. David Morse (Moffitt Cancer Center, Tampa, FL) where a 
gadolinium texaphyrin complex was developed that is able to target the melanocortin 1 
receptor (MC1R) when encapsulated in a micellar system. As detailed in this Chapter, 
these collaborateurs demonstrated that these gadolinium-texaphyrin micelles are able to 
target MC1R-expressing xenograft tumors in vivo. This work relied on the supply of a 
new set of texaphyrin derivatives that were prepared and characterized as part of this 
dissertation work 
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Chapter 5 of this disseration introduces sapphyrins, another class of expanded 
porphyrins with tumor selectivity.  This project is based on the hypothesis that a direct 
linkage of sapphyrin with an anticancer agent based on ruthenium(II) could improve the 
efficacy of both compounds. Since sapphyrins exhibit limited ability to form stable 
complexes with transition metals, an appended 1,10-phenanthroline unit was chosen as an 
efficient N-donor aromatic ligand for ruthenium(II). Therefore, extensive synthetic 
efforts were made to form this sapphyrin-1,10-phenanthroline construct in an effort to 
stabilize a mixed sapphyrin-metallo-phenanthroline complex. 
Finally, Chapter 6 of this dissertation demonstrates the author’s efforts to 
synthesize a planar rosarin species. Non-aromatic and non-planar rosarins have been 
known for over two decades. Through structural modification of the compound, namely 
through linking of both β positions on the bipyrrole unit, a new planar rosarin species has 
been synthesized exhibiting Hückel antiaromaticity.  
 ix 
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1. Cancer and Chemotherapeutics 
 
1.1 CANCER – DEFINITION AND BIOLOGY 
 The broad term cancer describes a vast group of diseases involving the 
uncontrolled growth of abnormal cells in the body. Medically known as a malignant 
neoplasm, cancerous cells may be able to invade neighboring tissues and organs as well 
as more distant regions of the body through the bloodstream or the lymphatic system 
(ability to metastasize).  In contrast, benign tumors do not grow uncontrollably and are 
still believed to be incapable of invading neighboring tissues or other body organs. 
However, this assumption is being reconsidered due to new research results.1 
Interestingly, cancer can 
develop in any body organ and more 
than 200 different cancer types are 
known to afflict humans2 with a risk of 
developing cancer generally increasing 
with age. 
While only 5-10% of cancers 
are entirely hereditary, the most 
common factors that are believed to 
increase the risk of cancer include 
radiation, certain infections, tobacco 
use, environmental pollutants, obesity and lack of physical activity.   
Since cancer is fundamentally a disease of failure to regulate tissue growth, a 
healthy cell has to transform into a cancer cell through alteration of cell growth and 
differentiating regulating genes.4 Malignant transformation can occur through the 
       
 
Figure 1.1:  Picture showing sampling of 
breast cancer cells taken for 
examination (biopsy).3   
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inappropriate over-expression of normal oncogenes (genes that promote cell growth and 
reproduction), through formation of novel oncogenes or by the under-expression or 
disabling of tumor suppressor genes. However, a great number of gene manipulations are 
required for the transformation of normal cells into cancer cells.5  
Genetic changes can occur by different mechanisms and at different levels. For 
instance, large-scale mutations involve the deletion or gain of a portion or an entire 
chromosome. Small-scale mutations, which may occur in the promoter region of a gene 
and affect its expression, include mutations, deletions and insertions. Various 
environmental factors, such as exposure to disruptive substances (carcinogens) or 
radiation, make mu- 
tations more likely to 
arise and propagate. 
The self-amplification 
of mutations may be 
supported by a more 
rapid and/or more 
frequent cell repro- 
duction rate. This often 
results in a chain 
reaction caused by 
initial errors, which 
compound into more severe errors. Ultimately, this allows the cell to escape control and 
repair mechanisms that limit normal tissue growth. Once cancer has begun to develop, 
this ongoing process, also termed clonal evolution, drives progression towards more 
invasive and potentially lethal stages. 
 
 
Figure 1.2: Development of cancer after a series of 
mutations.6 
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Metastasis is the spread of a disease from one organ or organ part to another non-
adjacent organ or organ part. Some cancer cells acquire the ability to penetrate the walls 
of lymphatic and/or blood vessels. Others are able to penetrate through the bloodstream 
through angiogenesis, i.e., a process involving the growth of new blood vessels that is 
often critical to ensure sufficient oxygen and blood supply to the tumorous tissue. A 
hypoxic tumor (i.e., tumorous tissue deprived of adequate oxygen supply) is able to 
stimulate new blood vessel development though the secretion of hormones.9 Additionally, 
more recent research describes the hormonal stimulation of a lymphatic drainage system 
by certain tumor types. This, in turn, increases the severity of the disease due to the 
                   
 
Figure 1.3:  Representation of metastasizing malignant cells and their spread 
through lymphatic or blood vessels.8  
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increased likelihood of metastasis formation.10 Most tumors and other neoplasms are able 
to metastasize, although to varying degrees.11 For instance, basal cell carcinoma rarely 
metastasize. 
Important to note is the fact that about 10% of patients presenting to oncology 
units will have metastases without an original tumor found. In these cases, the primary 
tumor is referred to as unknown or occult with the patient suffering from cancer of 
unknown primary origin.12 In some cases, a primary tumor may appear at later stages. 
However, it is believed that some primary tumors can regress entirely, leaving their 
metastases behind.   
 
1.2  RADIOTHERAPY AS A ROUTINE TREATMENT OPTION  
Considerable progress in the medicinal treatment of cancer has been achieved 
during the last decade, especially in the area of chemotherapy. Even so, a sustained need 
for novel anticancer agents and improved therapeutic approaches remains, as underscored 
by the fact that after cardiovascular diseases, cancer is the second leading cause of death 
in the United States.13 
The combination of chemotherapy and radiation has led to clinical breakthroughs 
in the control of several cancerous diseases. However, the challenge to develop better 
therapies remains. Of particular interest are systems that operate via novel mechanisms of 
action or which illustrate generalizable approaches to drug development.14 Separate from 
this, a range of clinical efforts are being devoted to acquire optimum combinations of 
proven chemotherapies or, more recently, various noncytotoxic agents.  
One treatment option routinely applied in combination with chemotherpeutic 
agents is radiation therapy (commonly referred to as radiotherapy). It is defined as the 
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medical use of ionizing radiation as part of cancer treatment. X-rays, γ−rays, and charged 
particles (e.g. protons or β−particles) as well as uncharged particles (neutrons, α−cores) 
are used in an effort to damage DNA sequences in cancer cells (Figure 1.4). The reason 
for the effectiveness of this treatment regimen can be found in the biological 
characteristics: Cancer cells are undifferentiated, stem cell-like and have a diminished 
ability to repair sub-lethal damage as compared to most healthy differentiated cells. The 
DNA damage is inherited through cell division, and as such, accumulated in the cancer 
cells. This causes them to die or reproduce slower.15, 16 
Merely five months after the discovery of X-rays by the German physicist 
Wilhelm Conrad Röntgen in 1895, Émil Herman Grubbé utilized X-ray radiation to treat 
a breast cancer patient.15 From that point onward, different radiation sources and 
treatment methods found their way into various cancer-related therapeutic protocols. 
However, it was only much later that it was understood how radiation propagated its 
              
                Figure 1.4:  Interaction of different ionizing radiation with DNA. 
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cytotoxicity. Today, the three main types of radiation therapy are classified as external 
beam radiation therapy (EBRT or more common XRT), brachytherapy (sealed source 
radiation therapy), and systematic radioisotope therapy (unsealed source radiotherapy). 
The position of the radiation source is a crucial aspect in this classification: external 
radiation is positioned outside the body, brachytherapy uses sealed radioactive sources 
that are placed in the area to be treated, and systemic radioisotopes are applied by 
infusion or oral ingestion. A special case of external beam radiation therapy is particle 
therapy. Here, particles such as protons or other heavier ionized nuclei are used to treat 
body areas with cancerous tissues.  In this context it is important to note is that photons, 
used in X-ray or gamma ray therapy, can also be considered particles. However, they are 
not classified as particle therapy.   
In 1923, Petry showed a correlation between radiosensitivity and the presence of 
oxygen based on a study of the effects of radiation on vegetable seeds.17 He theorized that 
a lack of oxygen decreases the cytotoxic effect of ionizing radiation, and in 1955 
Thomlinson and Gray established that radioresistant regions in tumor tissues are due to 
low oxygen tension.18 This latter observation reflects the fact that solid tumors usually 
outgrow their blood supply, causing a low-oxygen state known as hypoxia. Shown by 
modern detection techniques, these hypoxic regions cause limitations in the efficacy of 
XRT. Oxygenated tissue proves to be two to three times more sensitive towards radiation. 
However, in the absence of oxygen, DNA is repaired more efficiently. Thus, it appears 
that hypoxic cells, as found in many solid tumors, are difficult to destroy completely 
using XRT alone.19, 20 In this case radiosensitization could allow modulation of the 
radiation response and thus an improvement in local tumor control. Here, the idea is to 
administer radiosensitizers that would enhance the effects of radiation at cancerous sites, 
reduce cytotoxic effects for normal tissues, or both. 
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1.3 ESTABLISHED CHEMOTHERAPEUTICS AND RADIATION SENSITIZING DRUGS  
Traditional chemotherapeutic drugs that are widely used as radiation sensitizers 
include 5-fluorouracil (5-FU) 1 and gemcitabine 2 (Figure 1.5.).14 The pyrimidine moiety 
in 5-FU is an analog of the RNA 
building block uracil and functions as an 
antimetabolite. As a chemotherapeutic 
agent, it has both DNA- and RNA-
directed effects.21 Its presumed 
radiosensitizing ability is due to the 
prevention of DNA synthesis through 
thymidylate synthase inhibition.22  
Gemcitabine is a nucleoside 
analog used as chemotherapeutic and 
(“off label”) as a radiation sensitizer. It is marketed as Gemzar® by Eli Lilly and 
Company. Similarly to 5-FU and other pyrimidine analogs, the triphosphate derivative of 
gemcitabine (produced in situ) is able to replace one of the building blocks of nucleic 
acids, here cytidine, during DNA replication. Tumor growth is inhibited since only one 
additional nucleoside can be attached to this intentionally defective nucleoside. This leads 
to apoptosis or so-called programmed cell death. Apoptosis may also be induced through 
the inhibition of the enzyme ribonucleotide reductase. The diphosphate analog of 
gemcitabine binds to the active site and inactivates the enzyme irreversibly. Hence, the 
cell is unable to produce deoxyribonucleotides required for DNA replication and repair.23 
Administration of gemcitabine is not without problems, with a wide array of 
serious side effects having been recorded, including flu-like symptoms, nausea, vomiting, 
allergic reactions and shortness of breath. However, gemcitabine is exceptionally potent. 
 
Figure 1.5:  Structures of 5-fluorouracil 
and gemcitabine. 
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In 2006 the FDA approved gemcitabine 
for use in combination with carboplatin in 
the treatment of advanced ovarian cancer. 
Another common regimen involves the 
administration of gemcitabine in 
combination with cisplatin.   
Cisplatin and other platinated 
analogues are able to form DNA inter- 
and intrastrand (Figure 1.6) crosslinks.24 
When removed by repair processes, DNA strand breaks occur and cell reproduction 
mechanisms are inhibited. Furthermore, cisplatin is believed to cause mutations in DNA-
protein kinase (PK) subunits.24, 25 This particular type of mutation renders cells 
hypersensitive towards ionizing radiation; cisplatin is thus able to sensitize cells to 
radiation. A further proposal was put forward attributing cell sensitization to irradiation 
by inhibition of DNA-PK catalyzed phosphorylation.25 Since the latter is believed to play 
a significant role in DNA-repair mechanisms, inhibition of PK would lead to an increased 
number of defects as a result of precluding in DNA repair actions.25 
The cisplatin analogues 
oxaliplatin and carboplatin have 
also been explored as radiation 
sensitizers. Oxaliplatin, a recently 
introduced antineoplastic di- 
aminocyclohexane platinum 
derivative with activity against colorectal cancer, has been proposed to sensitize tumor 
cells more efficiently towards radiation than cisplatin based on preclinical studies.14, 26 
 
 
Figure 1.7:  Structures of cisplatin, carboplatin 
and oxaliplatin. 
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Figure 1.6:  Schematic representation of an 
intrastrand crosslink of 
cisplatin with DNA. 
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The diaminocyclohexane unit functions as a carrier and potentiates the formation of the 
DNA adducts. It is also thought to aid in the inhibition of DNA synthesis. Oxalicarbon is 
typically administered in combination with 5-FU. Several studies investigating the 
treatment of metastatic rectal cancer served to demonstrate that this combinatorial 
regimen improves survival compared to 5-FU alone.27 In addition to these trials, 
oxaliplatin has been combined with radiation in advanced but localized rectal cancer in 
order to improve local control. 
Carboplatin, another DNA-modulating agent, was introduced in the late 1980s 
and has since gained popularity as a chemotherapeutic. Carboplatin demonstrates vastly 
reduced side effects compared to cisplatin, mostly notably a reduced nephrotoxicity.28 
Carboplatin is also more stable in the bloodstream, and is bound less well by proteins, a 
feature that may contribute to reduced side effects.  
Although 5-FU and most cisplatin analogs represent traditional drugs, they 
continue to be explored in newer regimens, including those involving radiotherapy. Thus, 
their importance cannot be overstated.  
In addition to the more promising agents discussed immediately above, a vast 
number of traditional drugs have been explored as potential radiation sensitizers. 
Although discussion of these is beyond the scope of this dissertation, particularly 
noteworthy are irinotecan, temozolamide, capecitabine, tirapazamine and the taxanes.14 
Together with 5-FU and cisplatin analogs, these systems when used as radiation 
sensitizers, have shown promise in terms of therapeutic outcomes. Nevertheless, many 
clinically relevant questions remain. In fact, just as for the more traditional drugs, 
cisplatin and 5-FU, controversies still exist considering the optimal dose and treatment 
schedule that should be used in combination with radiation therapy. Side effects and 
compatibility issues are also a source of concern.   
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Given this current state-of-the-art and the rising demand for novel, more effective 
anticancer-drugs, there is not surprisingly an ongoing search for compounds displaying 
promise in terms of anticancer treatment. One such class is the porphyrins and their 
analogs, as discussed below.  
 
1.4 TRADITIONAL PORPHYRINIC ANTICANCER AGENTS 
Chemotherapeutic agents that are able to localize specifically in cancerous cells 
have long been desired. In theory, drugs displaying such selective localization will 
exhibit reduced systemic toxicity and increased efficacy due to a decreased damage to 
non-target tissues. Therapeutic porphyrinoids, i.e. synthetic pyrrolic heterocycles that 
contain four central nitrogen atoms, have long been studied as compounds that 
demonstrate inherent accumulation in tumors.  
Porphyrins and related macrocycles have various biological applications and are 
recognized for performing a great number of biological key functions. When found in 
naturally occurring systems, these essential redox-active molecules generally coordinate a 
core metal. Examples of such systems are chlorophyll (core metal: Mg), vitamin B-12 
(Co) and heme (Fe). Taken in concert, these prosthetic groups can act as oxidizing 
agents, electron transporters, catalysts for molecular rearrangements, and oxygen 
transporters, among other functions.29-34  
The idea of using porphyrinoids as radia- tion sensitizers derives support from 
their use in photodynamic therapy (PDT). In the area of PDT, porphyrins have been used 
as a promising alternative therapy for the treatment of early and localized tumors.35, 36 It 
was shown as early as 1924, that porphyrins and porphyrin analogs have the ability to 
accumulate selectively in tumor tissues, and persist there for long periods of time.37  
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Figure 1.8:  Porfimer, the canonical porphyrinic species 
present in Photofrin®.  
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Cohen and 
Schwartz were the first to 
assess the radiosensitizing 
properties of porphyrins. 
They tested a series of 
haematoporphyrin analogs 
and found that the effect 
varied from radio- 
sensitization at low 
porphyrin concentrations to radioprotection at high porphyrin concentrations.38 Improved 
local tumor control was achieved in the case of squamous cell carcinoma, 
rhabdomyosarcoma, fibrosarcoma and carcinoid tumors.39 The haematoporphyrin 
derivatives (HPD) used in these studies and more extensively in PDT came to be known 
as Photofrin®. Photofrin® is actually a purified mixture of porphyrin oligomers (active 
agent = 2-8 units) and is an agent that has been successfully used over the last two 
decades for the PDT-treatment of patients with melanoma, early and advanced stage 
cancer of the lung, digestive tract, and the genitourinary tract. It is solubilized as the 
anionic polycarboxylate and was the first clinically approved PDT agent. However, 
Photofrin® engenders a uniformly high level of induced cutaneous phototoxicity. Thus, 
this first generation system is far from ideal as both, a PDT and as a radiation sensitizer. 
A recognition of this deficiency spanned efforts that led to a more purified form, termed 
Photofrin II®. Additionally, it inspired the synthesis and study of other agents whose 
synthesis and characteristics have been extensively reviewed in the literature.40-44 
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The efficacy of radiotherapy prior to 
surgery for the treatment of maxillofacial tumors is 
reported to be 40% higher with Photofrin® than 
without.45 A radiosensitizing effect of HPD in the 
case of sarcoma ascites tumors transplanted into 
mice has been demonstrated by Chen.46 An 
interesting note is that Bellnier and Dougherty47, as 
well as Moan and Pettersen48, did not observe 
significant radiosensitization induced by porphyrins 
in vitro. Such seemingly difficult to rationalize 
results might reflect the fact that tumors and 
malignant cells used for in vitro investigations are 
biologically markedly diverse. However, other explanations to this conundrum can be 
envisioned. 
O`Hara et al. investigated metal complexes of tetrakis(4-N-methyl- 
pyridyl)porphyrins. The cobalt(III) complex appears to be the most effective radiation 
sensitizer; however, it is tumor line dependent.49, 50 Furthermore, functionalization with 
nitro groups and/or extra positive charges only resulted in slight increases in 
sensitization.50 
Cationic porphyrins 
continue to be the focus of attention 
because of the promise they entail 
for the use in photodynamic and 
anticancer therapy.51, 52 For instance, 
it has been shown that the strong 
         
Figure 1.10:  TEM picture of an Fe(III)-
porphyrin-loaded liposome.53 
 
 
 
 
 
Figure 1.9:  Structures of 
Co(III) and Fe(III) tetrakis(4-N-
methylpyridyl)porphyrin 7 and 8. 
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electrostatic interactions of a Fe(III)-porphyrin-loaded liposome (see Figures 1.9 and 
1.10) could render such systems to stay intact in vivo. This could be a potential target for 
the design and development of an efficient drug delivery system.53 
It has been hypothesized for many years that the relationship between anemia, 
hypoxia, and poor outcome, was not merely correlative, but causative, and that correcting 
the anemia would improve hypoxia and radiation efficacy.54, 55 Two studies looked at the 
impact of hypoxia and treatment outcome and demonstrated that patients with hypoxic 
tumors had a poor prognosis.54, 55 Based in part on this data, a randomized trial was 
initiated with the goal of testing the hypothesis that maintaining normal hemoglobin with 
transfusions would improve the outcome of radiation therapy. Although originally 
reported as a positive trial, subsequent analysis did not show a difference in disease-free 
survival.56 
 
1.5 EXPANDED PORPHYRINS WITH ANTICANCER PROPERTIES 
 
1.5.1 Sapphyrins 
 Research in the Sessler group at The University of Texas at Austin has largely 
focused on two tumor selective compounds belonging to the class of so-called expanded 
porphyrins, namely texaphyrin and sapphyrin. The latter is an expanded porphyrin that 
contains an arrangement of five pyrrole subunits, but only four meso carbons. Sapphyrin 
was discovered serendipitously by R. B. Woodward, et al. in the 1960’s57 during the 
course of investigations directed toward the synthesis of vitamin B12. It was the first 
expanded porphyrin to have been identified and characterized. A decade later, A. W. 
Johnson successfully prepared sapphyrin, as did the Woodward group in work that was 
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only reported after 
Woodward’s death. Sessler and 
coworkers then reported an 
optimized synthesis of 
sapphyrins in reasonable yields. 
This allowed the therapeutic 
potential of these macrocycles 
to be explored. Tumor 
localization58, 59 was observed and this made sapphyrins attractive as possible anticancer 
drug candidates. Hydrophilic sapphyrin analogs were prepared and shown to have 
promise for the treatment of solid tumors.59 Sapphyrins have also been proposed as 
potential photosensitizers for PDT.60 They absorb light in the red portion of the visible 
spectrum, which is considered to be an attractive feature. This is because tissue and blood 
cells exhibit a broad relative absorption minimum61 and are essentially transparent,62, 63 
which limits the penetration of visible photons with λmax ≤ 650 nm. To date, sapphyrins 
have been found to display efficient photosensitizing effects against superficial squamous 
cell carcinoma in mice.64  
 
1.5.2 Texaphyrins 
 
1.5.2.1 Tumor Localization, Cytotoxicity and MRI Activity 
 Efforts in the Sessler group to utilize texaphyrins as radiation sensitizers have 
focused on the synthesis and use of texaphyrin chelating gadolinium, later renamed as 
motexafin gadolinium (MGd, Xcytrin™). As with other porphyrinic species, texaphyrins 
  
Figure 1.11:  Basic structures of sapphyrin 9 and 
 texaphyrin 10. 
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accumulate preferentially in tumor 
tissues. Although the specific origins 
of the selective accumulation of MGd 
in neoplastic tissues remain unknown, 
it has already been observed that these 
compounds bind well to, and 
presumably modify, low density 
lipoproteins.65 Once modified, these 
latter blood components are believed 
to be taken up by rapidly prolifering cells, such as tumor cells. These cells exhibit a 
considerably less efficient lymphatic drainage system, which in turn results in a 
diminished elimination of any (potentially cytotoxic) foreign substances within the cells, 
including the porphyrinoid. 
MGd was selected for clinical development in the context of radiation therapy by 
Pharmacyclics, Inc.66, 67 Ultimately, the drug did not receive approval by the FDA. 
However, this work has provided insights into the cellular antioxidant system and 
inspired the discovery and investigation of new molecules capable of ROS generation 
within cancer.68 It has also inspired new research involving texaphyrins. 
One of the most important “lessons” learned is that MGd produces its observed 
radiation sensitizing function, at least in part, by acting as a redox mediator.69 This 
mechanistic rationale relies on the fact that MGd is easy to reduce in comparison to a 
porphyrin. Intracellularly, it accepts an electron from an endogeneous electron rich 
species and catalyzes the oxidation of various reducing metabolites, such as ascorbate, 
reduced nicotinamide-adenine dinucleotide phosphate (NADPH), thioredoxin reducase, 
glutathione, and dihydrolipoate. This leads to the formation of a reduced texaphyrin 
 
Figure 1.12:  Motexafin gadolinium (MGd). 
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radical that reacts with oxygen to produce superoxide in a rapid equilibrium process, 
which in turn regenerates MGd. In vitro, and presumably in vivo, this superoxide is 
converted quickly into hydrogen peroxide,70 a species that is a known to be a potent 
apoptosis trigger. The rate constant for non-enzymatic disproportionation of superoxide is 
estimated to be 1 x 105 M-1 s-1 at pH 7.4.71  
 Because MGd, in contrast to other redox active agents, localizes in tumors, the net 
effect of this catalytic (in MGd) process is (1) the site selective production of ROS and 
enhancement of cancer cell death and (2) a corresponding decrease in the concentration 
of reducing metabolites, such as ascorbate and glutathione, that under normal 
circumstances both ascorbate and glutathione serve to mitigate the effects of oxidative 
stress and ionizing radiation. Their removal is thus expected to make cells more 
susceptible to X-ray treatment (XRT). Consistent with this rationale was the observation 
that the addition of BSO, antimycins A, or diamide, compounds involved in inhibiting 
  
Scheme 1.1:  Metabolic processes affected by MGd. This scheme is a modified  
  version of one previously presented.69 
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glutathione metabolism or forming reactive oxygen species, enhanced the effects of 
MGd. 
 In addition to displaying 
modest cytotoxicity effects, MGd 
was also shown to be detectable 
by magnetic resonance imaging 
(MRI). This MRI detection 
reflects the presence of a centrally 
coordinated paramagnetic metal 
ion, gadolinium(III)72 which 
         
Scheme 1.2:  Mechanistic representation of how MGd is thought to act as a redox 
 mediator. 
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Figure 1.13: T1 weighted noncontrast brain MRI 
before (A) and after (B) adminis- 
tration of MGd.74 
!
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provides for a highly effective spin lattice (T1) relaxation. Based on MRI analyses, MGd 
was found to localize well in tumors. In contrast, no appreciable localization in adjacent 
normal tissue was observed.73 
Studies initiated by Viala et al. provided initial evidence for a cytotoxic benefit 
for patients with breast cancer treated with MGd. The tumoral response upon admin- 
istration of MGd can also be tracked in the MR images. The images in question (Figure 
1.16) are taken from a 41-year old woman with brain metastases from breast cancer.75 
The results based on Phase IB and II multidose trials provide support for the proposal that 
MGd is safe and, presumably due to its porphyrinic structure, also localizes well in 
tumors. In these studies, enhancements in the MR signal intensity were seen only in 
target lesions, but not in normal brain tissue. This provided further evidence for the 
selectivity of MGd. The ratio of MGd in tumor cells to that in surrounding normal cells is 
reported to be up to 9:1.76 However, this ratio, as inferred from MR images, increases to 
50:1 in the case of metastatic brain tumors.77 The uptake in target lesions was higher after 
ten daily injections than after the first dose. This finding is best interpreted in terms of an 
ability to accumulate and persist in brain metastases. Response to treatment at successive 
MRI examinations can be evaluated as well, since either the gadolinium texaphyrin or the 
gadolinium(III) cation, originally contained in its core, remains in tumor cells for several 
months. The administration of a paramagnetic contrast agent for follow-up MR 
examinations would be entirely redundant.75  
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Figure 1.14:  T1 weighted MR images (a-d) of brain metastases and clinical 
progress inferred after administration of MGd.75 
(a) MR image after the first injection (2.3µmol/kg) of MGd. No significant 
enhancement in the target lesions is observed. 
(b) MR image after the 10th injection of MGd. Enhancement is localized in the 
target lesions (arrowheads) and is described as grade 3 (high enhancement). 
(c) MR image 56 days after the first injection of MGd. Enhancement 
(arrowheads) is still visible and is still grade 3. At this stage, the tumor has 
decreased to 68% of its initial size. 
(d) MR image 16 weeks after the first injection of MGd. Enhancement 
(arrowheads) is still visible and is grade 1 (moderate enhancement). 
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1.5.2.2 Historical Syntheses of Texaphyrins 
 The condensation of primary α,ω-
diamines and heterocyclic dicarbonyl 
compounds has been thoroughly investigated 
and used to prepare a wide range of 
multidentate Schiff base-type cyclic ligands 
and their metal complexes.78-80 Much of the 
early work was carried out with 2,6-
dicarbonyl derivatives of pyridine as the 
heterocycle of choice. However, the use of 
pyrroles could give rise to interesting 
porphyrin analogs. Condensations involving 
pyrrolic precursors were first carried out by Mertes (a.k.a. Bowman-James), who reported 
the first “truly” expanded porphyrin tetrapyrrolic macrocycles 12 in the mid-1980s.79 
Unfortunately, these ligands could not be converted to the corresponding fully conjugated 
species due to the nature of the bridging methylene units,79 nor were they particularly 
stable. 
Perhaps the most exciting 
development in the field of expanded 
porphyrins was made in 1987 when Sessler´s 
group at the University of Texas at Austin 
reported the synthesis and crystal structure of 
a novel tripyrrane-containing porphyrinogen-
like macrocycle.81 Bearing resemblance to the 
shape of the five-pointed star in the state flag 
   
 
Figure 1.15:  Structural representation 
  of Mertes’ tetrapyrrolic 
  macrocycles.  
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Figure 1.16: Structural representation 
of texaphyrin and the 
state flag of Texas.85  
!
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of Texas, texaphyrins are pentaaza Schiff-base macrocycles that bear a strong, but 
“expanded” similarity to traditional porphyrins.82-84 As will be shown in later Chapters of 
this dissertation, recent efforts have demonstrated an ability of texaphyrins to chelate a 
variety of metal cations. However, the texaphyrins as prototypical expanded porphyrins 
were initially characterized in terms of their ability to coordinate “large cations”, 
specifically with those of the trivalent lanthanide series.82, 86, 87 One reason for this 
propensity is the fact that the central core of texaphyrins is roughly 20% larger than that 
of the porphyrins.88 At the time of this initial publication, texaphyrins were the first 
expanded porphyrins to be structurally characterized and the first to exhibit metal 
complexation behavior. 
The synthesis of the first texaphyrins hinged on the efficient synthesis of the key 
symmetric tripyrrane dialdehyde precursor. The synthesis of this important intermediate 
is shown in Scheme 1.1.  
 
 
 
 
 
 
 
 
 
 
Scheme 1.3:  Synthesis of tripyrrane dialdehydes 21 and 22. 
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In order to obtain the tripyrrane unit 16, 3,4-diethylpyrrole was condensed with 
two equivalents of (acetoxymethyl)pyrrole 13 under acidic conditions. Hydrogenolysis of 
the benzyl esters with 10% palladium on carbon under one atmosphere of hydrogen, 
followed by Clezy formylation89 of the intermediate diacid tripyrrane 19, provided the 
desired dialdehyde 21 in 68% yield.90 Shown also is a related sequence used to obtain the 
diformyltripyrrane 22 bearing two hydroxylpropyl substituents; this latter species is a key 
intermediate in the synthesis of MGd 11.  
The nonaromatic form of the texaphyrin ligand, commonly referred to as sp3-
texaphyrin, is synthesiszed by an hydrogen chloride catalyzed 1:1 Schiff base 
condensation between the tripyrrane dialdehydes 21 and 22 and an appropriately 
derivatized o-phenylenediamine (Scheme 1.2) under conditions of high dilutions. Here, 
the term sp3 refers to the hybridization of the two methylene-type carbon atoms bridging 
from the three pyrrole units in the scaffold. This procedure is similar to the one employed 
by Mertes et al. for the formation of the so-called “accordion” macrocycle 12, shown in 
Figure 1.15.   
 The protonated form of the texaphyrin porphyrinogens 31-41 can be isolated in 
nearly quantitative yield.  
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Initially, oxidation of the non-aromatic texaphyrin proved quite difficult. In fact, a 
number of oxidizing agents, including PbO2, SeO2, AgO2, Ph3CBF4, Ph3CPF6, and DDQ, 
were tested. However, only decomposition of the ligand was observed.91  
 It was subsequently discovered that stirring this nonaromatic macrocycle in an 
air-saturated mixture of chloroform and methanol with N,N,N´,N´-tetramethyl-1,8-
naphthalenediamine (“proton sponge”, a nonnucleophilic base) provided the free-base 
aromatic texaphyrin 42 in 12% yield.91 
The texaphyrin species 42 can be considered as a 22 π-electron benzannulene that 
possesses both 18 π- and 22 π-electron delocalization pathways. Consistent with its 
aromatic character, 42 is observed to be more stable than its precursor 31. Further 
evidence of the aromatic nature of 32 was obtained from spectroscopic studies: For 
instance, a 10 ppm upfield shift of the internal pyrrole NH signal (δ = 0.9) is observed in 
the 1H NMR spectrum of 42, as compared to the corresponding signals in 31.91, 92 An 
 
Scheme 1.4:  Synthesis of the protonated non-aromatic texaphyrin porphyrinogen 31-
41. 
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identical phenomenon (major changes in chemical shift values) is observed in the case of 
porphyrins, a finding that was interpreted as texaphyrins having a similar diamagnetic 
ring current. 
 
 
 
 
Even though the discovery of the aromatic texaphyrin was thought to be a major 
step towards the successful synthesis of this expanded porphyrin, the preparation was 
severely limited synthetically in terms of reproducibility, generality and yield. 
Unfortunately, these macrocycles showed no propensity to chelate metals.  
However, an important breakthrough occurred, when Dr. Toshiaki Murai, a 
postdoctoral fellow in Dr. Sessler’s group at that time, found that treating the precursor 
31 with CdCl2, and base under aerobic conditions furnished a strongly absorbing green 
substance 43. It was subsequently characterized as being the cadmium complex of the 
aromatic ligand.91-93  
 
 
Scheme 1.5: Synthesis of a free base, aromatic texaphyrin.90, 91  
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 Once the sp3 systems shown in Scheme 1.2 (31-41) were in hand, they were 
subjected to complexation attempts particularly with metals in the lanthanide series. The 
trivalent lanthanide cations have ionic radii ranging from 1.06 Å (for La(III)) to 0.85 Å 
(for Lu(III)).94 The reduction in size going from lanthanum to lutetium is due to an effect 
called the lanthanide contraction.94 This phenomenon results in the relatively poor 
shielding of nuclear charges by the 4f electrons. Thus, the 6s electrons are drawn towards 
the nucleus ultimately leading to a smaller atomic radius. Notably, the general size of 
lanthanide cations is 
roughly the same as 
cadmium(II) (radius = 0.92 
Å).94 This provided an 
incentive to explore the 
complexation character- 
istics of texaphyrins with 
metals from the lanthanide 
series.   
 
Scheme 1.6: Synthesis of an aromatic texaphyrin-Cd-complex.91, 92 
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Figure 1.17:  “Periodic table of texaphyrin”. Stable texa-
phyrin complexes with all metals shown in 
green are known. 
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 To date, stable texaphyrin 
complexes of almost every 
lanthanide(III) metal have been 
synthesized. Important to note is the 
fact that electron donating groups on 
the phenyl moiety of the macrocycle 
enhance the metal chelating ability, 
whereas electron-withdrawing groups 
have the opposite effect.  
The basic strategy of effecting 
metallation and oxidation has been 
successfully employed to obtain 
numerous other texaphyrin complexes 
with a wide range of relatively large cations, other than lanthanides. In all cases the metal 
cation is thought to stabilize the macrocycle as a result of a presumed thermodynamic 
template effect.80 Thus, once formed these metal complexes are extremely stable, except 
under acidic aqueous conditions, which readily leads to hydrolysis of the macrocycle.91  
 
1.5.2.3 Spectroscopic Features of Texaphyrins 
 One crucial feature of texaphyrin complexes is their ability to absorb strongly in 
the >700 nm spectral region.97, 98 As noted above, this region is of particular interest since 
it is a spectral region where bodily tissues and blood are maximally transparent.97 
 For instance, the UV-Vis spectrum of MGd 11 is dominated by two absorption 
bands. The higher energy Soret-like band at 474 nm is analogous to the ~400 nm band of 
 
 
Figure 1.18:  Representative stable texaphyrin 
 complexes.82, 90-96  
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porphyrins and is characteristic of the 
absorption bands seen for other vividly 
pigmented porphyrin-type moieties. 
The Soret-like band is flanked by N- 
and Q-like bands at higher and lower 
energies, respectively, with the lowest 
energy Q-band for MGd being seen at 
740 nm. 
  Interestingly, there is a steady 
shift in the Q-like band from red to the 
blue (∆ = 15 nm)99 as the Ln(III) ion in question is changed from lanthanum to lutetium. 
This shift in the Q-like bands appears to follow the contraction of the metal ions in the 
lanthanide series. A plot of the wavelength (in nm) of the Q-like band versus the ionic 
radius of the Ln(III) ion gives a linear relationship.99 
Another spectral feature of other 
metallated texaphyrins, especially 
diamagnetic texaphyrin species, is their 
ability to fluoresce. The resulting Q-type 
emission bands, like the Q-type absorption 
bands, are substantially red-shifted (by >100 
nm) compared to typical porphyrins.88, 97 
Further investigations of the spectroscopic 
properties of various texaphyrin complexes 
have established that, like the porphyrins, the 
Q-type band energies correspond to the 
 
Figure 1.20:  Plot of the wavelength 
(in nm) of the Q-like 
band versus the ionic 
radius of several Ln(III) 
ions.99 
 
 
Figure 1.19:  UV-visible spectrum of MGd 
11, 25 µM in methanol. 
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relevant π-electron 
HOMO-LUMO energy 
gaps. 
 Since, in 
texaphyrins, the benzo 
moiety is an intimate 
part of the π-system of 
the macrocycle, any 
variation to this ring will 
affect the π-conjugation 
and allow resonance 
interactions between the substituent and the main macrocyclic frame. Hence, by varying 
the nature of these substituents, it is possible to shift the maxima of the Soret-like and Q-
type bands to higher or lower energies. 
 
1.6 CONCLUSIONS 
The biomedical results obtained to date provide support for the notion that the 
expanded porphyrins, texaphyrin and sapphyrin could have a role to play in a variety of 
biomedical application areas. These include but are not limited to use as anticancer agents 
and isotope delivery vehicles for radiotherapy, site-localizing carriers, and treatments for 
neurodegenerative diseases. The unique mode of action of texaphyrins, which in some 
instances involves the manipulation of reactive oxygen species, and their inherent 
versatility in terms of sites for chemical modification and functionalization, make them 
attractive scaffolds for further study. The ensuing Chapters will give further insights into 
 
Figure 1.21:  Calculated HOMO- (left) and LUMO-surface 
 (right) of an unmetalated and 
 unfunctionalized aromatic texaphyrin 
 species.  
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the unique chemistry of this class of expanded porphyrins, and detail synthetic work 
designed to support collaborative studies that target new biomedical applications. 
Additionally, a new sapphyrin species will be introduced in an effort to potentially 
improve its anticancer properties. 
Sections of this Chapter are part of a review on texaphyrins (Arambula, J. F.; 
Preihs, C.; Borthwick, D.; Magda, D.; Sessler, J. L., Anti-Cancer Agents in Med. Chem. 
2011, 11, 222-232.). Dr. Jonathan F. Arambula, Christian Preihs and Dr. Jonathan L. 
Sessler co-wrote the paper, Derric Borthwick and Darren Magda contributed to 
corrections and discussions. Other sections of this Chapter were taken from: Preihs, C., 
M.A. Thesis, The University of Texas at Austin, December 2009. 
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2. Bismuth- and Lead-Texaphyrins as Potential α-Core Emitters for 
Radiotherapy 
 
2.1 INTRODUCTION 
The chemistry of bismuth has been largely unexplored, until recently when 
bismuth complexes have gained interest for the treatment of gastric ulcers1 and in cancer 
therapy.2 Whereas medical applications of bismuth salts (e.g. Pepto-Bismol®) have 
already been explored extensively, the coordination chemistry of this element remains 
poorly investigated. Trivalent and pentavalent oxidation states for bismuth are the most 
common ones, with the chemistry of Bi(III) being more extensively developed. Here, 
research efforts have led to the synthesis and characterization of various complexes with 
coordination numbers ranging from three to ten.3-7 
The high affinity of bismuth with nitrogen and oxygen chelates makes this metal 
an attractive candidate for the formation of complexes with a number of chelators and 
macrocycles, such as (4,7,10-tris-carboxymethyl-1,4,7,10-tetraaza-cyclododec-1-yl)-
acetic acid (DOTA).8  
Until the early 1980s, merely a few reports on the complexation of bismuth by 
porphyrins were published, presumably due to their inherent instability.9-10 Nevertheless, 
during the past decade, various studies and computational methods led to a better 
understanding of the coordination of bismuth in porphyrins, both, in organic and aqueous 
media.11-14 Prof. Bernard Boitrel and coworkers at the University of Rennes (Frances) 
were the first to succeed in the synthesis of stable bismuth(III) picket porphyrins (Figure 
2.1 (a.)).15 They also introduced hanging-carboxylate porphyrins (Figure 2.1. (b.))16 as 
bismuth(III) chelators. These systems are providing an advanced knowledge of the co-   53 
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ordination behavior of 
bismuth and, more 
notably, allowing for 
the preparation of drug 
delivery systems 
bearing alpha-emitting 
bismuth isotopes for 
applications in radio- 
therapy. The bismuth 
isotopes in question, 
namely 212Bi and 213Bi, 
are characterized by 
very limited half-lives 
(60.55 min and 45.65 
min for 212Bi and 213Bi, 
respectively). This has 
prompted lead(II) to be 
a more suitable metal 
for the purpose of 
creating alpha-emitting 
complexes. The lifetime of 212Pb is longer than that of 212Bi and 213Bi, it exhibits a half-life 
of 10.64 hours and produces 212Bi as its primary decay product along with a β-particle.  
The radiation chemistry of bismuth has provided an incentive to develop a so-
called in situ generator of 212Bi based on the initial complexation of 212Pb.16 Such a 
generator requires a chelator that can rapidly coordinate both, lead(II) and its isoelectric 
 (a) 
 
 
(b) 
     
Figure 2.1:  Valence bond structures (left) and X-ray crystal 
structures (right) of (a) Boitrel’s picket 
bismuth(III) porphyrin15 and (b) Prof. Boitrel’s 
hanging-carboxylate bismuth(III) porphyrin.16 
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neighbor bismuth(III). One 
series of ligands endowed with 
this ability is the so-called 
hanging carboxylate por- 
phyrins. Representative struc- 
tures are shown in Figures 2.1 
(b) and 2.2.  
However, the stable 
systems reported to date have 
been structurally complex and a 
challenge to produce syntheti- 
cally. The need for elaborate 
porphyrins reflects the fact that 
the lead(II) and bismuth(III) cations do not fit inside the cavity of a tetrapyrrolic 
porphyrin. Bi(III) or Pb(II) complexes of non-elaborated porphyrins generally suffer from 
stability problems, with decomplexation reactions having been specifically noted in the 
case of tetrakis(3-pyridyl)porphyrin,13 meso-tetra-n-popylporphyrin,17 and octaethyl- 
porphyrin18. This is most likely due to the large distance of the metal center from the 
plane of the four nitrogen atoms in the porphyrin ligand. Moreover, the insertion kinetics 
for typical unfunctionalized porphyrins are usually very slow, with heating at reflux in 
solvents such as methanol, dichloromethane, chloroform or toluene generally being 
required in the case of bismuth. Even more problematic, partial decomplexation is often 
observed during the course of purifying the resulting complexes.  In an effort to overcome 
these difficulties, a goal of the author was to explore the use of texaphyrin as a ligand for 
lead and bismuth.  
  
Figure 2.2: Valence bond structures (left) and X-ray 
crystal structures (right) of Boitrel’s 
hanging-carboxylate lead(II) por- 
phyrin.16 
  55 
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2.2 TEXAPHYRINS AS LIGANDS FOR BISMUTH(III) AND LEAD(II) 
 
2.2.1 Structural Characteristics 
As already mentioned in section 1.5.2.2, texaphyrins have a roughly 20% larger 
core than their tetrapyrrolic congeners,19 which allows for the complexation of larger 
cations, in this case bismuth(III) and lead(II). As detailed below, the reduced, sp3 
precursor form of texaphyrin is indeed able to complex these two cations rapidly; 
Specifically, exposure of the nonaromatic texaphyrin ligands to commercially available 
bismuth nitrate or lead nitrate in methanol in the presence of triethylamine and molecular 
oxygen lead to the aromatic complexes 58, 59, 60 and 61, respectively. In doing so, the 
first discrete binuclear µ-oxo bismuth(III) macrocyclic complex to be described in the 
literature is formed as judged by X-ray diffraction analysis. The present Bi(III) and Pb(II) 
species are chemically stable, a feature that coupled with their ability to be produced in a 
        
Scheme 2.1:  Synthesis and structure of Bi(III) and Pb(II)-texaphyrins. Note that 
 ancillary ligands are not shown. In fact, complex 60 exists in the form of 
 a µ-oxo binuclear complex under most conditions; see text. 
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water soluble fashion, has permitted their characterization and cytotoxicity studies in 
vitro using the A2780 ovarian cancer cell line. 
The chemical structures of the target Bi(III)- and Pb(II)-texaphyrin complexes are 
shown in Figure 2.3. Compounds 58 (MBi) and 59 (MPb) bear appended polyethylene 
glycol units and were expected to display water solubility sufficient to allow for cell 
studies.  
In contrast, 
complexes 60 and 61, 
with appended methoxy 
functionalities, were 
designed to allow for the 
growth of single crystals 
suitable for X-ray 
diffraction analysis. 
While diffraction grade 
crystals were obtained in 
the case of 60 (Figure 
2.4), to date no crystals 
of 61 suitable for 
complete X-ray analysis and refinement could be obtained. However, a preliminary X-ray 
structure of 61 is shown in Figure 2.5. 
 
Figure 2.3:  Single crystal X-ray structure of 60. Note 
that the top structure shows only one 
individual texaphyrin subunit viewed from 
the top. 
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Crystals of 60 suitable for X-ray diffraction analysis were obtained by slow 
evaporation from methanol. The complex exists as a binuclear dimer in the solid state 
with a µ-oxo atom bridging the Bi(III) centers ligated by the individual texaphyrin 
subunits. One axial nitrate anion and 
one methanol molecule are bound to 
each bismuth(III) metal center. This 
binding of ancillary ligands is consistent 
with the oxophilicity of bismuth. The 
out-of-mean plane distance of the Bi(III) 
center is roughly 0.3 Å.  
The preliminary X-ray structure 
of 61 is best interpreted in terms of a 
trimeric fashion with bridged µ-hydroxy 
groups between the texaphyrin moieties. While representing a unique structure in 
porphyrin chemistry, this conclusion is not secure due to the fact that an advanced 
refinement of the structural parameters is not possible.  
To the best of our knowledge, the dimeric structure of the bismuth(III) texaphyrin 
complex 60 (Figure 2.4) is the first structurally characterized binuclear macrocyclic 
µ-oxo bismuth(III) complex, and the first stacked expanded porphyrin system to be 
prepared with a texaphyrin and a non-transition metal. In contrast to what is true for 
texaphyrins, however, a number of µ-oxo metalloporphyrin complexes are known (albeit 
not with bismuth). In general, the µ-oxo bridge in these latter complexes can be cleaved 
by addition of an aqueous acid, such as hydrochloric or hydrobromic acid to yield, as a 
general rule, the corresponding monomeric species. In the case of 60, however, such 
treatments led only to decomposition, presumably through hydrolysis. On the other hand, 
 
Figure 2.4:  Preliminary single crystal 
 X-ray structure of 61.  
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the use of non-aqueous conditions (trifluoroacetic acid (TFA) in DMSO-d6) allowed 
conversion of the binuclear species 60 to its mononuclear form (Figure 2.6), as inferred 
from 1H NMR spectroscopic analyses (see Figure 2.7). This process (conversion to the 
mononuclear form) is fully reversible by addition of triethylamine (TEA), which serves 
to regenerate the µ-oxo binuclear complex 60.   
   
The broad signals in the 1H NMR spectrum of 60 provide support to the notion 
that a dimeric µ-oxo-bridged structure is stable in solution as well. The line broadening in 
(a) is mainly due to extensive overlap of the signals: Presumably, the two texaphyrin ring 
systems are able to rotate freely around the µ-oxo axis which makes the corresponding 
hydrogen atoms rather 
indistinguishable on the 
NMR timescale. Upon 
addition of TFA, 
spectrum (b), the µ-oxo 
bond is believed to 
break with the now 
mononuclear texa- 
phyrin systems existing 
independently in so- 
lution. 
 
 
 
 
 
 
 
 
 
 
Figure 2.5:   Reactions involving the µ-oxo bond in 60
 observed upon the addition of trifluoroacetic 
 acid (TFA) and triethylamine (TEA). 
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(a) No TFA added: 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
(b) TFA added: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6:  1H NMR spectrum (400 MHz, DMSO-d6, 25 °C) for 60. Upon addition of 
TFA (one equiv), the three signals for the protons on the sp2 hybridized 
carbons (‘meso’ carbons) appear as sharp singlets between 9.5 and 13 ppm. 
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2.2.2 Kinetics of Metal Insertion 
The kinetics of metal insertion were monitored by observing the increase in the 
absorption at λmax = 478 nm (Soret-like band) as a function of time using commercially 
available bismuth(III) nitrate or 
lead(II) nitrate as the cation 
source. When the reaction was 
carried out at 75 °C in 
methanol, the spectral changes 
associated with the insertion of 
Bi(III) were completed within 
34 minutes (Figure 2.8), 
leading us to infer that the 
insertion reaction is also 
complete. The insertion of 
Pb(II) was complete after 
approximately 98 minutes. In 
other words, the insertion time 
for Bi(III) is about 50% of the 
half-life of 212Bi and the insertion time for Pb(II) is about 14% of the half-life of 212Pb. 
This leads us to infer that texaphyrin may have a role to play as a ligand for the 
complexation of 212Bi or 212Pb under conditions of α-particle therapy. 
 
 
 
 
Figure 2.7:  Changes in the UV-Vis spectrum of 60 
produced when the sp3 precursor was 
treated with Bi(III) nitrate in methanol at 
75 °C under aerobic conditions. Note that 
the spectrum recorded at 34 minutes is 
identical to that recorded at 38 minutes. 
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2.2.3 Cytotoxicity Studies 
In accord with design expectations, the water-soluble texaphyrin derivatives 
coordinating bismuth (58, MBi) and lead (59, MPb) displayed high levels of stability in 
buffered aqueous solution as judged by HPLC analyses. No appreciable decomposition 
products were observed in solutions of 58 and 59 at pH values ranging from 6 to 7.5. 
These complexes were thus deemed suitable for biological testing. To determine the 
inherent cytotoxicity of 58 and 59 towards potential tumor targets, cell proliferation 
assays were conducted using an A2780 ovarian cancer cell line that was recently found to 
display sensitivity towards 
MGd.20 As shown in Figure 
2.9, both MBi 58 and MPb 59 
gave IC50 values of 2.2 and 2.9 
µM, respectively. While such 
values are not particularly 
noteworthy per se, they are of 
interest in that they reflect a 
two to three fold increase in 
cytotoxicity relative to MGd 
(IC50 = 6.3 µM in this cell 
line).  
At this point, it is unknown whether the observed cytotoxicity is due to the redox 
mediation typically noted for texaphyrin complexes21, 22 or due to heavy metal toxicity, or 
some combination thereof. However, we favor the former rationale. This is because, in 
this particular cellular assay, the cytotoxicity (antiproliferative activity) of the free metal 
salts (i.e. Bi(NO3)3 and Pb(NO3)2) was significantly lower than that of the corresponding 
 
Figure 2.8:  Cell proliferation versus complex 
concentration for MBi and MPb 
(complexes 58 and 59 of this study) 
using the A2780 ovarian cancer cell 
line.  
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metal complexes. Bismuth(III) nitrate 
has an IC50 value of 7.9 µM, and under 
the conditions of our experiments the 
IC50 value for lead(II) nitrate was found 
to be between 100 and 300 µM. An 
accurate value for the latter could not 
be determined due to solubility limits 
of the metal salts.  
 
2.3 CONCLUSIONS 
In summary, we have shown 
that both the bismuth(III) and lead(II) 
metal cations form stable complexes 
with texaphyrins. A single crystal X-
ray crystallographic analysis of the 
bismuth(III) complex 60 reveals that it 
forms a binuclear µ-oxo sandwich 
complex that can be cleaved to its corresponding monomer by addition of TFA under 
non-aqueous conditions. The water-soluble complexes functionalized with polyethylene 
glycol groups, 58 and 59, show cyototoxic activity in A2780 ovarian cancer cell lines. On 
the basis of the present studies and appreciating the tumor-selective properties of 
texaphyrins, we suggest that this class of ligands would make good complexants for 212Bi, 
213Bi, or 212Pb and thus warrant further study as candidates for radiotherapy. The present 
study also serves to underscore how new coordination modes, namely µ-oxo Bi(III) 
(a) 
 
 
(b) 
 
 
Figure 2.9:   Toxicity studies of (a) MBi 58 
 in comparison with Bi(NO3)3 
 and (b) MPb 59 in comparison 
 with Pb(NO3)2. 
 
!
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complexes, can be stabilized using texaphyrins as opposed to, e.g., porphyrins. This 
provides an incentive to study further the fundamental coordination chemistry of this and 
other new porphyrin analogues. 
All compounds were synthesized, purified and characterized by the author. All  
X-ray quality single crystals were grown by the author. All cytotoxicity studies were 
performed by Dr. Jonathan F. Arambula at The University of Texas MD Anderson 
Cancer Center under supervision of Dr. Zahid H. Siddik. All crystal structures were 
solved and refined by Dr. Vincent M. Lynch of the Department of Chemistry and 
Biochemistry at The University of Texas at Austin. Dr. Jonathan L. Sessler supervised 
the project. 
Sections of this Chapter were taken from Preihs, C.; Arambula, J. F.; Lynch, V. 
M.; Siddik, Z. H.; Sessler, J. L., Chem. Commun. 2010, 46, 7900-7902. 
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3. Gadolinium Texaphyrin Functionalized Magnetic Nanoparticles 
 
3.1. DEVELOPMENT OF DUAL MODE MRI CONTRAST AGENTS 
Achieving high accuracy and precision are the main challenges in a variety of 
imaging techniques used in disease diagnostics such as positron emission tomography 
(PET), computed tomography (CT), optical microscopy and magnetic resonance imaging 
(MRI). As discussed in Chapter 1 of this 
dissertation, MRI is a powerful technique for 
producing tomographic images of biological 
targets in a noninvasive manner and with a 
high spatial resolution. Basic MRI scans often 
involve so-called T1 weighted scans, a term 
that refers to a set of standard scans that 
depict differences in the spin-lattice 
relaxation time of various tissues within the 
body. In the body, T1 weighted scans work 
well for differentiating fat from water, with 
water appearing darker and fat brighter. In 
contrast, T2 weighted scans depict differences 
in the spin-spin relaxation time and result in 
fatty tissues appearing darker in the MRI 
image and regions with high water 
concentrations appearing brighter. Typically, 
T1 contrast agents are comprised of 
   
Figure 3.1:  Representation of T1 
and T2 MRI modes (taken from a 
patient suffering from complications 
from measles). 
(A) and (C) are T1 weighted images, 
(B) and (D) are T2 weighted images. 
Note the hypointense (dark) signal on 
the T1-weighted image (arrow in A) 
and a hyperintense (bright) signal on 
the T2-weighted image (arrow in B).1  
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paramagnetic materials, such as manganese oxide nanoparticles or gadolinium 
complexes.2, 3 T2 contrast agents commonly consist of superparamagnetic nanoparticles 
(e.g., iron oxide).3-5 Unfortunately, such single mode contrast agents are far from ideal, 
particularly when accurate imaging of small biological targets is required.6, 7 Therefore, 
multimodality imaging techniques combining the imaging results from two or more 
devices, have been employed in an effort to increase the accuracy of disease diagnosis 
and improve therapeutic outcome.8-11 Clinically, the best example of multimodality 
imaging is seen in the rapid evolution of PET-SPECT (Single-photon emission computed 
tomography) and PET-CT scanner hybrids. Hence, the PET modality has developed into 
perhaps the most used multimodal imaging method.12 
However, the implementation of multimodal imaging techniques is far from ideal. 
For instance, discrepancies resulting from different penetration depths and spatial/time 
resolutions of multiple imaging devices can lead to inaccuracies and unintentional errors 
in disease diagnostics.   
Therefore, the development of dual imaging strategies and devices that employ a 
single instrumental system represent an attractive target since they overcome the inherent 
disadvantages associated with more classic multimodal imaging techniques. 
Prof. Jinwoo Cheon (Yonsei University, Seoul, Korea) and coworkers were the 
first to develop magnetic nanoparticles that can act as dual-mode MRI contrast agents. In 
their seminal studies they use a so-called “magnetically decoupled” core-shell design, 
which is described in greater detail below. This leads to the generation of two different T1 
and T2 imaging modes that are utilized simultaneously, potentially leading to more 
accurate MR imaging.13 
 54  
The difficulties 
associated with the efficient 
design of T1 and T2 dual-mode 
MRI contrast agents is at least 
in part due to the fact that, in 
the case of a direct contact of 
the T1 active and the T2 active 
compounds, the magnetic field 
generated by the super- 
paramagnetic T2 contrast 
material perturbs the relaxation process of the paramagnetic T1 contrast material. This 
phenomenon induces the quenching of the T1 signal.13 Therefore, a rational design of a T1 
and T2 dual mode MRI contrast agent requires the physical insertion of a separating layer 
between the T1 contrast 
material and the T2 contrast 
material. One example of such 
a sophisticated design is 
shown in Figure 3.3.13 Here, 
the T2 contrast material 
(MnFe2O4) is located in the 
core of the nanoparticle, while 
the T1 contrast material (Gd2O(CO3)2) is located on the shell. A silicon dioxide layer with 
varying thicknesses is able to isolate both materials sufficiently from each other. In 
applying this strategy, Prof. Cheon and coworkers have been able to develop 
 
Figure 3.2:  Electronic spins of paramagnetic T1 
contrast materials affected by a 
magnetic field from superparamagnetic 
T2 contrast materials when they are in  
close proximity.13 
       
        
Figure 3.3:  Schematic and transmission electron 
microscope (TEM) image of core-shell 
type dual mode contrast agents.13 
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nanoparticles that function as the first efficient dual mode MRI contrast agents (DMCA) 
with enhanced contrast effects in both T1 and T2 modes.13  
 
This project was undertaken with the initial goal of using texaphyrin macrocycles 
as T1 contrast material in Prof. Cheon’s DMCA systems. In doing so it was demonstrated 
that texaphyrin functionalized magnetic nanoparticles are efficient dual-mode MRI 
contrast agents but can also effectively sensitize cancer cells to make them highly 
vulnerable to apoptotic magnetic hyperthermia at low temperatures. These findings will 
be discussed in subsequent sections. Before the discussion of these experimental results, 
the concept of magnetic hyperthermia as an experimental anticancer treatment method 
will be introduced. 
 
 
(a)   T1 image   (b)  T2 image   
 
Figure 3.4:  (a) T1 and (b) T2 weighted MR images and their color-coded images of 
DMCA with varying SiO2 thickness by using a 4.7 Tesla MRI machine. 
Contrast agents: 200 μM (Gd) for the T1 image, 100 μM (Mn + Fe) for the 
T2 images. The images of Gd-DTPA (DTPA = diethylenetriamine- 
pentacetate) and Feridex (ferumoxides) were taken together for the purpose 
of comparison. In the color-coded image, positive and negative contrasts are 
indicated by the red and blue colors, respectively.13    
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3.2 MAGNETIC HYPERTHERMIA AS EXPERIMENTAL ANTICANCER TREATMENT 
Temperature control is an important self-defense tool for many higher organisms. 
For example, one response mounted by humans in an effort to fight injury including viral 
and bacterial infections, involves an increase in body temperature. This reaction produces 
the well-recognized symptoms of fever.14, 15 Today, the idea of using artificial temperature 
control for disease treatment is being realized with the aid of various techniques, such as 
ultrasound, near-infrared light, and magnetic fields by increasing localized temperature in 
a targeted region, i.e. hyperthermia.16-21 Magnetic nanoparticles have attracted 
considerable attention for hyperthermia applications due to their unique ability to 
generate heat effectively when exposed to an alternating magnetic field (AMF). More 
                 
 
Figure 3.5:  Schematic illustration of a therapeutic strategy involving the use of 
magnetic nanoparticles as a tool for cancer diagnosis via MRI 
enhancement (or as magnetoimpedance (MI) sensors). Therapy via 
hyperthermia can then be induced by exposure to an alternating 
magnetic field (AMF).22 
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importantly, this can be achieved without limitations in penetration depth.23-34 
Hyperthermia, the artificially induced heat treatment of a disease, uses temperatures 
ranging between 42 oC and 47 oC. Generally speaking, temperatures below 45 oC induce 
apoptotic cell death.35, 36 As compared to necrosis, i.e. the premature death of cells in 
living tissue, apoptosis is a far more benign form of “programmed” cell death.37 
Nonliving cells produced as the result of apoptotic process are cleaned by phagocytosis 
without affecting neighboring normal cells. In contrast, necrosis, such as that produced 
by harsh and high temperature hyperthermia, is considered relatively harmful since it can 
be correlated with inflammatory disease and metastasis.38, 39 Unfortunately, effective 
hyperthermia under apoptotic conditions is often difficult to achieve due to the fact that 
cells typically acquire resistance to induced thermal stress.40-42 In fact, repeated exposure 
to high temperatures with a high concentration of magnetic nanoparticles is usually 
necessary to reach a sufficient level of therapeutic efficacy. Regrettably, these conditions 
favor necrotic cell death rather than apoptosis. Because cancer cells are more susceptible 
to heat, initial heat damage in cancer cells can be observed at temperatures of 
approximately 43 °C.  While healthy cells and normal tissue remain mostly undamaged at 
these temperatures,43, 44 the goals of selective, cancer focused hyperthermia at this and 
other relatively low temperatures defines a recognized but unmet goal. 
 
3.3 USE OF TEXAPHYRIN FUNCTIONALIZED MAGNETIC NANOPARTICLES WITH DUAL-
MODE MRI ACTIVITY FOR ROS PRODUCTION AND HYPERTHERMIA TREATMENT   
In collaboration with Prof. Jinwoo Cheon we introduced a new design concept for 
a double effector magnetic nanoparticle system for high performance apoptotic mild 
hyperthermia. Double effector nanoparticles are composed of two functional components, 
which serve as sources of reactive oxygen species (ROS) and efficient heat production. 
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We demonstrate that ROS-generating magnetic nanoparticles can effectively sensitize 
cancer cells to make them highly vulnerable to subsequent apoptotic magnetic 
hyperthermia at low temperatures (Scheme 3.1).  
 
3.3.1 Preparation of Texaphyrin Functionalized Nanoparticles 
The synthesis of these double effector nanoparticles starts with the synthesis of a 
texaphyrin species with an appended amine functionality. Generally, the hydroxy 
functionality in 11 is rather unreactive towards a variety of functionalization reactions. 
However, the conversion of the alcohol to an amine via Mitsunobu reaction can be 
carried out efficiently.45 Prior to the Mitsunobu reaction, one OH-group has to be 
protected using 4,4’-dimethoxytrityl chloride as a protecting group. The Mitsunobu 
 
Scheme 3.1:  Double effector nanoparticles for apoptotic magnetic hyperthermia. 
Double effector nanoparticles generate reactive oxygen species 
(ROS). ROS sensitize cancer cells to hyperthermia even at relatively 
low temperatures (~43 oC). This sensitization strategy is effective for 
apoptotic hyperthermia, both in vitro and in vivo. Conventional 
unsensitized hyperthermia results in only marginal efficacy. 
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reaction and deprotection using acetic acid then yields the amine functionalized 
texaphyrin 63. While this texaphyrin species is considerably less stable than 11 and prone 
to hydrolysis, it is also more reactive towards functionalization of the appended amino 
group. The texaphyrin species 63 obtained can be linked (via in situ reaction with 
disuccinimidyl suberate) to nanoparticles bearing amine functionalities on the surface 
(Scheme 3.2). 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3.2:  Synthesis of amine functionalized texaphyrin 63. 
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With the amine functionalized texaphyrin 63 in hand, the next step involves the 
functionalization of the magnetic nanoparticles. For this conversion, it turned out to be 
advantageous to first react the amine functionality on the texaphyrin scaffold with 
disuccinimidyl suberate, a compound frequently used in bioconjugation methods as a 
protein cross-linking agent. However, due to instability of the resulting NHS-appended 
texaphyrin, this reaction has to be performed in situ with 64 instantly reacting with the 
nanoparticles. 
After multiple ineffective functionalization attempts, it was concluded that a long 
linker between the nanoparticle surface and the texaphyrin unit is necessary for a 
successful conjugation step. The nanoparticles used in this study contain a zinc doped 
iron oxide core (T2 active material) coated with a layer of silicon dioxide functioning as a 
separating layer. Further functionalization of the hydroxy functionalities on the SiO2 layer 
 
Scheme 3.3:  In situ preparation of MGd-NHS 64. 
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with 3-aminopropyltrimethoxysilane (APTMS) followed by reacton with succinic 
anhydride results in the formation of terminal COOH-groups on the surface. Conjugation 
of the latter groups via EDC/Sulfo-NHS (N-hydroxysulfosuccinimide) with poly(ethylene 
glycol) bis(amine) then results in the formation of terminal amines that can be subjected 
to the final conjugation step with 64 (Scheme 3.4).  
The presence of the gadolinium 
texaphyrin (GdTx) units on the magnetic 
nanoparticles (MNPs) was confirmed by 
UV-Vis absorption spectroscopy, which 
revealed the presence of spectral features 
ascribable to both the gadolinium 
      
 
Scheme 3.4:  Funtionalization of nanoparticles with texaphyrin 64. 
  
Figure 3.6:  TEM images of (i) core-
  MNPs and (ii) GdTx- 
  MNPs  
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texaphyrin and magnetic nanoparticles in the spectrum. 
 
                         
Figure 3.7: UV-Vis absorption spectra of gadolinium texaphyrin (green), magnetic 
nanoparticles (black), and GdTx-MNPs (red). The spectrum of the latter 
corresponds to a linear combination of the individual spectra of the 
gadolinium texaphyrin and the magnetic nanoparticles. 
 
3.3.2 In vitro Experiments with GdTx-MNPs 
In accord with what is expected for a magnetic nanoparticle containing appended 
gadolinium texaphyrin moieties, an MRI phantom study reveals both T1 and T2 contrast 
enhancements, a finding that provides support for the notion that conjugation had been 
successfully achieved.13 Simultaneous T1 bright and T2 dark contrast effects are ascribable 
to the gadolinium texaphyrin (T1 active material) and magnetic nanoparticle (T2 active 
material) portions of the constructs, respectively (Figure 3.8). In contrast, MR images 
associated with the control groups display either only bright T1 contrast or dark T2 
contrast, but not both.  
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The internalization of GdTx-MNP conjugates into cancer cells and the generation 
of reactive oxygen species (ROS) was examined using optical methods (Figure 3.9). This 
was done by monitoring the 
oxidation of 2′,7′-dichloro- 
fluorescein diacetate (DCFA, 
Molecular Probes) and its 
ensuing conversion to 2′,7′-
dichlorofluorescein (DCF).46 
After the addition of GdTx-
MNPs to MDA-MB-231 cells 
(a breast cancer cell line), a 
weak red fluorescence signal is 
observed, which is ascribed to 
the gadolinium texaphyrin 
portion of the internalized 
GdTx-MNPs (Figure 3.9 (ii)). 
In analogy to what proved true 
for MGd, the internalized 
 
Figure 3.8:  MRI contrast images of several contrast materials (T1 and T2 modes 
shown). 
 
Figure 3.9:  Intracellular uptake of GdTx-MNPs and 
their ROS generation in MDA-MB-231 
cells. Confocal microscopic images of 
MDA-MB-231 cells treated with GdTx-
MNPs. (i) Differential interference 
contrast (DIC) image of GdTx-MNPs 
treated MDA-MB-231 cells, (ii) 
Internalized GdTx-MNPs are shown in a 
red fluorescence of GdTx, (iii) ROS 
generation is manifest by green 
fluorescence, which results from 
oxidation of 2’,7’-dichlorofluorescein 
diacetate (DCFA) to 2’,7’-dichloro- 
fluorescein (DCF). (iv) Overlay of red 
and green fluorescence gives a yellow 
color. 
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GdTx-MNPs are expected to react with cellular metabolites, such as ascorbate present in 
cancer cells to generate ROS. The initial product of these electron transfer processes is 
superoxide, which is eventually transformed into hydrogen peroxide (see section 1.5.2.1, 
Figure 1.14). In the present instance, support for the proposed ROS came from the 
observation of a green fluorescence that has spread within the cells (Figure 3.9 (iii)). 
GdTx-MNPs and the proposed ROS generation in the same cell are inferred from an 
overlay of red and green fluorescence resulting in a yellow color (Figure 3.9 (iv)). 
GdTx-MNPs display a high specific loss power (=heating power) value  
(471 Wg—1), which is four times higher than the commercially available iron oxide 
nanoparticle, Feridex (an FDA approved MRI contrast agent, Figure 3.10 (a)). As a 
consequence, it only takes approximately 60 seconds to warm an aqueous medium from 
37 oC to 43 oC with 0.2 mg/mL of MNPs whereas approximately 250 seconds are 
required to generate the 
same degree of warming 
using an equivalent amount 
of Feridex® under otherwise 
identical conditions (Figure 
3.10 (b)). The reduced 
number of GdTx-MNPs 
required for adequate heat 
generation is considered a 
useful feature that may 
permit lower dosage levels 
when translated into a 
clinical setting. 
 
     
Figure 3.10:  (a) Specific loss power value of GdTx-
MNPs in comparison with that of Feridex 
in a 500 kHz AC magnetic field at 30 
kAm−1. 
(b) Heat profile of 0.2 mg/mL of GdTx-
MNPs and Feridex under an AC magnetic 
field for 500 seconds. 
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The dual effector nature of the GdTx-MNPs, namely an ability to produce both 
reactive oxygen species and heat, was initially tested in vitro. Towards this end MDA-
MB-231 cells (1.0 × 104 cells/well) and 0.2 mg/mL of GdTx-MNPs were coincubated for 
five hours at a GdTx-concentration of 100 µM. Next, an AC magnetic field was applied. 
A schematic representation of the experimental setup is shown in Figure 3.11.  
The temperature of the medium was found to increase to 43 oC (±1 oC). It was 
then maintained at this temperature for up to 60 min (Figure 3.12 (a)). Cell viability was 
then measured by CCK-8 assay. In the case of the bare MNPs, cell viability was found to 
decrease monotonically from 100% to 98%, 90%, 83%, and 75% (blue line, Figure 3.12 
(b)) as the time of the hyperthermia treatment is increased (i.e., 0, 10, 20, 30, and 60 
min). GdTx-MNPs also reduced the cell viability from 93% to 76%, 66%, 42%, and 36% 
as the treatment time increased (0, 10, 20, 30, and 60 min) (red line, Figure 3.12 (b)). 
However, these functionalized MNPs proved more effective. 
The slight loss in cell viability observed before magnetic hyperthermia (t = 0) (red 
line, Figure 3.12 (b)) is caused by surface coated GdTx, an agent that is known for its 
weak, but noticeable cytotoxic effect through the generation of ROS.47 We ascribe the 
     
Figure 3.11:  Schematic illustration of the in vitro experiment. Briefly, GdTx-
MNPs treated MDA-MB-231 cells are incubated for five hours and 
then an AC magnetic field is applied to effect hyperthermia. 
!
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significant enhancement in 
hyperthermia effects seen with the 
GdTx-MNPs to ROS mediated 
sensitization. Although ROS itself 
show little anti-cancer effect, ROS 
production dysregulates cancer cell 
redox homeostasis and induces 
oxidative stress. These effects, in 
turn, are expected to render the cells 
more susceptible to magnetic heat 
treatment. The dual effect is the most 
significant at 30 min of thermal 
treatment where 57% of the cancer 
cells are eliminated by the GdTx-
MNPs after applying an AC magnetic 
field. In contrast, only 17% of cancer 
cells are nonviable with MNPs. The 
amount of GdTx can be correlated 
with ROS concentration. As the 
relative GdTx loading level is 
increased from 0 to 1500 and 3000 
(i.e., the number of GdTx molecules 
conjugated to a given MNP in- 
creases), cell death markedly 
increases from 17% to 21%, and 57% 
     
 
Figure 3.12:  (a) Temperature profile. After 
warming, a  temperature of 43 
oC (±1 oC) is  maintained by 
applying an AC magnetic  field 
of 3.7 kAm−1 at 500 kHz. 
                    (b) Time dependence of the 
magnetic hyperthermia treatment 
effect. Here, 0.2 mg/mL of MNPs 
and  GdTx-MNPs containing 
100 μM of  GdTx are used. 
                        (c) Dependence of the magnetic 
 hyperthermia efficacy on GdTx 
 loading level. 
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under magnetic hyperthermia conditions (red line, Figure 3.12 (c)). In contrast, the 
number of non-viable cells increases only from 0% to 3% and then 7% as the loading 
level is raised in the absence of an applied AC magnetic field (blue line, Figure 3.12 (c)). 
This result provided support for the notion that the dominant role of GdTx is as a 
sensitizer for hyperthermia, rather than as direct cytotoxin. 
GdTx-MNPs, under conditions of mediated hyperthermia could potentially kill 
cancer cells via a number of pathways, including apoptosis and necrosis. In order to 
determine the predominant 
cell death pathway induced 
by the GdTx-MNPs, 
standard annexin V-
fluorescein isothiocyanate 
(annexin V-FITC) and 
propidium iodide (PI) 
staining studies were 
carried out (Figure 3.13). 
These assays detect changes 
in plasma membrane 
integrity and the release of 
DNA. Apoptosis initially 
induces the inversion of 
phosphatidylserine, which 
allows for binding to 
annexin V-FITC, while PI 
is unable to enter into the 
  
 
Figure 3.13:  Monitoring of the MDA-MB-231 cell 
death  pathway induced by magnetic 
hyperthermia using GdTx-MNPs. 
Microscopic images of MDA-MB-231 
cells before (i), 6 hours (ii) and 24 hours 
(iii) after magnetic field application. In 
these experiments, the nuclei are stained 
with DAPI (4',6-diamidino-2-phenyl- 
indole) (blue), and membrane inversion 
followed by membrane rupture is 
detected by annexin V-FITC (fluorescein 
isothio- cyanate) (green) and propidium 
iodide (red, PI), respectively. 
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cells to bind to DNA, at least at this initial stage. Before AC magnetic field application, 
neither annexin V-FITC nor PI-stained cells are detected (Figure 3.13 (i)). At six hours 
post-hyperthermia treatment, only annexin V-FITC stained cells are detected, a result 
consistent with the conclusion that the cause of cell death is primarily apoptosis (Figure 
3.13 (ii)). If necrosis were occurring, a red fluorescence signal would be observed early 
on as the result of PI-DNA interactions following membrane rupture. At 24 hours post-
hyperthermia treatment, both annexin V and PI stained cells are observed, a finding that 
presumably reflects membrane rupture, a classic hallmark of late stage apoptosis. (Figure 
3.13 (iii)). These results are thus fully consistent with the notion that GdTx-MNPs 
hyperthermia occurs predominantly through apoptosis. 
 
3.3.3 In vivo Experiments with GdTx-MNPs 
The Cheon group further tested the efficacy of GdTx-MNPs induced magnetic 
hyperthermia in vivo. MDA-MB-231 breast cancer cells were xenografted to the right 
hind leg of nude mice in several experimental groups (n = 3). GdTx-MNPs (75 µg), 
dispersed in normal saline (50 µL), was directly injected into the tumor (100 mm3). Then, 
the mouse was placed in a water-cooled magnetic induction coil (Figure 3.14 (a)) and an 
AC magnetic field (500 kHz at 30 kAm-1) was applied to maintain a constant temperature 
at the tumor (43 ± 1 oC) for 30 min. After a single hyperthermia treatment, the tumor size 
was monitored for 14 days. In the mice making up the untreated control group, the tumor 
size increased approximately sevenfold by day 14 (Figure 3.14 (b) and (c)). However, for 
the group receiving hyperthermia treatment with GdTx-MNPs, the tumor was absent after 
eight days (Figure 3.14 (b) and (c)). For comparison, another group of mice was 
subjected to hyperthermia treatment after administration of pure MNPs at an identical 
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dosage. Although the size of the tumor regresses initially, a significant amount of tumor 
mass remains at day eight (V/Vinitial = 0.6) and the tumor starts to regrow at day 12. 
 
      
Figure 3.14:  In vivo magnetic hyperthermia  
(a) Schematic representation of the in vivo magnetic hyperthermia study. Magnetic 
nanoparticles (75 µg) were directly injected into the tumor tissue (tumor volume, 100 
mm3, n = 3) of a mouse and subjected to an AC field for 30 min at 43 ± 1 oC.  
(b) Plot of tumor volume (V/Vinitial) versus the number of days after treatment. In the 
group treated with GdTx-MNPs hyperthermia (one treatment at 43 oC for 30 min, red 
line), the tumor is completely eliminated by day 8, whereas the MNPs hyperthermia 
group (green line) shows only initial reduction in tumor volume, followed by regrowth. 
(c) Images of xenografted tumors (MDA-MB-231) on nude mice before treatment (left 
column) and 14 days after treatment (right column). Note the different outcomes for 
untreated control and the mice subjected to hyperthermia with MNPs and GdTx-MNPs. 
Each scale bar indicates 5 mm. 
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3.4 CONCLUSIONS 
This study, based on the use of double effector nanoparticles, has demonstrated a 
new approach to achieving apoptotic magnetic hyperthermia. Until now, attempts to use 
low temperature magnetic hyperthermia for cancer therapy have been challenging due to 
the development of thermal tolerance. The dramatic reduction in tumor burden seen in 
vivo and the high degree of efficacy seen in vitro are ascribed to the sensitization effect 
arising from ROS, which are thought to play a key role in enhancing the treatment 
efficacy. The efficient heat generation produced by GdTx-MNPs is also advantageous 
because lower concentrations of nanoparticles are required to achieve the same biological 
effect at low temperatures (43 oC). The pathway of cell death involves predominantly 
apoptosis, a mode of action that is considered beneficial for ultimate clinical use. Prior to 
the present study, low temperature hyperthermia and high therapeutic efficacy had proved 
incompatible. However, the use of the present double effector nanoparticle system allows 
these seemingly disparate goals to be realized. More broadly, we have shown that it is 
possible to achieve efficient apoptotic hyperthermia at low temperature. 
Important to note is that this project was done in close collaboration with Prof. 
Jinwoo Cheon’s research group at Yonsei University (Seoul, Korea), which the author 
visited in October 2011. The texaphyrin precursors shown were synthesized by the author 
at The University of Texas at Austin. While the idea of using GdTx-MNPs for hyper- 
thermia treatment was developed during the author’s visit to Yonsei University, all MRI, 
confocal microscopy, in vitro and in vivo experiments were carried out by Dr. Dongwon 
Yoo and Ms. Heeyeong Jeong. Drs. Jinwoo Cheon and Jonathan L. Sessler supervised the 
project. A manuscript summarizing this project has been published: Yoo, D.; Jeong, H.; 
Preihs, C.; Choi, J.-S.; Shin, T.-H.; Sessler, J. L.; Cheon, J. Angew. Chem., Int. Ed. 2012, 
51, 1-5. Parts of this Chapter have been taken from this manuscript. 
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4. In Vivo MR imaging of Polymer Micelles Targeted to the 
Melanocortin 1 Receptor  
 
4.1 INTRODUCTION 
Rationally-designed, polymer-based micelle carriers represent a promising 
approach to the delivery of therapeutic and/or diagnostic agents. They offer a variety of 
potential advantages as drug delivery systems and could serve to (i) enhance the 
solubility of lipophilic drugs, (ii) increase circulation times, and (iii) lower the toxicity of 
the agent in question.  Micelles with diameters ranging between 20 and 200 nm are 
particularly attractive targets due to the fact that particles of this size can escape renal 
clearance. This generally translates into longer circulation times and can lead to improved 
accumulation behavior in tumor tissues as the result of enhanced permeability and 
retention (EPR) effects.1, 2 The latter describes the property by which certain sizes of 
molecules, such as nanoparticles, macromolecular drugs and liposomes, tend to 
accumulate in tumor tissues much more than they do in normal tissues. A few reasons for 
this phenomenon are explained in Chapter 1 of this dissertation; they include an increased 
blood supply, as well as a generally less effective lymphatic drainage system, in cancer 
cells. It has also been suggested that selective accumulation in tumors relative to normal 
tissues can be enhanced through the use of tumor-specific cell-surface targeting groups, 
and that binding events may be used to trigger release mechanisms.  Such strategies are 
appealing since they could serve not only to enhance tumor uptake relative to normal 
tissues, but also to reduce toxicity in peripheral organs.1-3  
Despite the advantages offered by micelle delivery systems, to date no micellar 
system has been described that achieves the full promise of targeting in vivo. Of 
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additional concern is the fate of micelle delivery systems in biological media.4 Previously 
described micelle delivery systems have suffered from an inherent instability in vivo, 
generally undergoing collapse in the presence of serum lipids and proteins.4 Micelles can 
be stabilized for in vivo use through crosslinking of individual acyl chains. To date, 
numerous crosslinking reactions have been attempted, employing strategies that range 
from the use of disulfides5, 6 and other redox-sensitive bonds7 to temperature-8 and pH-
sensitive9-11 functional groups. In this Chapter a novel crosslinking procedure is described 
that relies on the pH-sensitivity of metal-oxygen coordination bonds.12 This particular 
form of crosslinking behavior is known to increase blood circulation times and results in 
the formation of a stable micelle delivery system that is able to selectively dissociate and 
release its contents at generally slightly lower pH values in tumor microenvironments.13     
There are a number of micelle-based delivery systems for drugs such as 
doxorubicin and paclitaxel currently in Phase I and II clinical trials.1, 2 These systems do 
provide for increased circulation times and larger area-under-the curve pharmacokinetics 
relative to the corresponding free drug. Some systems now in preclinical study are also 
“passively targeted,”6, 14, 15 meaning they lack any specific surface ligands and rely solely 
on EPR effects to deliver their payload.5, 8, 16 A significant disadvantage with passive 
targeting of micelle delivery systems is an increased probability for nonspecific delivery 
and accumulation in clearance organs, such as liver and kidney, relative to tumor.2, 17 
Additionally, the significance of EPR in human cancers remains largely unproven and 
there is increasing evidence that EPR alone may not be enough to ensure the selective 
delivery of a drug.17 
Most attempts at micelle targeting have come from the use of ligands such as 
(Arg-Gly-Asp)-based ligands (RGD) of αvβ3 integrin, epithermal growth factor receptor 
(EGFR), or folate.7, 18-23 Unfortunately, most of these targeted systems suffer from high 
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peripheral toxicity,5, 7, 16, 19, 20 have only seen limited testing in vivo (e.g., in animal models 
lacking tumor xenografts21, 22), or have not yet quantitatively demonstrated selective 
tumor accumulation relative to peripheral organs.7, 11, 18, 23, 24 It is also noteworthy that 
various other targeted systems have been reported to provide little improvement in tumor 
uptake as compared to their untargeted controls.7, 19, 20 Thus, there remains a need for 
more specific biological targeting agents, including those that rely on localization 
strategies that are not EPR dependent. This may be of particular relevance in clinical 
systems, where it has recently been proposed that human cancers have only a modest 
EPR as compared to murine xenografts.17    
One attractive target is the melanocortin 1 receptor (MC1R), which is expressed 
on over 80% of malignant melanomas.25 Not surprisingly, MC1R has been investigated as 
a target for delivery of imaging and therapeutic agents. Indeed, a number of MC1R 
ligands have been developed for this purpose.26-29 The best known of these, [Nle4,DPhe7]-
α-MSH (NDP-α-MSH, 69),30 is considered the “gold standard” for in vitro assays due to 
its ease of synthesis, low cost and high MC1R affinity.29, 31 However, NDP-α-MSH is not 
selective for MC1R and displays strong nanomolar binding affinities to other competing 
melanocortin receptor isoforms, e.g. MC4R and MC5R.32-34 Such off-target binding is 
undesirable given the presence of these receptors in the kidney, brain and central nervous 
system.35-39  Koikov et al. has reported the development of a ligand, 4-phenylbutyryl-His-
DPhe-Arg-Trp-NH2, with high selectivity and specificity for MC1R.28 Dr. Natalie Barkey 
(Moffitt Cancer Center, Tampa, FL) et al. has recently altered this ligand with an alkyne 
(4-phenylbutyryl-His-DPhe-Arg-Trp-Gly-Lys(hex-5-ynoyl)-NH2; 68)40 for click 
attachment to a micelle-forming triblock polymer. Moreover, it was demonstrated in vitro 
that micelles decorated with compound 68 retain the high binding affinity (2.9 nM Ki) of 
the free ligand and display improved target selectivity.  In this prior work, the Ki of 
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targeted crosslinked (XL) micelles for MC1R was found to be four times lower than the 
corresponding targeted uncrosslinked (UXL) micelles while not binding to either of the 
undesired targets, MC4R or MC5R.40 However, the following studies show how these 
micelles can be used to deliver a T1 MRI contrast-enhancing agent, namely gadolinium 
texaphyrin (GdTx). 
As described in section 1.5.2 of this dissertation, the ratio of the water-soluble 
texaphyrin species MGd 11 in tumor cells to that in surrounding normal cells is reported 
to be 9:1.41 However, we believe that incorporation of a different, hydrophobic texaphyrin 
species into a micelle (acting as a drug delivery system) would further improve this ratio. 
Furthermore, the incorporation of gadolinium into the texaphyrin macrocycle allows the 
tissue distribution of GdTx to be studied non-invasively via standard magnetic resonance 
imaging methods. To develop micelles containing GdTx, a triblock polymer micelle 
system with enhanced stability (IVECTTM) was used that was initially developed by 
Intezyne Technologies Inc. (Tampa, FL).13, 40  
                    
Figure 4.1:  Schematic representation of the design and function of targeted 
IVECT™ micelles.42 
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This triblock polymer is composed of a hydrophobic encapsulation block, a 
responsive stabilizer block, and a hydrophilic masking block that contains an azide for 
functionalization via click chemistry. The main advantage of IVECTTM micelles over 
traditional micelles is the incorporation of the stabilization block, which allows the 
micelles to be crosslinked via a pH-sensitive Fe(III) metal coordination reaction.12, 13, 40 
They are also biodegradable and designed to release their payload in the acidic 
microenvironment of tumors.13 As detailed below, this approach has allowed for the 
generation of a stabilized IVECTTM micelle system that incorporates GdTx and which 
both penetrates into xenografted tumors with high selectively and clears from circulation 
without being retained in the kidney or liver. Tumor penetration, as inferred from MRI 
studies, was not observed with either untargeted or uncrosslinked micelles. These results 
provide support for the notion that this approach for tumor-specific targeting is superior 
to that provided by EPR alone.  
 
4.2 DESIGN AND SYNTHESIS OF GDTX-POLYMER MICELLES 
For the incorporation of GdTx into the GdTx-polymer micelles a texaphyrin 
species was chosen that demonstrates low solubility in water but high solubility in a wide 
range of organic solvents, including apolar solvents such as chloroform or polar solvents 
such as methanol and dimethyl sulfoxide. The latter was chosen as the solvent for the 
incorporation step. The synthesis of the GdTx 67 is shown in Scheme 4.1. Briefly, 1,2-
veratrole 65 is subjected to dinitration as published previously.43 Hydrogenation of 1,2-
dimethoxy-4,5-dinitrobenzene 66 and condensation with the tripyrrane species 22 in the 
presence of hydrochloric acid results in the formation of a sp3 nonaromatic texaphyrin 
intermediate. Addition of triethylamine as a base in the presence of gadolinium(III) 
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acetate tetrahydrate and air leads to the formation of texaphyrin 67, which can be 
obtained as a deep green powder after column chromatographic purification. 
Single crystals suitable for X-ray diffraction were obtained by treating 67 with 
sodium nitrate (ligand exchange, Scheme 4.2) and by slow diffusion of ethyl ether into a 
solution of the texaphyrin in methanol and chloroform. 
 
 
 
 
 
 
 
 
 
 
 
          
 
         Scheme 4.1: Synthesis of gadolinium texaphyrin (GdTx) species 67. 
O
O
O2N
O2N
1. H2, Pd/C
2.                                         cat. HCl, 
                                             MeOH
3. Gd(OAc)3 
4. Et3N
5. O2 (air), 50°C, 2h
5. AcOH
AcO
N
N
N
N
N Gd
AcO
OH
OH
O
O
O
O
HNO3 / H2SO4
65 66
90%
67
22
N
H
H
O
N
H
N
H O
H
HO OH
42%
               
Scheme 4.2:  X-ray crystal structure of 67. These were crystals obtained after 
ligand exchange. Note that of the two nitrate counterions, only 
one is coordinated to gadolinium. The other axial ligands are 
methanol and water. 
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IVECTTM triblock polymers with a terminal azide were obtained from Intezyne 
Technologies (Tampa, FL) and either 6840 or NDP-α-MSH-lys-hexyne 69 were used as 
the MC1R-selective ligands, i.e. cell targeting groups (Scheme 4.3). Standard click 
chemistry was conducted for the design of the micelle construct as previously described.40 
NDP-α-MSH 69 was chosen as a model ligand for competition due to its 
relatively high affinity for MC1R (1.9 nM Ki), and for the ease of synthesis that it 
provides.29, 31 
In the percent targeting optimization assays with an alkyne-functionalized NDP-
α-MSH 69 there was a clear difference between the binding affinities of the crosslinked 
 
Scheme 4.3: Design of the IVECT™ micelle systems. 
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(XL) and uncrosslinked (UXL) micelles. This finding is ascribed to the Fe(III) 
crosslinking, which serves to stabilize the micelles in biological media. In the absence of 
crosslinking, the micelles dissociate, in whole or in part, to free monomers, leading to a 
loss of structural integrity and the premature release of the payload (the encapsulated 
contrast agent, GdTx 67, in the present instance).  
A second advantage of crosslinking is that it leads to an operational increase in 
binding avidity, a result that may reflect a benefit of multivalent interactions. The 
targeted (T) micelles based on texaphyrin 68 that was used in this study also exhibited a 
stronger avidity to the MC1R receptor when crosslinked (T-XL) as compared to their 
uncrosslinked counterpart (T-UXL). This finding can be interpreted as further support for 
the contention that (i) crosslinking stabilizes micelles and (ii) multiple targeting ligands 
on the micelle surface provide for enhanced binding.  In vitro europium time-resolved 
fluorescence (TRF) competition binding assays conducted with both 68- and 69-targeted 
micelles provide support for this central hypothesis. 
While in vitro MR imaging studies conducted with different GdTx-polymer 
micelle phantoms showed no apparent contrast effect attributable to the different micelle 
formulations (UT-UXL, UT-XL, T-UXL and T-XL, see experimental section), the 
stability, accumulation and MRI contrast properties of these systems could be studied in 
vivo. 
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4.3 IN VIVO STUDIES OF GDTX-POLYMER MICELLES 
The above GdTx containing 
micelles (0.5% GdTx w/w) were further 
studied in vivo using mice xenografted 
with HCT116 (colon cancer carcinoma) 
tumor tissue. In accord with the design 
expectations, these in vivo experiments 
revealed improved MRI contrast 
enhancements upon administration of the 
GdTx containing T-XL micelles, with 
maximal enhancement observed at 24 
hours. As can be seen by an inspection of 
Figure 4.2 and 4.3, this enhancement was 
not seen with the other micelle systems, 
supporting the contention that the T-XL 
micelles provide good systems for 
effecting tumor localization and imaging.  
This unique ability of the T-XL micelles to 
penetrate the tumor appears to result from 
a combination of the MC1R-specific 
targeting group and the enhanced stability 
provided by the Fe(III) crosslinking. If 
targeting alone were enough to produce 
effective tumor enhancement, one would 
also observe a substantial uptake in the 
 
 
Figure 4.2:  Buildup data for GdTx as 
inferred from contrast 
enhancement in the tumor 
((b) shows mean norma- 
lized intensity 24 hours 
post-injection).  
 All groups contained three 
mice except where noted. 
 ┴One mouse expired 
between the 24 hours and 
48 hours time point.  
 ┼One mouse expired upon 
injection of the micelle 
agent.  
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case of T-UXL micelles. Likewise, if crosslinking and EPR alone were enough to affect 
accumulation, one would observe an increased build-up in the UT-XL group. Finally, it is 
important to note that the enhancement observed in the T-XL group was not the result of 
free gadolinium texaphyrin (which is known to accumulate in tumors selectively, see 
previous sections of this dissertation). If this were the case, one would have observed 
enhanced uptake in all four micelle groups (i.e., UT-UXL, T-UXL and UT-UXL, in 
addition to the T-XL system). However, this was not seen. Furthermore, the GdTx 
 
 
Figure 4.3:  T1 weighted spin echo multi slice (SEMS) images of mice treated with 
different GdTx micelle formulations.  Representative images from each 
group of mice treated with GdTx micelles at selected time points (0, 12, 
24 and 48 hours).  White arrows denote location of tumors.  
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species 67 used in this study alone and without micelles acting as drug delivery systems 
does not show sufficient solubility characteristics to be used in vivo. Thus, the in vivo 
data obtained form the micelle system are consistent with the conclusion that the T-XL 
micelles containing GdTx 67 allow for functionally acceptable binding avidity, stability, 
tumor penetration and uptake. Presumably, the crosslinking reaction stabilizes the 
micelles after administration and during initial time points while they circulate 
throughout the bloodstream, while the targeting group allows the system to bind to, and 
be retained within, the tumor cells.  
 
4.4 CONCLUSIONS 
The synthesis, characterization and incorporation of a new gadolinium texaphyrin 
(GdTx 67) into polymer micelles has been described. The GdTx is characterized by a 
high inherent T1 relaxivity. Its encapsulation within the IVECTTM system and the 
production of crosslinked micelles by reaction with Fe(III) has also been detailed. 
Moreover, it was demonstrated that the targeted GdTx micelles are selectively retained in 
target-expressing xenograft tumors in vivo. To the best of our knowledge, this is the first 
example of a targeted micelle that is capable of carrying a payload and which 
outperforms systems based on EPR in terms of tumor penetration, uptake and retention.  
Advantages of the current system include the following: (i) the target, MC1R, is 
highly expressed in melanoma cells and not in healthy tissues, except for melanocytes; 
(ii) high short-term stability, and (iii) an ability to accumulate in tumors, rather than 
various clearance organs. These attributes are reflected in the in vivo images that reveal 
uptake deep within the tumor with peak accumulation at 24 hours for T-XL micelles. In 
contrast, peak kidney and liver accumulations were seen at one to four hours. These 
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differences are thought to reflect the benefits of targeting. However, biodegradation of 
the stabilized micelles may contribute to the effect; to the extent it occurs on short time 
scales (on the order of hours), it would allow for release of payload (GdTx) within the 
tumor while concurrently clearing from circulation. While further investigations will be 
required to detail the full pharmokinetic profile of these new micelles, it is important to 
appreciate that from an operational perspective they constitute the first examples of 
micelle systems that are capable of delivering a payload in a tumor selective fashion. 
The gadolinium texaphyrin used in this study was synthesized and characterized 
by the author. The X-ray quality single crystal of complex 67 (obtained after ligand 
exchange) was grown by the author, the crystal structure was solved and refined by 
Dr. Vincent M. Lynch of the Department of Chemistry and Biochemistry at The 
University of Texas at Austin. All micelles described in this Chapter were designed and 
synthesized by Dr. Natalie Barkey (Moffitt Cancer Center, Tampa, FL) and other 
coworkers listed below. All in vitro and in vivo studies were conducted by Dr. Barkey 
and other coworkers listed below. Drs. Jonathan L. Sessler, Robert J. Gillies and David L. 
Morse supervised the project. Sections of this Chapter have been taken from the 
following manuscript: Barkey, N.; Preihs, C.; Cornnell, H. H.; Martinez, G.; Sill, K. N.; 
Carie, A.; Lloyd, M.; Xu, L.; Lynch, V. M.; Sessler, J. L.; Gillies, R. J.; Morse, D. L. 
submitted. 
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5. Phenanthroline Linked Sapphyrins 
 
5.1 INTRODUCTION 
As mentioned in section 1.5.1 of this dissertation, sapphyrins represent another 
class of expanded porphyrins with promising anticancer activity and which display 
selective localization in tumorous tissues, including hematological malignancies.1, 2 
Sapphyrins were initially explored in the context of photodynamic therapy where the 
absorption of light in the 700-800 nm is particularly important. In this spectral region, 
tissues and blood cells exhibit a broad absorption minimum.3 This makes them relatively 
transparent,3, 4 resulting in a more efficient photosensitizing treatment.  
Sapphyrins also attracted interest early on as possible ligands for metal 
complexation. Because of their basic resemblance to porphyrins, it was initially expected 
that the sapphyrins would mimic, at least on some level, the rich coordination chemistry 
displayed by the porphyrins. However, the larger core size (approximately 5.5 Å inner N-
N diameter vs. ca. 4.0 Å for porphyrins)5, the greater number of potentially chelating 
heteroatom centers, and the fact that pentaazasapphyrins when fully deprotonated are 
potentially trianionic ligands made sapphyrin a likely candidate for the chelation of larger 
metals, particularly as a potential ligand for the trivalent lanthanides and actinides. 
Unfortunately, in spite of extensive effort, this expectation remains largely unrealized.  
Complexation attempts with first-row transition elements yielded in only a few 
poorly characterized metal complexes. For instance, Woodward and his group, who 
investigated the metal-chelating properties of sapphyrins, found that when dedcamethyl 
sapphyrin was treated with the acetate salts of Ni2+, Fe2+, Cd2+, Mn2+, Co2+, and Zn2+ in the 
presence of sodium acetate, changes occurred in the visible spectra that could be 
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interpreted in terms of complexes being formed from each of these salts. However, only 
the Co2+ and Zn2+-containing species could be isolated. Unfortunately, crystals suitable 
for X-ray diffraction analyses could not be obtained in either case.6 
Successful metalation of sapphyrin with second- and third row transition metals 
was finally achieved by Sessler, et al. by using the carbonyl salts of rhodium(I) and 
iridium(I) as the metalating agents, in plane complexation was not observed. Rather, a 
variety of “sitting-a-top” complexes were obtained.7 A uranyl complex of a furan-
containing analogue of sapphyrin was also obtained by Sessler and coworkers.8  
Given the inherent limitations associated with the use of sapphyrin as a ligand, we 
sought to combine it with other chelating groups. Initial efforts along these lines, and the 
focus of this section centered around the use of phenanthroline. Phenanthroline has a time 
honored role in inorganic chemistry. It is currently receiving increased attention in the 
context of DNA recognition. 
 
5.2 RUTHENIUM COMPLEXES AS POTENTIAL ANTICANCER AGENTS 
There is a great interest in understanding the factors that control the binding of 
metal ions to nucleic acids. This has been fuelled in part by the successful introduction 
into the clinic of several platinum complexes that exert anticancer activity by forming 
covalent adducts with the purine bases of DNA (see section 1.3). However, the dose-
limiting nephrotoxicity and the development of drug resistance are main drawbacks in the 
use of platinum based anticancer agents. To date, a varity of other transition metal 
complexes are being studied for their potential use in chemotherapy and photodynamic 
therapy. This is part of a broad effort to create metallo drugs that are less toxic and more 
effective for chemotherapeutic applications. These studies have led to the development of 
 93 
several experimental 
ruthenium(II)-based anticancer 
agents.9-11 The prototype DNA-
binding ruthenium(II)-1,10-
phenanthroline complex [Ru-
(phen)32+] (Figure 5.1) was 
reported by Barton et al. in 
1984.12  
The propeller-shaped 
molecule binds by partial insertion of one phenanthroline ligand into the base-pair stack.13 
Another analogous compound that has been investigated in terms of its DNA-binding 
affinity is the Ru(phen)2DPPZ2+ (phen = 
1,10-phenanthroline; DPPZ = 
dipyrido[3,2-α:2’, 3’-c]phenazine).14 The 
resulting complex is a mixture of both ∆- 
and Λ-enantiomer. The latter prefers 
adenine- and thymine-rich DNA, but with 
modest selectivity.15 The ∆-enantiomer 
prefers guanine- and cytosine-rich DNA 
and is some six to ten times more 
selective.16 Upon binding to DNA, cell division by mitosis is hindered and apoptosis is 
initiated if DNA-repair mechanisms fail. Another complex, [Ru(phen)2(p-MOPIP)]2+ 
(phen = 1,10-phenanthroline, p-MOPIP = 2-(4-methoxyphenyl) imidazo[4,5-f][1,10]-
phenanthroline), is able to effectively inhibit proliferation of the A375 (skin cancer) cell 
line with a low IC50 (5.9 ± 1.1 mM).16 
 
 
Figure 5.1: Λ and Δ-enantiomer of [Ru(phen)32+] 68. 
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Figure 5.2:  Structure of the Λ-enantiomer 
of Ru(phen)2DPPZ2+ 69. 
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In light of these findings, we 
decided to design a molecule 
containing the key structural 
features discussed above, namely 
(a) a sapphyrin as a potential 
cancer-localizing core and (b) a 
1,10-phenanthroline unit as a N-
donor ligand that would allow for 
the stable complexation of 
ruthenium(II). Furthermore, while designing this sapphyrin species, particular 
consideration was devoted to finding a way to increase the relative absorption of the 
compound in the 700-800 nm region. Such a red shifting of the spectral features could 
allow for a more efficient use of excitation light energy in PDT applications. 
 
5.3 SYNTHESIS OF 1,10-PHENANTHROLINE LINKED SAPPHYRIN 
The synthesis of a phenanthroline-sapphyrin chimera is shown below. Briefly, it 
follows the “3+2” synthetic approach (3 = tripyrrane unit together with 2 = bipyrrole 
unit) for traditional sapphyrins as published previously.6, 17 The synthesis of the diformyl 
bipyrrole unit 77 is shown in Scheme 5.1.6 It follows a general procedure leading to 
diformyl-ß,ß,ß,ß-tetraalkylbipyrroles that is well established in the Sessler group. 
 
 
Figure 5.3:  Structure of the Λ-enantiomer of 
[Ru(phen)2(p-MOPIP)]2+ 70. 
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Scheme 5.1: Synthesis of diformyl bipyrrole unit 77. 
The synthetic route to obtain the tripyrrane precursor 83 is shown below. This 
procedure is a modified protocol reported by Lash et al.18 The synthesis of compounds 
1419 (via 81 and 82) and 8018 have been reported previously. 
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Scheme 5.2: Synthesis of tripyrrane unit 83. 
Commercially available 1,10-phenanthroline 78 was nitrated according to 
published procedures.20 The resulting 5-nitro-1,10-phenanthroline 79 was subjected to 
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Barton-Zard conditions. Following saponification and decarboxylation, 1,10-
phenanthrolinopyrrole 80 was obtained. Reaction of the latter species with the 
acetoxymethylpyrrole 14 (also used as a precursor for texaphyrin; see section 1.5.2.2) in 
2-propanol under reflux in the presence of acetic acid yielded the tripyrrane unit 83. 
Single crystals suitable for X-ray diffraction analysis were obtained for 83 
through slow evaporation of hexanes into a solution of 83 in chloroform containing 5% 
triethylamine. The addition of the latter base is important due to the fact that both 
nitrogen atoms on the phenanthroline moiety are basic and can be partially protonated by 
any proton source present in solution. This protonation, particularly if not complete, 
could lead to formation of non-crystalline species. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                         
                    
Figure 5.4: Single crystal X-ray structure of compound 83 (dimer shown). 
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The next step in the synthesis of the desired phenanthroline linked sapphyrin 
involves hydrogenolysis of the benzyl ester. However, attempts to cleave the benzyl 
esters of 83 with hydrogen over 10% palladium-charcoal or Pearlman’s catalyst 
(Pd(OH)2) were unsuccessful. Catalytic transfer hydrogenation reactions using 
cyclohexene, cyclohexadiene or ammonium formate also failed. The 1,10-phenanthroline 
unit appears to poison the catalyst through interaction with palladium. This renders the 
use of benzyl esters unsuitable as protective groups in this synthesis.  
 
 
Scheme 5.3: Failed hydrogenolysis of compound 83. 
 
Given the above findings, the author decided to use tert-butyl esters as protecting 
groups for the tripyrrane unit instead of benzyl esters. The synthetic protocols for the 
synthesis of pyrrole precursor 8421 and 8522-24 have been published previously. The 
synthesis of the tripyrrane is shown in Scheme 5.4. 
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Scheme 5.4: Synthesis of tripyrrane unit 86. 
 
Single crystals of 86 suitable for X-ray diffraction were obtained through slow 
diffusion of diethyl ether into a solution of 86 in chloroform, methanol and 5% 
triethylamine.  
 
 
 
OO
OMeO
1.
2. NaNO2
3. Zn / CH3COOH
OtBu
OO
29%
N
H
O
OMe
tBuO
O
Pb(OAc)4 / CH3COOH
82%
N
H
O
OMe
tBuO
O
OAc
81 84 85
80     +      85
2-propanol / CH3COOH
67%
86
N
N
NH
H
N
N
H
O
O
O
O
O
O
O
O
 100 
 
Figure 5.5: Top and side view of the single crystal X-ray structure of compound 86. 
 
Having precursors 77 and 86 in hand, the “3+2” synthesis of the desired 
sapphyrin could be completed. The cleavage of the tert-butyl esters in 86 and the 
subsequent decarboxylation reaction was achieved via the addition of trifluoroacetic acid 
(TFA, used as the solvent here) at 120 ºC. Then, addition of bipyrrole 77 dissolved in 
dichloromethane results in the formation of the sapphyrin.    
Note that during cleavage of the tert-butyl ester and the decarboxylation reaction 
of the tripyrrane 86 in TFA, both methyl esters appear to be cleaved as well resulting in 
the formation of a tripyrrane dicarboxylate and eventually a sapphyrin dicarboxylate. 
Since column chromatographic purification of this highly polar species is not feasible, a 
final esterification step in ethanol with a catalytic amount of sulfuric acid is required.  
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Scheme 5.5: Synthesis of 1,10-phenanthroline linked sapphyrin species 87. 
 
Single crystals suitable for X-ray diffraction were obtained for 87 through slow 
evaporation of hexanes into a solution in chloroform and. The sapphyrin scaffold proved 
to be highly planar, as expected for this aromatic expanded porphyrin. The 
phenanthroline moiety is slightly tilted (17.6º) out of the sapphyrin plane. One molecule 
of chloroform coordinates to the phenanthroline moiety in the solid state. Furthermore, 
one molecule of water resides inside the sapphyrin ring system. 
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Figure 5.6: Top and side view of the single crystal X-ray structure of compound 87. 
 
After purification and characterization, compound 87 was reacted with 
Ru(phen)2Cl2 (compound 88, synthesized from 1,10-phenanthroline as published 
previously25) in the presence of silver nitrate. This gave the Ru(II) complex of sapphyrin 
89 (Scheme 5.6) in virtually quantitative yield.  
 
 103 
 
Scheme 5.6: Synthesis of Ru(phen)2Cl2 88 and formation of complex 89. 
 
Interestingly, compound 89 proved to be water soluble, unlike the sapphyrin 
precursor 87. Presumably, the two nitrate counteranions serve to improve water solubility 
of the complex drastically. Unfortunately, to date no crystals of complex 89 suitable for 
X-ray analysis in the solid state could be obtained. 
N
N
N
N
Ru NH
N
HN
HN
N
N
N
O
O
O
O
Cl
Cl
N
N
N
N
Ru
EtOH
N
N
78
1.
2. AgNO3
DMF
58%
RuCl3 
LiCl
88
89
87
99%
 104 
In accord with the author’s design expectations, the UV-Vis spectrum of complex 
89 in comparison to the sapphyrin species 87 and the known, water soluble sapphyrin 
species 90 shows that the revealed intensity of the Q-band absorption centered around 
715 nm is significantly increased. This low energy spectral feature is particularly 
important for potential photosensitizers since blood and membranes largely absorb in the 
blue-green area of the spectrum, which limits the penetration of visible photons with 
λmax ≤ 650 nm as noted earlier. Hence, an increased intensity for this is considered to be 
an attractive feature for potential photosensitizers (Figure 5.7).  
 
                       
                  Figure 5.7: UV-Vis spectra of three structurally modified sapphyrins. 
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5.4 CONCLUSIONS 
The findings described in this Chapter demonstrate a way to design and 
synthesize a sapphyrin compound that contains a N-donor ligand, namely 1,10-
phenanthroline in its scaffold. This unit is able to stabilize a boud ruthenium(II) center 
which permits formation of a stable [Ru(phen)2(phenanthroline-sapphyrin)(NO3)2] 
complex 89. Unfortunately, X-ray quality single crystals of compound 89 have not yet 
been obtained. Various methods including counteranion exchange (to, e.g., PF6-) were 
tried in an effort to improve crystallization, albeit without success. This inability to obtain 
diffraction grade crystals may reflect the fact that complex 89 is a mixture of both the ∆- 
and Λ-enantiomer. So far, attempts to isolate the individual enantiomers have proven 
unsuccessful.  
Cell studies are now underway to examine the anticancer properties of compound 
89 in vitro. If promising results are obtained, in vivo studies would follow. 
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6. Synthetic Approaches to Antiaromatic Rosarins 
 
As detailed in previous Chapters, expanded porphyrins, heteroannulenes with 
more than five pyrrolic subunits in the macrocyclic scaffold, have been thoroughly 
investigated in part due to their biological, anion recognition and coordination properties. 
Particularly intriguing is the interplay between the both concepts of aromaticity and 
antiaromaticity. This is especially true in the case of expanded porphyrins since many of 
the key properties of porphyrins reflect their unique electronic characteristics. Most 
expanded porphyrins reported to date are aromatic. This includes such classic species as 
the texaphyrins and sapphyrins described in previous Chapters. As detailed below, the 
author also explored another class of expanded porphyrins, namely rosarins. This work 
was undertaken in an effort to synthetically access structures that would exhibit Hückel 
antiaromaticity.  
 
6.1 INTRODUCTION 
Most reported expanded porphyrins are 
aromatic and characterized by well-defined π-
conjugation pathways with absorption and emission 
features in the near-infrared (NIR) region.1 However, a 
limited number of antiaromatic congeners are known. 
They are identified by featureless, broad absorption 
spectra, the nonfluorescent nature, relatively shortened 
excited state lifetimes, and small two-photon 
  
Figure 6.1: Structure of free 
base orangarin 90. 
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absorption cross-section values.2 An early example of an antiaromatic expanded 
porphyrin is orangarin (Figure 6.1). This pentaaza system contains 20 π-electrons in its 
core.3 Osuka et al. also reported the gold(III) complex of hexaphyrin, another fully 
planar, antiaromatic expanded porphyrin.4 More recently, amethyrin has been shown to 
display antiaromatic features.5 Other fully planar antiaromatic porphyrinoids are 
extremely rare mostly due to the fact that expanded porphyrins often deviate from 
planarity when the number of pyrrole rings exceeds five. This distortion either makes 
them non-aromatic or allows them to adopt Möbius topologies and gain Möbius 
aromaticity.6  
Meso-aryl hexaphyrins (1.0.1.0.1.0), termed rosarins, are a class of expanded 
porphyrinoids with a 4n π-electron conjugated electronic circuit in the ground state.7, 8 
According to Hückel’s rule, the published β-dodecaalkyl substituted rosarin species 91 
(shown in Figure 6.2) should be formally antiaromatic. However, the compound exhibits 
only weak antiaromaticity as judged from it spectral features. Presumably, this reflects 
the fact that it adopts non-planar conformations that minimize the effects of extended π-
                         
Figure 6.2: Distorted non-planar structure of rosarin species 91.7 
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conjugation as inferred from a single crystal X-ray diffraction analysis.7 To test this 
rationale, we have designed and synthesized a new rosarin derivative named 
benzorosarin. This system differs from 91 in that it contains rigid (‘fused’) β,β’-
phenylene bridges that serve to enforce planarity (Figure 6.2). As detailed below, the 
beonzorosarin displays spectroscopic and structural features expected for a 4n π-electron 
antiaromatic system.  
 
 
 
Figure 6.3:  Conformational restriction of rosarin derivatives by β,β’-phenylene bridges 
is expected to give a planar 24 π-electron conjugated porphyrinoid, 92. 
 
6.2 SYNTHESIS AND CHARACTERIZATION OF BENZOROSARIN 
The β,β’-fused rosarin derivative 92 was designed to contain a planar core 
geometry. To achieve this desired planarity, benzobipyrrole9 would be a useful precursor 
since it would be expected to allow formation of the desired planar macrocycle. 
However, the use of unsubstituted benzobipyrrole (Scheme 6.1) did not yield any 
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macrocyclic products when reacted with benzaldehyde in the presence of trifluoroacetic 
acid. Instead, pyrrolic oligomers were formed. Presumably, substitution of both beta 
positions in the benzobipyrrole subunit is required to force reaction of the alpha positions 
of the bipyrrole. 
 
 
Scheme 6.1:  Failed synthetic procedure for the formation of benzorosarin species 92 
from β-unsubstituted benzobipyrrole 93. 
 
Later it was found that β,β-dimethylbenzobipyrrole would indeed react in a 
productive fashion with a substituted benzaldehyde (either pentafluorobenzaldehyde or 4-
tert-butyl benzaldehyde, see below) to form the desired expanded porphyrin, 
benzorosarin (Scheme 6.2).  
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Scheme 6.2:  Retrosynthetic analysis and synthetic procedure used to obtain the 
benzorosarin species 95 and 96 from β,β-dimethylbenzobipyrrole 97. 
 
The basic benzorosarin macrocycle was initially prepared via the acid catalyzed 
condensation of β,β-dimethylbenzobipyrrole with pentafluorobenzaldelhyde, followed by 
2,3-dichloro-5,6-dicyano-pbenzoquinone (DDQ) oxidation. However, the macrocycle 
demonstrated very low solubility in a variety of organic solvents and proved merely 
slightly soluble in DMSO. A complete and satisfactory characterization of the 
macrocycle was not possible. Therefore, 4-tert-butyl benzaldehyde was used instead of 
pentafluorobenzaldehyde as the condensation partner for the benzobipyrrole unit. 
The synthesis of β,β-dimethylbenzobipyrrole 97 is shown in Scheme 6.3.  
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Scheme 6.3: Synthesis of β,β-dimethylbenzobipyrrole 97. 
 
Mononitration10 of 1,4-dimethyl-2-nitrobenzene 98, followed by double 
condensation of dimethylformamide diethyl acetal (DMFDEA) with 1,4-dimethyl-2,3-
nitrobenzene 99, results in the formation of the bis-enamine 100. Catalytic hydrogenation 
of 100 directly affords benzobipyrrole 93.11  
3,6-Diformylbenzobipyrrole 101 was then obtained via a Vilsmeier-Haack 
formylation of benzobipyrrole 93,9 which upon Wolff-Kishner reduction using hydrazine 
and potassium hydroxide in ethylene glycol resulted in the formation of compound 96 in 
high yield. As has been noted for other structurally similar β-substituted α-free bipyrrole 
species, β,β-dimethylbenzobipyrrole proved to be highly unstable and decomposes 
quickly when exposed to ambient conditions. Therefore, it was used directly for the 
formation of both benzorosarin macrocycles 95 and 96. 
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Addition of β,β-dimethylbenzobipyrrole  97 to a stoichiometric amount of 4-tert-
butyl benzaldehyde in dichloromethane and addition of catalytic amounts trifluoroacetic 
acid (TFA) results in the formation of a nonaromatic porphyrinogen which is blue in 
color. Addition of DDQ then affords macrocycle 96 in 8% yield. 
Compound 96 displays spectral features consistent with antiaromaticity, namely 
featureless, broad absorption spectra, a lack of appreciable fluorescence, and a vastly 
downfield shifted signal for the NH protons in the 1H NMR (δ = 24.95 ppm, Figure 6.4). 
The π-conjugation pathway for rosarin 96 contains 24 π-electrons. It thus corresponds to 
a Hückel [4n]π antiaromatic species. Particular attention in this context is given to the 
inner NH protons. The published rosarin species. 91 does not show any substantial ring 
current effects and its NH protons resonate at ~12.3 ppm most likely due to its nonplanar 
structure. Hence, it is essentially considered to be nonaromatic.  
On the other hand, the enforced molecular planarity by fusing the β-positions in 
the bipyrrole moieties and therefore rigidifying the rosarin macrocycle 96 results in a 
drastic downfield shift of the inner NH protons to 24.95 ppm. This may be an indication 
for a strong paratropic ring current in benzorosarin. Of a particular interest is the large 
change in the chemical shift value of NH protons of 91 upon rigidification to form 96. 
The difference in chemical shift corresponds to a Δδ value of ~13 ppm.   
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Figure 6.4:  Structure and low-temperature 1H NMR spectrum (400 MHz, CDCl3,  
 -40 °C) of compound 96. 
 
6.3 NAPHTHOROSARIN 
Extensive efforts were devoted to experiments that would result in the generation 
of single crystals of macrocycle 96. Unfortunately, to date no X-ray quality crystals of 96 
could be obtained. This is could reflect the fact that compound 96 is fairly basic. It is thus 
easily protonated, even by solvent impurities. However, once protonated, compound 96 
tends to decompose rapidly.  
Because of this scientific drawback, we decided to focus crystallization efforts on 
a different rosarin macrocycle, synthesized by Prof. Chang Hee-Lee’s group (Kangwon 
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National University, Chun-chon, Korea). In contrast to benzorosarin 96, Prof. Lee’s 
rosarin, termed naphthorosarin, 102, proves to be chemically quite stable. X-ray quality 
crystals of the macrocycle were grown and the X-ray structure was solved by Dr. Jung-Su 
Park at The University of Texas at Austin. The valence bond structure of 102 together 
with its refined X-ray structure are shown below. 
 
     
Figure 6.5:  Valence bond structure and single crystal X-ray structure of naphtho- 
rosarin 102. Hydrogen atoms have been omitted for clarity. Note that in the 
solid state one water molecule is found in the central core of the macrocycle.   
 
As true for benzorosarin 96, conformational restriction in the case of 
napthorosarin 102 results in the formation of a planar 24 π-electron conjugated 
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porphyrinoid. In accord with the Hückel rule, napthorosarin 102 displays featues that are 
consistent with a 4n (n = 6) antiaromatic electronic structure. Initial support for the 
assignment of 102 as an antiaromatic species came from 1H NMR spectroscopic studies. 
For instance, in analogy to what was seen in the case of benzorosarin 96, a dramatic 
downfield shift in the NH proton signal (δ = 26.22 ppm) was obtained in the 1H NMR 
spectrum recorded at -60 ºC in CD2Cl2. Further evidence for the proposed antiaromaticity 
came from optical absorption studies. Specifially, the UV-Vis-NIR absorption spectrum 
of 102 (Figure 6.6) is characterized by a broad band at 462 nm along with an extremely 
weak and broad near-IR band in the 900-1600 nm spectral region. Similar near-IR 
spectral features are typically seen for other antiaromatic porphyrinoids.12-14 However, the 
effect is particularly dramatic in the case of 102. 
In order to test whether the 4n π-electron napthorosarin 102 could be reduced to 
the corresponding 4n+2 π-electron congener (which was expected to exhibit Hückel 
aromaticity), it was exposed to sodium dithionite in water saturated dichloromethane. 
(Note: These studies were carried out in 
Prof. Dongho Kim’s group at Yonsei 
university by postdoctoral fellow Dr. 
Masatoshi Ishida). The product of this 
reaction, presumably the 2-electron 
reduced form of 102, demonstrates 
spectral features typical of aromatic 
porphyrinoids. For instance, a sharp 
Soret band at 612 nm and Q-bands with 
clear vibronic structure are seen in the 
absorption spectrum of the reduced 
 
Figure 6.6:   
Steady-state absorption spectra of 102 
(black line), and 103 (blue line) in 
dichloromethane. 
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form, naphthorosarin 103. This stands in clear contrast to the broad and featureless 
absorption spectrum of naphthorosarin 102. In addition to dithionite, it was found that 
chloride anion could act as a reductant. In this case, conversion of the antiaromatic to the 
corresponding aromatic form takes place as the result of a proton-coupled electron 
transfer reaction. 
 
 
 
 
 
 
 
 
  
 
 
Scheme 6.4: Reduction of napthrorosarin 102 using sodium dithionite. Also shown is the 
use of manganese(IV) oxide to effect reoxidation. 
 
The author of this dissertation was able to grow X-ray diffraction quality single 
crystals of the reduced form of 102, compound 103. An X-ray diffraction structural 
analysis revealed that product 103 retains the initial quasi-planar geometry with a mean 
plane deviation of 0.235 Å being observed. A chloride counter anion (presumably from 
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free chloride present in the solvent) was found to be located inside the core and stabilized 
via multiple hydrogen bonding interactions involving the NH protons of the pyrrole rings. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7:  X-ray crystal structure showing (a) top and (b) side views of 102, (c) top and 
(d) side views of 103. Meso-aryl substituents are omitted for clarity in the 
side views. The thermal ellipsoids are scaled to the 50% probability level. 
 
The 1H NMR spectrum of 103 (recorded in CD2Cl2 at 25 ºC) revealed two pairs of 
deshielded outer C-H and β-H resonances (at 8.20, 9.90 and 11.00 ppm, respectively), as 
well as β-pyrrolic resonances at 11 ppm. A singlet at −5.30 ppm is also seen; it was 
assigned to the inner NH protons on the basis of D2O exchange experiments. The distinct 
diatropic ring current observed in the case of 103 is as expected for a Hückel-type 4n+2 
π- electron aromatic expanded porphyrin.15-17  
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6.4 CONCLUSIONS 
We have synthesized and characterized a presumably coplanar benzorosarin. This 
new system was designed to allow the effect of enhanced molecular planarity on the 
electronic properties of potentially antiaromatic expanded porphyrins to be probed in 
detail. While X-ray crystallographic data support could not be obtained, we believe that 
by linking the beta positions on two adjacent pyrroles with phenylene linkers does serve 
to enforce rigidity. As a result, the molecular planarity and the paratropic ring current are 
enhanced. This assumption is supported by observations made from naphthorosarin, a 
related macrocycle synthesized in Prof. Chang-Hee Lee’s group and further studied by 
Prof. Dongho Kim’s group. Both β,β’-fused rosarins, benzorosarin 96 and naphthorosarin 
102 exhibit a drastic downfield shift in the resonances for the inner NH protons. These 
signals appear at 24.95 ppm for benzorosarin 96 and 26.22 ppm for napthrorosarin 102, 
respectively. Interestingly, naphthorosarin 102 can be reduced by addition of sodium 
dithionite; this forms an aromatic macrocycle 103 with a 4n + 2 π-electron periphery. X-
ray diffraction analysis of the latter species (as the HCl salt) reveals a near-planar species. 
Detailed solution phase studies provided support for the notion that 103 is formed via a 
proton-coupled electron transfer process.  
The author of this dissertation performed the synthesis of compound 96 and 
carried out X-ray diffraction analyses on the crystals under supervision of Dr. Jonathan L. 
Sessler and Dr. Vincent Lynch. Dr. Masatoshi Ishida carried out the bulk of the 
experimental work for compound 102 under supervision of Dr. Dongho Kim. All authors 
contributed to discussions. Sections of this Chapter were taken from Ishida, M.; Kim, S.-
J.; Preihs, C.; Ohkubo, K.; Lim, J. M. Lee, B. S.; Park, J. S.; Lynch, V. M.; 
Roznyatovskiy, V. V.; Panda, P. K.; Lee, C.-H.; Fukuzumi, S.; Sessler, J. L. Nature 
Chem. 2012, in press. 
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7. Experimental Procedures 
 
7.1 GENERAL PROCEDURES 
All chemicals were obtained from commercial sources (Fisher Scientific, Acros 
Chemicals, Sigma-Aldrich or Strem Chemicals) and used as supplied unless otherwise 
noted. All solvents were of reagent grade quality. Fisher silica gel (230-400 mesh, Grade 
60 Å) and Sorbent Technologies alumina (neutral, standard activity I, 50-200 µm) were 
used for column chromatography. Thin layer chromatography (TLC) analyses were either 
performed on silica gel (aluminum backed, 200 µm or glass backed, 250 µm) or alumina 
neutral TLC plates (polyester backed, 200 µm), both obtained from Sorbent 
Technologies. All NMR solvents were purchased from Cambridge Isotope Laboratories, 
Inc. 1H NMR and 13C NMR spectra used in the characterization of products were 
recorded on Varian Unity+ 300 MHz or Varian Mercury 400 MHz spectrometers. 
Chemical shifts are reported in units of δ (parts per million; ppm) and referenced to the 
residual solvent. Spectral splitting patterns are designated as s (singlet), d (doublet), t 
(triplet), q (quartet), m (multiplet) and br (broad). Low- and high-resolution ESI mass 
spectra were obtained at the Mass Spectrometry Facility of the Department of Chemistry 
and Biochemistry at The University of Texas at Austin using a Thermo Finnigan LTQ 
instrument and a Qq FTICR (7 Tesla) instrument, respectively. UV-Vis spectra were 
recorded either on a Beckman DU 640B spectrophotometer or a Varian Cary 5000 UV-
visible spectrophotometer. HPLC spectra were taken on a Shimadzu High Performance 
Liquid Chromatograph (Fraction Collector Module FRC-10A, Auto Sampler SIL-20A, 
System Controller CBM-20A, UV-Vis Photodiode Array Detector SPD-M20A, 
Prominence).  
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The macrocyclic, methylene-bridged texaphyrin precursor used to prepare MGd 
(compound 56, generally referred to as sp3-TexPEG) and the so-called sp3 form of the 
analogous texaphyrin precursor with appended methoxy functionalities (compound 57, 
generally referred to as sp3-TexOMe) were prepared as reported previously.1-4 
The tripyrrane dialdehyde species 22 was provided by Pharmacyclics Inc. and 
synthesized as previously described.5 The precursor 1,2-dimethoxy-4,5-dinitrobenzene 66 
was synthesized as previously described.6 
MGd 11 has been synthesized according to procedures previously described in the 
literature.5  
 
7.2 EXPERIMENTAL DETAILS FOR CHAPTER 2  
 
7.2.1 Synthesis and Characterization of Complex 58 
The hydrochloride salt of sp3-TexPEG 56 (189.8 mg, 216.2 mmol) was dissolved in 
20 ml methanol. Bismuth(III) nitrate pentahydrate (157.3 mg, 324.3 mmol, 1.5 equiv.) 
was added together with 1 ml triethylamine. The solution was stirred at 70 °C and 
gradually changed color from deep red to deep green. UV-Vis spectra were taken every 
two to four minutes (50 μL taken directly from the reaction mixture and diluted with 4 ml 
MeOH in the case of each sample). The insertion reaction was deemed complete after 34 
minutes. No further increase in the intensity of the Soret band was observed after that 
time, a finding interpreted in terms of the formation of the stable, aromatic texaphyrin 
scaffold being complete. The solvent was removed in vacuo and the residue was 
subjected to column chromatography (silica gel, eluents: first 90% dichloromethane and 
10% methanol, then 25% dichloromethane and 75% methanol). The deep green fraction 
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was collected and the solvent was removed in vacuo to give complex 58 as a deep green 
crystalline material (152.0 mg, 64%).  
UV-Vis (MeOH, 25 °C): λ [nm] = 480 (Soret-type band); 723 (Q-type band); 1H NMR 
(400 MHz, DMSO-d6, 25 °C): δ[ppm] = 1.74 (t, J = 7.2 Hz, 6H); 2.24 (q, J = 6.8 Hz, 4H); 
3.23 (s, 6H), 3.45 (m, 4H); 3.49 (s, 6H); 3.58 (m, 4H); 3.66 (m, 8H), 3.82 (m, 4H); 3.93 
(m, 8H); 4.16 (br t, J = 4 Hz, 4H); 4.95 (br t, J = 4 Hz, 2H); 9.76 (s, 2H); 10.30 (s, 2H); 
12.93 (s, 2H); 13C NMR (125 MHz, DMSO-d6, 25 °C): δ[ppm] = 4.6 (2 C); 15.4 (2 C); 
22.0 (2 C); 32.2 (2 C); 37.8 (2 C); 55.2 (2 C); 59.5 (2 C); 69.0 (2 C); 70.1 (2 C); 71.3 (2 
C); 100.1 (2 C); 116.7 (2 C); 117.1 (2 C); 118.0 (2 C); 128.4 (2 C); 150.1 (2 C); 150.9 (2 
C); 151.4 (2 C); 155.5 (2 C); low resolution MS (ESI): 1098.47 (M+, monomeric Bi(III)-
texaphyrin with axial hydroxide ligand); high resolution MS (ESI): calculated for 
C48H67N5O11Bi+1 = 1098.4641; found: 1098.46354 (C48H67N5O10Bi+1, M+); HPLC (tC18 
reverse phase column, eluents: water (1% TFA) and acetonitrile) spectrum shows ≥96% 
purity;  
 
7.2.2 Synthesis and Characterization of Complex 59 
The hydrochloride salt of sp3-TexPEG 56 (189.8 mg, 216.2 mmol) was dissolved in 
20 ml methanol. Lead(II) nitrate (107.4 mg, 324.3 mmol, 1.5 equiv.) was added together 
with 1 ml triethylamine. The solution was stirred at 70 °C and gradually changed color 
from deep red to deep green. The mixture was stirred at that temperature for two hours. 
The solvent was removed in vacuo and the residue was then subjected to column 
chromatography (silica gel, eluents: first 90% dichloromethane and 10% methanol, then 
25% dichloromethane and 75% methanol). The deep green fraction was collected and the 
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solvent was removed in vacuo to give complex 59 as a deep green crystalline material 
(109.8 mg, 47%).  
UV-Vis (MeOH, 25 °C): λ [nm] = 471 (Soret-type band); 743 (Q-type band); 1H NMR 
(400 MHz, CD3OD, 25 °C): δ[ppm] = 1.57 (m, 6 H); 2.19 (br, 4 H); 3.27 (br, 6 H), 3.30 
(m, 8 H); 3.50 (m, 4 H); 3.63 (m, 8 H); 3.74-3.95 (m, 16 H); 4.14 (br, 2H); 8.38 (s, 2 H); 
8.98 (s, 2 H); 10.92 (br, 2 H); 13C NMR (125 MHz, DMSO-d6, 25 °C): δ[ppm] = 5.8 (2 
C); 18.5 (2 C); 22.9 (2 C); 30.2 (2 C); 38.1 (2 C); 55.5 (2 C); 63.5 (2 C); 70.6 (2 C); 71.4 
(2 C); 72.6 (2 C); 98.4 (2 C); 113.3 (2 C);  114.3 (2 C); 115.6 (2 C); 128.2 (2 C); 135.1 (2 
C); 151.3 (2 C); 152.0 (2 C); 152.5 (2 C); 167.1 (2 C); low resolution MS (ESI): 1080.40 
(M+, monomeric Pb-Tx, no axial ligand); high resolution MS (ESI): calculated for 
C48H66N5O10Pb+1 = 1080.4576; found: 1080.45706 (C48H66N5O10Pb+1, M+); HPLC (tC18 
reverse phase column, eluents: water (1% TFA) and acetonitrile) spectrum shows ≥99% 
purity. 
 
 
7.2.3 Synthesis and Characterization of 60 
The hydrochloride salt of sp3-TexOMe 57 (140.6 mg, 216.2 mmol) was dissolved in 
20 ml methanol. Bismuth(III) nitrate pentahydrate (157.3 mg, 324.3 mmol, 1.5 equiv.) 
was added together with 1 ml triethylamine. The solution was stirred at 70 °C and 
gradually changed color from deep red to deep green. The mixture was stirred at that 
temperature for two hours. The solvent was removed in vacuo and the residue was then 
subjected to column chromatography (silica gel, eluents: first 95% dichloromethane and 
5% methanol, then 60% dichloromethane and 40% methanol). The deep green fraction 
was collected and the solvent was removed in vacuo to give complex 60 as a deep green 
crystalline material (129.9 mg, 72%).  
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UV-Vis (MeOH, 25 °C): λ [nm] = 479 (Soret-type band); 722 (Q-type band); 1H NMR 
(400 MHz, DMSO-d6, 25 °C): δ[ppm] = 1.74 (t, J = 7.6 Hz, 6H); 2.25 (br t, J = 7.2 Hz, 
4H); 3.16 (s, 2H), 3.51 (br s, 6H); 3.66 (t, J = 6 Hz, 4H); 3.95 (m, 6H); 4.45 (s, 6H); 9.77 
(s, 2H); 10.35 (s, 2H); 13.01 (s, 2H); 13C NMR (125 MHz, DMSO-d6, 25 °C): δ[ppm] = 
9.8 (2 C); 16.4 (2 C); 21.1 (2 C); 28.5 (2 C); 30.3 (2 C); 59.4 (2 C); 70.0 (2 C); 96.5 (2 
C); 112.4 (2 C); 116.9 (2 C); 118.0 (2 C); 133.3 (2 C); 138.2 (2 C); 144.6 (2 C); 145.5 (2 
C); 146.8 (2 C); 158.3 (2 C); low resolution MS (ESI): 834.27 (M+, monomeric Bi(III)-
texaphyrin with axial hydroxide ligand); high resolution MS (ESI): calculated for 
C36H43N5O5Bi+1 = 834.3068; found: 834.30626 (C48H67N5O10Bi+1, M+);HPLC (tC18 
reverse phase column, eluents: water (1% TFA) and acetonitrile) spectrum shows ≥98% 
purity.This complex was also characterized by X-ray diffraction analysis (see section 7.7 
and Appendix section).  
 
7.2.4 Synthesis and Characterization of Complex 61 
The hydrochloride salt of sp3-TexOMe 57 (140.6 mg, 216.2 mmol) was dissolved in 
20 ml methanol.  Lead(II) nitrate (107.4 mg, 324.3 mmol, 1.5 equiv.) was added together 
with 1 ml triethylamine. The solution was stirred at 70 °C and gradually changed color 
from deep red to deep green. The mixture was stirred at that temperature for two hours. 
The solvent was removed in vacuo and the residue was subjected to column 
chromatography (silica gel, eluents: first 95% dichloromethane and 5% methanol, then 
60% dichloromethane and 40% methanol). The deep green fraction was collected and the 
solvent was removed in vacuo to give complex 61 as a deep green crystalline material 
(123.6 mg, 70%).  
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UV-Vis (MeOH, 25 °C): λ [nm] = 479 (Soret-type band); 740 (Q-type band); 1H NMR 
(300 MHz, CD3OD, 25 °C): δ[ppm] = 1.62 (t, J = 7.2 Hz, 6 H); 2.19 (t, J = 6.8 Hz, 4 H); 
3.66-3.92 (m, 12 H), 4.56 (s, 6 H); 8.58 (s, 2 H); 9.13 (s, 2 H); 11.12 (s, 2 H); 13C NMR 
(125 MHz, DMSO-d6, 25 °C): δ[ppm] = 6.0 (2 C); 17.1 (2 C); 22.7 (2 C); 26.6 (2 C); 
32.8 (2 C); 58.3 (2 C); 66.2 (2 C); 97.2 (2 C); 108.3 (2 C); 119.5 (2 C); 120.2 (2 C); 
135.5 (2 C); 140.8 (2 C); 148.8 (2 C); 149.9 (2 C); 150.4 (2 C); 159.9 (2 C); low 
resolution MS (ESI): 816.40 (M+, monomeric Pb-Tx, no axial ligand); high resolution 
MS (ESI): calculated for C36H42N5O4Pb+1 = 816.3003; found: 816.29977 (C36H42N5O4Pb+1, 
M+); HPLC (tC18 reverse phase column, eluents: water (1% TFA) and acetonitrile) 
spectrum shows ≥98% purity. 
 
7.2.5 In Vitro Anti-Proliferative Activity of Complexes 58 (MBi) and 59 (MPb) 
The proliferation of exponential phase cultures of A2780 cells was assessed by a 
dye reduction assay and assessing the formazan product.7 Briefly, tumor cells were 
seeded in 96-well microtiter plates at 300 cells/well, respectively, and allowed to adhere 
overnight in RPMI 1640 medium supplemented with 2 mM L-glutamine, 10% heat 
inactivated fetal bovine serum, and antibiotics (200 U/cm3 penicillin and 200 μg/cm3 
streptomycin). Stock solutions of MBi 58 and MPb 59 (30% v/v methanol/H2O) were 
formulated in the indicated solvent for maximum stability and then diluted in medium for 
secondary stocks. Secondary stock solutions were serially diluted in medium and 
immediately added to wells to give the final concentrations indicated in the figures, 
whereupon plates were incubated at 37 oC under a 5% CO2 and 95% air atmosphere. 
After a total of five days, the tetrazolium dye, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT, Sigma Chemical) was added to each well, the plates 
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incubated at 37 oC, whereupon the medium was removed, the formazan dissolved in 
50 μM DMSO and absorbances measured at 560-650 nm using a microplate reader 
(Molecular Devices, Sunnyvale, CA). Absorbances were corrected for background and 
the values normalized to wells containing untreated cells to allow plate-to-plate 
comparison. The data are shown as mean inhibition of proliferation or growth as a % of 
control cells from eight to ten replicate values. Error bars represent the associated 
standard deviation.  
 
7.3 EXPERIMENTAL DETAILS FOR CHAPTER 3  
 
7.3.1 Synthesis of Double Effector Nanoparticles (GdTx-MNPs) 
 
7.3.1.1 Synthesis of Complex 62 
This is a modified protocol of the synthetic procedures described previously8: To 
a dark green solution of MGd 11 (2.29 g, 2 mmol) in a mixture of 300 ml dry 
dichloromethane and 30 ml dry THF, diispropylethylamine (1.05 cm3, 6 mmol) was 
added under argon at room temperature. Then, 4,4’-dimethoxytrityl chloride (1.7 g, 5 
mmol) was added to the solution in one portion. The solution was stirred for 8-12 hours 
at room temperature. The reaction was monitored by HPLC. Three major peaks were 
seen: MGd (unfunctionalized), DMTO-MGd 62 (monofunctionalized) and (DMTO)2-
MGd (difunctionalized) in the HPLC-spectrum. When the integrated area of the peak 
corresponding to DMTO-MGd appeared to be maximal (around 40%), the reaction was 
quenched with 10 ml of methanol. At this point, a reverse-phase tC18 cartridge column 
was used for separation, with a mixture of acetonitrile and 0.1 M buffer (pH = 4.3, 0.1 M 
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ammonium acetate and 1% glacial acetic acid in water) being used as the eluent. MGd 
eluted first from the column with 25-30% acetonitrile-buffer, DMTO-MGd 62 with 50% 
acetonitrile-buffer and the doubly protected species (DMTO)2-MGd with 70% 
acetonitrile-buffer. Compound 62 was desalted using a new tC18 column using deionized 
water. The product was eluted from the column with neat methanol and a deep green 
solid was obtained after evaporation and drying in vacuo (870 mg, 30%) 
UV-Vis (MeOH, 25°C): λ [nm] = 475 (Soret-like band); 740 (Q-type band); low 
resolution MS (ESI): 1392 (M+ - AcO); high resolution MS (ESI): calculated for 
C71H87GdN5O14 = 1391.5491; found: 1391.5502 (C71H87GdN5O14, M+ - AcO); HPLC 
(tC18 reverse phase column, eluents: water (1% TFA) and acetonitrile) spectrum shows ≥ 
94% purity.  
 
7.3.1.2 Synthesis of Complex 63 
This complex was prepared using a modified version of the synthetic procedures 
described previously8: Complex 62 (530 mg, 0.37 mmol), phthalimide (269 mg, 1.83 
mmol) and triphenylphosphine (479 mg, 1.83 mmol) were dried overnight using a 
vacuum pump. Dry DCM (50 mL, dried over calcium hydride and redistilled under 
argon) was added and to the resulting deep green solution, diethyl azodicarboxylate (287 
mg, 1.65 mmol) was added dropwise at 0 ˚C and stirred for 5 hours. The solvent was 
removed in vacuo and hydrazine (24 mg, 0.75 mmol) in 20 mL methanol were slowly 
added to the flask. The turquoise solution was stirred for 4 hours under argon. Buffer (50 
mL, pH = 4.3, 0.1 M ammonium acetate and 1% acetic acid in deionized water) was 
added and the solution was extracted with 3 x 50 mL chloroform. The organic layers 
were combined, dried over sodium sulfate and evaporated to dryness. The resulting crude 
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product was loaded onto a reverse-phase tC18 cartridge column. A mixture of acetonitrile 
and aqueous buffer was used to as the eluent. Finally, the material was subjected to 
further purification on a new tC18 column to remove excess ammonium salt. After 
evaporation of all solvents, the green solid was dissolved in 2 mL dichloromethane and 1 
mL glacial acetic acid was added. The ensuing deprotection of the hydroxyl group was 
monitored by TLC and HPLC. After approximately three hours, the spot/peak 
corresponding to the starting material could no longer be observed. Dichloromethane was 
quickly removed using a vacuum pump. The resulting brownish liquid was immediately 
poured into 50 mL of the buffer described above and the resulting green solution was 
loaded onto a tC18 column. A mixture consisting of 30% acetonitrile/70% buffer was 
used to collect the green band. A pure green solid, corresponding to complex 63, was 
obtained after removing the ammonium salt via passage through a new tC18 cartridge, 
washing with deionized water, eluting with neat methanol, and drying in vacuo (93 mg, 
21%). 
UV-Vis (MeOH, 25°C): λ [nm] = 478 (Soret-like band); 750 (Q-type band); lor 
resolution MS (ESI): 1148 (M+ - AcO); high resolution MS (ESI): calculated for 
C52H74GdN6O13 = 1148.4264; found: 1148.4232 (C71H87GdN5O14, M+ - AcO); HPLC 
(tC18 reverse phase column, eluents: water (1% TFA) and acetonitrile) spectrum shows 
≥ 97% purity. 
 
7.3.1.3 Synthesis of Zn0.4Fe2.6O4 Nanoparticles and Surface Modification 
Zinc doped iron oxide magnetic nanoparticles (Zn0.4Fe2.6O4) were prepared as 
described previously9 and redispersed in toluene. These nanoparticles were coated with a 
16 nm SiO2 shell using a modified base-catalyzed sol-gel process.10 Briefly, 
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polyoxyethylene (5) nonylphenylether (1.95 mL, 4.40 mmol, also termed Igepal CO-520 
containing 50 mol % hydrophilic groups) and 2.5 mg of the nanoparticles were dispersed 
in cyclohexane and subject to vortex mixing. Treatment with 30% aqueous ammonium 
hydroxide (0.26 mL) followed by tetraethyl orthosilicate (0.46 mL, 2.04 mmol, TEOS) 
provides silica coated nanoparticles. With these in hand, 3-aminopropyltrimethoxysilane 
(12.5 μL, 0.07 mmol, APTMS) was added to introduce the amine functional group. After 
72 hours of aging at room temperature, the resulting amine functionalized nanoparticles 
were precipitated via addition of methanol. After collecting by centrifugation, the 
precipitates were treated with succinic anhydride (2.5 mg, 0.10 mmol, SA) in dimethyl 
sulfoxide (DMSO) and stirred for 24 hours. After filtration and rinsing, the carboxylate 
functionalized nanoparticles were redispersed in DMSO.  
 
7.3.1.4 Synthesis of Gadolinium-Texaphyrin - Zn0.4Fe2.6O4 Magnetic Nanoparticles 
(GdTx-MNPs) 
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (50 mM, EDC) 
and N-hydroxysulfosuccinimide (5 mM, Sulfo-NHS) were added to a solution of 
carboxylated Zn0.4Fe2.6O4 nanoparticles in DMSO. Then, 3500 molecular weight 
poly(ethylene glycol) bis(amine) (50 mg, 0.03 mmol, PEG) was added to the reaction 
mixture. After stirring for two hours at room temperature, the PEGylated Zn0.4Fe2.6O4 
nanoparticles (MNPs) were isolated by centrifugation and redispersed in DMSO. Next, 
complex 63 (34.42 mg, 0.03 mmol, GdTx) and disuccinimidyl suberate (10 mg, 0.03 
mmol, DSS) in anhydrous N, N-dimethyl-formamide (DMF) were stirred for four hours 
under argon. The above MNPs were then added to the mixture. After four hours, the 
GdTx-MNPs were precipitated by addition of acetone, and redispersed in DMSO. The 
GdTx-MNPs (as a dispersion in DMSO) were then transferred to an aqueous solution.  
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7.3.2 T1 and T2 MR Imaging of GdTx-MNPs, GdTx, and MNPs  
MR imaging of the GdTx-MNPs of this study was performed using a 1.5 Tesla 
MRI instrument (Philips, Germany). T1 scans were obtained using a standard sequence 
(TR = 625 ms, TE = 10 ms, FOV = 75 mm, matrix = 256 × 256, slice thickness = 0.7 
mm, acquisition number = 1). T2 scans were obtained by using fast spin-echo sequence 
(TR = 4000 ms, TE = 80 ms, FOV = 75 mm, matrix = 256 × 256, slice thickness = 0.7 
mm, acquisition number = 1).  
 
7.3.3 Measurement of Specific Loss Power 
Magnetic heating of aqueous suspensions of GdTx-MNPs with a concentration of 0.2 
mg/mL was performed under an alternating magnetic field (500 kHz at 30 kA/m, AC 
magnetic field), provided by a high-radiofrequency heating machine (HF 10K, Taeyang 
System Co., Korea). The temperature change was monitored by fiber optic thermometer 
(M602, Lumasense Technologies Inc., USA). The specific loss power (SLP) values 
(watt/g) for the samples are calculated using the following equation, where dT/dt is the 
initial slope of the graph (temperature change vs. time) in Figure 7.1.10          
 
                                     
C: volumetric specific heat capacity of the sample solution (JL-1K-1) 
Vs: sample volume (L) 
m: mass of magnetic material in the sample (g) 
dT/dt: initial slope of the change in temperature versus time curve (Ks-1) 
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Figure 7.1:   Temperature profile of GdTx-MNPs and Feridex subjected to an AC 
magnetic field. Each black linear line indicates the initial slope of GdTx-
MNPs (red) or Feridex (blue). The fourfold increase in the initial slope for 
the GdTx-MNP experiments (0.12) compares favorably to the one 
produced by Feridex (0.03). The SLP values were 471 Wg-1 and 115 Wg-1 
for GdTx-MNPs and Feridex, respectively. 
 
7.3.4 Cytotoxicity Testing of MNPs 
The breast cancer cells, MDA-MB-231, were cultured in culture media composed 
of minimal essential medium (MEM) supplemented with 10% fetal bovine serum (FBS), 
25 mM HEPES buffer, and penicillin/streptomycin at 37 °C in a 5% CO2 and 95% air 
atmosphere. The cytotoxicity of the MNPs was assessed using a cell counting kit-8 
(CCK-8, Dojindo Molecular Technology). 1 × 105 MDA-MB-231 cells were seeded in a 
24-well plate and incubated overnight. The cells were then incubated with 200 μL of a 
fresh media containing 12.5 – 300 μg/mL concentrations of MNPs for 24 hours. After the 
solution was replaced with a fresh media (OPTI-MEM), cells were incubated with 10 μL 
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of the CCK-8 solution for each well for two hours. Then, the absorbance of each sample 
was measured at 450 nm.  
 
                    
Figure 7.2:   In vitro antiproliferative effect of MNPs on the MDA-MB-231 cancer cell 
line. The results provide support for the assumption that the inherent 
viability of these cells is not perturbed by the MNPs even at high (300 
µg/ml) concentrations and in the absence of an applied magnetic field.  
 
7.3.5 Cytotoxicity Testing of GdTx 63 
The experiment was carried out in the same way described in section 3.5.4 but 
using complex 63 instead of the MNPs.  
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Figure 7.3:   Anticancer effect of compound 63. Note the decrease in cell viability as 
the concentration of compound 63 increases. At concentrations less than 
25 µM, no cell death is observed. 
 
7.3.6 Detection of Reactive Oxygen Species (ROS) in MDA-MB-231  
ROS production was measured in live cells by monitoring the oxidation of 2′,7′-
dichlorofluorescein diacetate (DCFA, Molecular Probes) and its ensuing conversion to 
2′,7′-dichlorofluorescein (DCF).11 In these experiments, 5 x 104 MDA-MB-231 cells/well 
were incubated in MEM supplemented with 10% FBS containing 0.2 mg/mL GdTx-
MNPs and 100 μM ascorbate for 24 hours. After washing several times in PBS, the cells 
were incubated in 4 μM DCFA for 15 minutes at 37 °C in the dark. Cells were washed 
with PBS and imaged immediately using a FV1000 confocal microscope (Olympus). 
 
7.3.7 Monitoring of Apoptosis Induced by Mild Hyperthermia in MDA-MB-231 
To monitor the presumed apoptosis, the Annexin V-FITC Apoptosis Detection 
Kit (Biovision) was used. Here, MDA-MB-231 cells were incubated with 0.2 mg/mL of 
GdTx-MNPs for five hours and then subjected to an AC magnetic field for 30 min. At six 
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hours and 24 hours post treatment, 5 μL of Annexin V and PI in binding buffer were 
added to the cells. The treated cells were fixed with 4% paraformaldehyde at 4 oC for 30 
minutes and washed twice with cold PBS solution. At this junction, a mounting solution 
containing DAPI (4',6-diamidino-2-phenylindole) was added. The cells were observed 
using a FV1000 confocal microscope (Olympus). 
 
7.3.8 Intracellular T1-, T2- MR images of GdTx-MNPs. 
MDA-MB-231 cells were incubated with GdTx-MNPs for 24 hours and their T1-, 
T2-weighted MR images were obtained. Untreated cells served as control. Cells were 
incubated in OPTI-MEM containing 40 μg/mL of GdTx-MNPs and 1.6 μg/mL of poly L-
lysine as a transfection agent for 24 hours. After rinsing several times with cold 
Phosphate buffered saline (PBS), the cells were fixed with 4% formaldehyde solution for 
30 min at 4 oC. After the cells were washed with cold PBS and resuspension in PBS, an 
aliquot of 1 x 105 cells was placed in a PCR tube. MR imaging of GdTx-MNPs incubated 
cells was performed by using a 1.5 Tesla MRI. T1- and T2-weighted MR scans were 
obtained by using the same method described in section 7.3.2 (vide supra). 
 
 
 
 
 
 
 
 
                       
Figure 7.4:  T1- and T2-weighted MR images of MDA-MB-231 cells 
incubated with GdTx-MNPs.  
 139 
7.4 EXPERIMENTAL DETAILS FOR CHAPTER 4  
 
7.4.1 Synthesis and Characterization of Compound 67 
1,2-dimethoxy-4,5-dinitrobenzene 66 (1 g, 4.38 mmol) was dissolved in 10 mL 
methanol and placed in a hydrogenation flask. The solution was purged with nitrogen for 
five minutes and palladium on activated carbon (10%, 0.1 g) was added. The mixture was 
degassed and allowed to react with hydrogen gas at 100 psi with agitation for 18 hours, 
filtered under Schlenk conditions through a minimal pad of Celite, and added instantly to 
a solution of 22 (2.11 g, 4.38 mmol) in 15 mL methanol under nitrogen at 70 ºC. 
Aqueous hydrochloric acid was added (2 mL, 0.5 M) and the resulting deep red reaction 
mixture was stirred for four hours. Next, gadolinium acetate tetrahydrate (2.67 g, 6.57 
mmol, 1.5 equiv) was added together with 3 ml triethylamine and the solution was stirred 
at 70 °C for 16 hours, during which time the solution gradually changed color from deep 
red to deep green. The solvent was removed in vacuo and the residue was subjected to 
column chromatography (silica gel). To remove apolar impurities, the column was eluted 
with a mixture of 95% dichloromethane and 5% methanol. The product slowly starts to 
elute when a mixture of 60% dichloromethane and 40% methanol is used as the eluent. 
The deep green fraction isolated using this eluent mixture was collected and the solvent 
was removed in vacuo to give GdTx 67 as a deep green crystalline material (1.63 g, 
42%). UV-Vis (MeOH, 25 °C): λmax = 470 (Soret-type band); 739 (Q-type band); low 
resolution MS (ESI in MeOH): 797.25 (M+ - 2OAc + OMe), 825.42 (M+ - OAc); high 
resolution MS (ESI in MeOH): calculated for [C38H45N5O6Gd+1]+ = 825.2611; found: 
825.2621 ([C38H45N5O6Gd+1]+; M+ - OAc); HPLC (tC18 reverse phase column, eluents: 
water (1% TFA) and acetonitrile) spectrum shows ≥98% purity. 
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7.4.2 Formulation and Stabilization of GdTx-Polymer Micelles 
For targeted formulations, 5% of the targeted polymer and 95% of the untargeted 
polymer were used. The triblock polymer (750 mg) was dissolved in water (150 mL) at a 
concentration of 5 mg/mL and stirred with slight heating until fully dissolved. After 
cooling to room temperature, the polymer solution was placed in a sheer mixer and a 
solution of GdTx 67 (0.5% w/w in 380 μL dimethyl sulfoxide) was added. The resulting 
solution was then passed through a microfluidizer (Microfluidics, M-110Y) at 23,000 
PSI, filtered through a 0.22 μm Steriflip-GP Filter Unit (Millipore) and lyophilized.   
For stabilized formulations, the micelles were subjected to an Fe(III)-mediated 
crosslinking reaction.12 FeCl3 was prepared at a concentration of 1.35 g/mL in 20 mM 
Tris-Cl (pH = 7.4). The targeted and untargeted micelles were then dissolved in the 
Fe(III)-tris solution at a concentration of 20 mg/mL and the solution was adjusted to pH = 
8 through dropwise addition of 0.1 – 1 M aqueous NaOH. The crosslinking reaction was 
stirred for 12 hours and the contents of the reaction vessel were then lyophilized.  
 
7.4.3 Cell Culture 
HCT116 (Human colon carcinoma) cells overexpressing hMC1R were engineered 
at Moffitt Cancer Center, Tampa, FL. HCT116 cells were transfected with the pCMV6-
Entry Vector (Origene, RC 203218) using the Fugene 6 transfection reagent (Roche, 
1814-443). Transfected cells were grown in a selection media containing 0.4 mg/ml 
geneticin (Life Technologies, 11811-031) and tested for the hMC1R cell surface 
expression by saturation binding assay.13 Cells were maintained under standard 
conditions (37 °C and 5% CO2) and were grown in Dulbecco’s modified Eagle medium 
(DMEM) supplemented with 10% FBS and 5% penicillin/streptomycin. Geneticin 
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(G418S, 0.8%) was added to the media to ensure proper selection. Expression of hMC1R 
was verified through immunohistochemistry (Figure 7.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.4.4 Europium Binding Assays 
Europium binding assays were conducted as previously published.14, 15 
 
7.4.5 In Vivo Murine Tumor Models 
All animal experiments were carried out at The Moffitt Cancer Center (Tampa, 
FL). The studies were approved by the institution review board and conformed by 
guidelines on the care and use of animals in research.  HCT116/hMC1R-expressing 
tumor models were studied in female SCID/beige mice obtained from Harlan 
                                         
Figure 7.5:  In vivo characterization of MC1R surface expression for 
HCT116/MC1R cells. (a-b) IHC staining of representative left (a) 
and right (b) tumors from a SCID mouse.  
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Laboratories at 6-8 weeks of age. HCT116/hMC1R cells were injected at concentrations 
of 3 X 106 – 10 X 106 cells per 0.1 mL of phosphate-buffered saline. Tumor volume 
measurements were made bi-weekly and calculated by multiplying the length by the 
width squared and dividing by two. Final volume measurements were determined through 
region of interest (ROI) analysis on the MRI.  
 
7.4.6 MRI Imaging and Analysis 
All imaging was completed at The Moffitt Imaging Center on a 7 Tesla, 30 cm 
horizontal bore Agilent magnetic resonance imaging (MRI) spectrometer ASR310 
(Agilent Life Sciences Technologies, Santa Clara, CA). Once the tumors in the animals 
reached an average of ~ 500 mm3, the animals were pair-matched by tumor size and 
sorted into four groups to receive the following micelles: TG-XL; UT-XL; T-UXL; or 
UT-UXL. Each animal was imaged the day before micelle injection for “pre” images. 
The following morning, each animal was individually administered 12 μmol/kg GdTx (as 
GdTx micelles) dissolved in 200 uL saline, via tail vein injection, and the time of 
injection was noted. Follow-up MRI images were taken at one hour, 4 hours, 12 hours, 24 
hours and 48 hours post-injection of the micelles. 
All animals were sedated using isoflurane and remained under anesthesia for the 
duration of the imaging. Animals were kept at body temperature (~37 ºC) using a warm 
air blower; the temperature of the air was adjusted to maintain the body temperature and 
was monitored using a fiber optic rectal probe. SCOUT images were taken to determine 
animal position within the magnet and setup the slices for the T1 weighted spin echo 
multi slice (SEMS) images. The SEMS images were taken as coronal-90 images (read 
direction along the X-axis, phase-encode along the Z-axis), with data matrix of 128 X 
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128 and a FOV of 40 mm (read) X 90 mm (phase); 15 one-mm thick slices were taken 
with a 0.5 mm gap between slices; the TR was 180 ms, and TE was 8.62 ms; there were 
eight averages taken for each image, resulting in a total scan time of about three minutes 
per SEMS image. 
Images were processed using MATLAB (Mathworks, Natick, MA) to draw 
regions of interest (ROI) in the tumors, kidney, liver and thigh muscle over multiple 
slices for each mouse at each time point. All intensities for each area of interest were 
averaged to determine a mean intensity. The mean intensity of each area was then 
normalized to the mean intensity of the thigh to generate a normalized intensity (NI): 
              
A percent change value was then calculated by comparing each normalized time 
point after injection to the normalized pre-injection intensity mean:   
                    
Since the right and left tumors are histologically equivalent as judged by 
immunohistochemistry (Figure 7.5), the % change values for all tumors were averaged to 
obtain an “average tumor % change” at time points 1 – 24 hours. Percent change values 
were also averaged for R and L kidney to obtain an “average kidney % change” at time 
points 1 – 24 hours. 
 
7.4.7 GdTx Micelle Stability 
Crosslinked GdTx micelles were dissolved in PBS at the critical micelle 
concentration (CMC, 0.02 mg/mL) and dialyzed for six hours against PBS (pH = 8 and 
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pH = 3). HPLC analyses of the GdTx micelles pre- and post-dialysis indicated that the 
crosslinked micelles retained >95% of the encapsulated GdTx after dialysis at pH = 8 and 
50% of the encapsulated GdTx at pH = 3. 
 
7.4.8 Competitive Binding Assays 
Time-resolved lanthanide fluorescence competitive binding assays14, 15 were 
performed in an effort to optimize ligand loading for maximal avidity. In these assays, 
increasing concentrations of micelles were measured for their ability to displace 
competitively displace europium-labeled NDP-α-MSH 69. The remaining europium was 
then measured using time resolved fluorescence. As gadolinium(III) cations can 
potentially interfere with the lanthanide-based TRF binding assays,14 unloaded triblock 
polymer micelles (i.e., free of GdTx) targeted with 2.5% to 30% ligand 69 by weight 
loading were used. Micelles stabilized with Fe(III) crosslinking had the highest binding 
avidity at 5% ligand loading, as reflected in the lowest Ki (1.49 ± 0.12 nM; n = 4). It was 
also observed that XL micelles had significantly higher binding avidities at all ligand 
loading levels (p < 0.001). In vitro assays were also conducted with ligand 68-targeted 
XL and UXL micelles at 5% ligand loading, as well as 68-targeted monomers.15 The Ki of 
the 68-targeted XL micelles (2.9 ± 0.42 nM; n = 4) was four times lower than the 
corresponding UXL micelles (12 ± 2.6 nM; n = 4).15 Control assays with untargeted 
micelles (XL and UXL) and untargeted polymer revealed no detectable interaction with 
the receptor. 
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7.4.9 In Vitro MR Imaging 
In vitro imaging of GdTx micelle phantoms was completed using a SCOUT 
image for slice selection, and a multiple TR SEMS (TR = repetition time, SEMS = 
structural equation modeling) image was performed in order to calculate T1 values. The 
TR calculation sequence consisted of TR values of 20, 10.99, 6.03, 3.31, 1.82, 1.00, 0.55, 
0.30, 0.17, 0.09 and 0.05 s; the echo time (TE) was 8.62 ms, the data matrix was 128 x 
128, 4 averages, two dummy scans, field of view (FOV) was 80 mm x 40 mm or 40 mm 
x 90 mm and the slice thickness was 1 - 2 mm (depending on the phantom). The T1 
values were calculated using the VnmrJ software (Agilent Life Sciences Technologies, 
Santa Clara, CA), and values were verified using MATLAB (Mathworks, Natick, MA). 
To determine the MRI relaxivity of GdTx labeled micelles, phantoms were 
constructed in which each sample (T-XL, T-UXL, UT-XL, UT-UXL micelles) was 
prepared at the same GdTx concentration (0.01 mg/mL). T1 values were determined by 
progressive saturation relaxation measurements using an Agilent seven Tesla small 
animal MRI spectrometer using a spin echo sequence, SEMS and T1 values for each 
cohort of samples were averaged. There was no apparent T1 effect attributable to the 
different micelle formulations, with coefficients of variation (CVs) ranging from 0.02 to 
0.1 for each row of T1 measurements. The phantom studies served to confirm the 
expectation that the observed T1 values are positively correlated with GdTx weight 
loading, with 0.5% w/w encapsulated GdTx providing the lowest mean T1 value (1.6 s). 
 
7.4.10 In Vivo MR Imaging 
Severe combined immunodeficiency (SCID) mice with subcutaneous MC1R-
expressing tumors were injected with 0.5% w/w GdTx micelles (T-XL, T-UXL, UT-XL, 
UT-UXL) via tail vein at a dose of 12 μmol GdTx/kg. Targeted micelles (T-UXL and T-
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XL) were formulated with 5% (w/w) of 69-targeted polymer. Using an Agilent seven 
Tesla small animal MRI spectrometer, coronal T1-weighted spin echo multi slice (SEMS) 
images were acquired of each animal prior to and 1, 4, 12, 24 and 48 hours after injection 
of the micelles. Following imaging, MC1R expression was confirmed in each tumor by 
immunohistochemistry staining (Figure 7.5).  
To quantify enhancement due to tumor uptake of the micelles, intensity 
histograms for right (R) and left (L) whole tumors, kidneys and livers were prepared 
using a MATLAB program (Mathworks) by drawing a region of interest (ROI) across all 
applicable slices for each time point. A mean intensity value was then calculated and 
normalized to thigh muscle. Figure 4.2 (section 4.3) shows the tumor uptake data for each 
0.5% GdTx micelle group in the tumor.  
The T-XL micelle group is the only one to show significant contrast enhancement 
in the tumors, with a peak accumulation occurring at 24 hours. The increased 
enhancement in the tumors of animals injected with the 0.5% GdTx T-XL micelles can 
be visualized in the post-injection MR images relative to tumors in all other animals 
 
Figure 7.6:  Clearance data for GdTx as inferred from contrast enhancement data 
recorded in the kidney and liver. All groups contained three mice except 
where noted.  
 ┴One mouse expired between the 24 hours and 48 hours time point.  
 ┼One mouse expired upon injection of the micelle agent.  
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injected with the control formulation (UT-XL, T-UXL, UT-UXL). Again, no other 
micelle group displayed visible tumor uptake. The contrast enhancement for the T-XL 
micelles peaked in the kidneys at four hours and steadily decreased thereafter, whereas 
enhancement in the liver peaked at one hour (Figure 7.6).  
To test whether the enhancement observed in the 0.5% GdTx, T-XL tumors was 
statistically different from the other groups, a one-way ANOVA analysis (Dunnett’s 
Multiple Comparison Test) was carried out. While no significant difference was observed 
among the groups at one hour, the T-XL group was statistically different from all other 
groups at four hours to 48 hours (p < 0.001 for 4  – 24 hours; p < 0.05 at 48 hours). 
Additional analyses using the Student’s t-test revealed that there are no statistical 
differences among the control groups (UT-XL, T-UXL or UT-UXL) at any time point.  
 
7.5 EXPERIMENTAL DETAILS FOR CHAPTER 5  
 
7.5.1 Synthesis of Tripyrrane Precursor 83 
A mixture of phenanthrolinopyrrole 80 (250 mg, 1.14 mmol) and benzyl 5-
(acetoxymethyl)-4-(3-methoxy-3-oxopropyl)-3-methyl-1H-pyrrole-2-carboxylate 14 (894 
mg, 2.39 mmol) was dissolved in 2-propanol (5 mL) and glacial acetic acid (5 mL). The 
mixture was heated at reflx under nitrogen overnight. The solvents were evaporated off 
under reduced pressure. Repeated recrystallization from triethylamine (10 mL) and 
ethanol (20 mL) yielded the tripyrrane (781 mg, 81%) as a yellow powder. 
1H NMR (400 MHz, DMSO-d6, 25 °C): δ[ppm] = 1.74 (t, J = 7.2 Hz, 4H); 2.10 (s, 6H); 
2.25 (t, J = 7.3 Hz, 4H); 4.47 (s, 4H); 5.24 (s, 4H); 7.31-7.45 (m, 10H); 8.40 (d, J = 7.6, 
2H); 8.67 (d, J = 4.4, 2H); 11.41 (s, 2H);  13C NMR (125 MHz, DMSO-d6, 25 °C): 
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δ[ppm] = 10.8 (2 C); 19.8 (2 C); 23.0 (2 C); 35.1 (2 C); 52.0 (2 C); 65.4 (2 C); 117.0 (2 
C); 119.5 (2 C); 121.4 (2 C); 125.9 (2 C); 127.3 (2 C); 128.0 (4 C); 129.7 (4 C); 130.6 (2 
C); 131.1 (2 C); 132.8 (2 C); 135.6 (2 C); 136.1 (2 C); 144.5 (2 C); 150.2 (2 C); 161.4 ( 2 
C); 173.5 (2 C); low resolution MS (EI): 846.3 (M+ + H); high resolution MS (ESI): 
calculated for C50H47N5O8+1 = 845.3425; found: 846.3426 (C50H47N5O8, M+ + H); 
 
7.5.2 Synthesis of Tripyrrane Precursor 86 
A mixture of phenanthrolinopyrrole 80 (250 mg, 1.14 mmol) and tert-butyl 5-
(acetoxymethyl)-4-(3-methoxy-3-oxopropyl)-3-methyl-1H-pyrrole-2-carboxylate 85 (811 
mg, 2.39 mmol) was dissolved in 2-propanol (5 mL) and glacial acetic acid (5 mL). The 
mixture was heated at reflux under nitrogen overnight. The solvents were evaporated off 
under reduced pressure. Repeated recrystallization from triethylamine (10 mL) and 
ethanol (20 mL) yielded the tripyrrane (594 mg, 67%) as a yellow powder. 
1H NMR (400 MHz, DMSO-d6, 25 °C): δ[ppm] = 1.44 (s, 18H); 2.21 (s, 6H); 2.40 (t, J = 
7.2 Hz, 4H); 2.67 (t, J = 7.1 Hz, 4H); 3.53 (s, 6H); 4.45 (s, 4H); 7.42-7.45 (q, 2H); 8.23 
(d, J = 8 Hz, 2H); 9.06 (br, 3H); 13C NMR (125 MHz, DMSO-d6, 25 °C): δ[ppm] = 10.6 
(2 C); 19.6 (2 C); 22.9 (2 C); 29.2 (6C); 35.0 (2 C); 51.9 (2 C); 82.2 (2 C); 119.5 (2 C); 
121.5 (2 C); 125.3 (2 C); 125.6 (2 C); 126.7 (4 C); 130.4 (4 C); 132.6 (2 C); 136.1 (2 C); 
144.1 (2 C); 150.0 (2 C); 166.1 (2 C); 173.7 (2 C); low resolution MS (EI): 778.4 (M+ + 
H); high resolution MS (ESI): calculated for C44H51N5O8+1 = 777.3738; found: 778.3740 
(C50H47N5O8, M+ + H); 
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7.5.3 Synthesis of 1,10-Phenanthroline Linked Sapphyrin 87 
Diformyl-ß,ß,ß,ß-tetramethylbipyrrole 77 was synthesized according to published 
procedures.16  
The tripyrrane precursor 86 (200 mg, 0.26 mmol) was dissolved in neat 
trifluoroacetic acid (10 mL) and stirred under nitrogen for 15 minutes at 120 ºC. The 
reaction mixture was diluted with 100 mL dry dichloromethane. Then, diformyl-ß,ß,ß,ß-
tetramethylbipyrrole 77 (62.81 mg, 0.26 mmol) was added in one portion and the 
resulting mixture was stirred under nitrogen for four hours at room temperature. Air was 
bubbled through the reaction mixture for 10 minutes and the resulting deep green solution 
was stirred for an additional 18 hours. After removal of the solvents in vacuo, the 
resulting green material was redissolved in ethanol. One drop of concentrated sulfuric 
acid was added and the reaction mixture was heated at reflux for two hours. All solvents 
were removed under reduced pressure. Column chromatography (neutral alumina, 95% 
chloroform, 5% methanol) afforded compound 87 as a blue-green powder with a metallic 
luster (122 mg, 58%). 
1H NMR (400 MHz, CDCl3, 25 °C): δ[ppm] = 1.23 (t, J = 14.8 Hz, 6H); 2.11 (s, 6H); 
2.23 (s, 6H); 2.47 (t, J = 7.5 Hz, 4H); 2.88 (t, J = 7.5 Hz, 4H); 4.27 (q, J = 7.2 Hz, 4H); 
8.43 (br, 2H); 9.75 (s, 2H); 9.80 (br s, 2H); 10.2-10.5 (br, 3H); 13C NMR (125 MHz, 
DMSO-d6, 25 °C): δ[ppm] = 9.2 (2 C); 11.1 (2 C); 11.8 (2 C); 14.2 (2 C); 22.2 (2 C); 
36.6 (2C); 62.0 (2 C); 85.7 (2 C); 115.2 (2 C); 120.5 (2 C); 121.6 (2 C); 126.7 (2 C); 
127.2 (2 C); 126.7 (4 C); 128.6 (2 C); 133.1 (2 C); 136.4 (2 C); 144.3 (2 C); 148.2 (2 C); 
148.4 (2 C); 149.7 (2 C); 151.2 (2 C); 173.4 (2 C); low resolution MS (EI): 812.4 (M+ + 
H); high resolution MS (ESI): calculated for C50H49N7O4+1 = 811.3846; found: 811.3851 
(C50H49N7O4, M+1); 
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7.5.4 Synthesis of [Ru(phen)2(phenanthroline-sapphyrin)(NO3)2] Complex 89 
Compound 87 (50 mg, 61.6 mmol) was dissolved in ethanol (50 mL). 
Ru(phen)2Cl2 8817 (32.8 mg, 61.6 mmol) was added together with silver nitrate (21 mg, 
123.2 mmol). The resulting mixture was heated to reflux under nitrogen for 18 hours. The 
solvents were removed in vacuo and the resulting green-brown solid was subjected to 
column chromatography (neutral alumina, 98% chloroform, 2% methanol) to afford 89 as 
a green-brown solid that appears orange in solution (86 mg, quantitative). 
1H NMR (400 MHz, CDCl3, 25 °C): δ[ppm] = 1.24 (t, J = 14.7 Hz, 6H); 2.12 (s, 6H); 
2.24 (s, 6H); 2.49 (t, J = 7.6 Hz, 4H); 2.90 (t, J = 7.5 Hz, 4H); 4.29 (q, J = 7.3 Hz, 4H); 
4.58 (br, 4H); 8.0-8.2 (br, 6H); 8.28 (br, 4H); 8.6-8.8 (br, 6H); 8.89 (br, 6H); 10.95 (br, 
3H); 13C NMR (125 MHz, DMSO-d6, 25 °C): δ[ppm] = 9.3 (2 C); 11.2 (2 C); 11.9 (2 C); 
14.3 (2 C); 22.4 (2 C); 36.7 (2C); 62.2 (2 C); 85.9 (2 C); 115.4 (2 C); 120.7 (2 C); 121.6 
(8 C); 126.3 (2 C); 127.5 (4 C); 129.7 (4 C); 133.0 (2 C); 134.3 (2 C); 136.6 (8 C); 148.2 
(6 C); 148.8 (6 C); 151.8 (2 C); 149.7 (2 C); 173.5 (2 C); low resolution MS (EI): 636.7 
(M++); high resolution MS (ESI): calculated for C74H65N11O4Ru, M++ = 1273.4492 
(636.7246); found: 636.7137 (C74H65N11O4Ru, M++); 
 
7.6 EXPERIMENTAL DETAILS FOR CHAPTER 6  
 
7.6.1 Synthesis of Benzobipyrrole 97 
3,6-Diformylbenzobipyrrole 10118 (500 mg, 2.36 mmol) was dissolved in ethylene 
glycol (30 mL). Potassium hydroxide (1.06 g, 18.89 mmol) and hydrazine hydrate (945 
mg, 18.89 mmol) were added and the resulting mixture was heated to reflux under 
nitrogen for two hours at 180 ºC. The brownish solution was poured into ice water (500 
 151 
mL) and the precipitates were filtered off, washed multiple times with distilled water and 
dried in vacuo. The product was obtained as off-white prisms (391.3 mg, 90%) that 
quickly decompose upon standing. 
1H NMR (400 MHz, DMSO-d6, 25 oC): δ[ppm] = 10.25 (s, 2H); 7.14 (s, 2H); 6.97 (m, 
2H); 2.31 (s, 6H); 13C NMR (125 MHz, DMSO-d6): δ[ppm] = 10.21 (2 C); 110.7 (2 C); 
111.04 (2 C); 119.24 (2 C); 123.36 (2 C); 123.60 (2 C); low resolution MS (EI): 185.1 
(M+ + H); high resolution MS (ESI): calculated for C12H12N2+1 = 184.2371; found: 
184.2374 (C12H12N4, M+); 
 
7.6.2 Synthesis of Benzorosarin 96 
Benzobipyrrole 97 (391.3 mg, 2.12 mmol) was dissolved in dry dichloromethane 
(600 mL). 4-tert-butyl benzaldehyde (343.9 mg, 2.12 mmol) was added together with 
trifluoroacetic acid (TFA, 0.25 mL). The mixture was stirred under nitrogen for 18 hours 
at room temperature. Then, 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (DDQ, 1.44 g, 
6.36 mmol) was added and the reaction mixture was stirred for an additional two hours at 
room temperature. The reaction was stopped by addition of triethylamine (0.27 mL, 1.94 
mmol). Then, the mixture was combined with 5% sodium hydroxide solution (100 mL) 
and extracted with CH2Cl2. (3 x 50 mL). The combined organic layers were dried over 
magnesium sulfate, filtered and the solvent was removed in vacuo. The remaining solid 
was purified by column chromatography (silica gel, 90% dichloromethane, 9% methanol, 
1% triethylamine). The blue fraction was collected and repeated column chromatography 
was necessary in order to obtain reasonably pure product. Analytically pure product was 
obtained using preparative TLC (silica gel, 90% dichloromethane, 9% methanol, 1% 
triethylamine). The compound should be stored in solution (99% dry chloroform, 1% dry 
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triethylamine). If stored as a solid, protonation and eventually decomposition reactions 
can be observed (166 mg, 8%).  
UV-Vis (CHCl3, 25 °C): λ [nm] = 522 (broad); 1H NMR (400 MHz, CDCl3 -40 °C): 
δ[ppm] = 1.31 (s, 18H); 1.58 (s, 27H), 7.36 (d, J = 7.6 Hz, 6H); 7.55 (s, J = 7.8 Hz, 6H); 
7.82 (d, J = 7.7 Hz, 6H); 24.95 (br s, 3H); 13C NMR (125 MHz, CDCl3, 25 °C): δ[ppm] = 
12.7 (6 C); 32.5 (9 C); 34.1 (3 C); 113.2 (6 C); 121.3 (6 C); 122.0 (6 C); 123.6 (6 C); 
125.5 (6 C); 129.1 (6 C); 130.1 (3 C); 132.0 (3 C); 140.2 (6 C); 156.6 (3 C); low 
resolution MS (MALDI): 979.6 (M+ + H); high resolution MS (MALDI): calculated for 
C69H66N6+1 = 978.5349; found: 979.5453 (C69H66N6 + H+); 
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7.7 X-RAY EXPERIMENTAL 
 
7.7.1 General Procedures 
Details of crystal data, data collection and structure refinement are listed in the 
appendix section of this dissertation. Data reduction were performed using the Rigaku 
Americas Corporation’s Crystal Clear version 1.40.19 All structures were solved by direct 
methods using SIR9720 and refined by full-matrix least-squares on F2 with anisotropic 
displacement parameters for the non-H atoms using SHELXL-97.21 The hydrogen atoms 
on carbon atoms were calculated in ideal positions with isotropic displacement 
parameters set to 1.2 x Ueq of the attached atom (1.5 x Ueq for methyl hydrogen atoms).  
The function, Σw(|Fo|2 - |Fc|2)2, was minimized, where w = 1/[(s(Fo))2 + (0.0789*P)2 + 
(0.8963*P)] and P = (|Fo|2 + 2|Fc|2)/3.  Rw(F2) refined to 0.134, with R(F) equal to 
0.0479 and a goodness of fit, S = 1.094.  Definitions used for calculating R(F), Rw(F2) 
and the goodness of fit, S, can be found in the reference section.22 The data for each 
structure was checked for secondary extinction effects but no corrections was necessary. 
Neutral atom scattering factors and values used to calculate the linear absorption 
coefficient are from the International Tables for X-ray Crystallography (1992).23 Tables 
summarizing the crystallographic data along with figures for all structure are included in 
the appendix section of this dissertation. All figures herein were generated using 
SHELXTL/PC.24  
 
7.7.2 X-ray Experimental for Complex 60 
Crystals grew as small, dark green prisms by slow evaporation from methanol. 
The data crystal had approximate dimensions; 0.18 x 0.13 x 0.04 mm. The data were 
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collected on a Rigaku AFC12 diffractometer with a Saturn 724+ CCD using a graphite 
monochromator with MoKa radiation (λ = 0.71069 Å). A total of 736 frames of data 
were collected using w-scans with a scan range of 0.5° and a counting time of 40 seconds 
per frame. The data were collected at 100 K using a Rigaku XStream low temperature 
device.  
 
7.7.3 X-ray Experimental for Complex 67(2NO3) 
Crystals suitable for X-ray diffraction were obtained by dissolving GdTx (2 mg, 
2.26 µmol) in 1 mL methanol. Sodium nitrate (0.2 mg, 4 equiv) was added and the 
solution was heated to reflux at 60 °C for 24 hours. At this point, 0.25 mL chloroform 
was added and the solution was placed in a vial and diethyl ether was allowed to slowly 
diffuse into the solution at 5 °C.  
The data crystal had approximate dimensions: 0.23 x 0.07 x 0.07 mm. The data 
were collected on a Nonius Kappa CCD diffractometer using a graphite monochromator 
with MoKa radiation (λ = 0.71073 Å). A total of 384 frames of data were collected using 
ω-scans with a scan range of 1.2° and a counting time of 144 seconds per frame. The data 
were collected at 153 K using an Oxford Cryostream low temperature device.  
 
7.7.4 X-ray Experimental for Compound 83 
Crystals grew as yellow prisms by slow diffusion of hexanes into a solution of 
compound 83 in acetone.  The data crystal had approximate dimensions; 0.08 x 0.08 x 
0.03 mm.  The data were collected on a Nonius Kappa CCD diffractometer using a 
graphite monochromator with MoKα radiation (λ = 0.71073Å).  A total of 208 frames of 
data were collected using ω-scans with a scan range of 2° and a counting time of 268 
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seconds per frame.  The data were collected at 153 K using an Oxford Cryostream low 
temperature device.   
A molecule of acetone was disordered.  The molecule could not be adequately 
modeled.  The contributions to the scattering factors due to this molecule were removed 
by use of the utility SQUEEZE.25    
 
7.7.5 X-ray Experimental for Compound 86 
Crystals grew as large, yellow plates by slow diffusion of diethyl ether into a 
solution of 86 in chloroform, methanol and 5% triethylamine. The data crystal was cut 
from a larger crystal and had approximate dimensions; 0.35 x 0.35 x 0.14 mm. The data 
were collected on a Rigaku SCX-Mini diffractometer with a Mercury CCD using a 
graphite monochromator with MoKa radiation (l = 0.71073Å). A total of 625 frames of 
data were collected using w-scans with a scan range of 1° and a counting time of 45 
seconds per frame. The data were collected at 153 K using a Rigaku XStream low 
temperature device.   
One of the ester groups was disordered. The disorder could be reasonably 
modeled for all atoms except the carbonyl oxygen atom, O3, which appeared to be 
dynamically disordered across a wide range of positions. With the exception of the 
carbonyl oxygen, O3, the remaining atoms were modeled by assigning the variable x to 
the site occupancy factor for atoms C34, C35, O4 and C36, with (1-x) set to the site 
occupancy for C34a, C35a, O4a and C36a. A common isotropic displacement parameter 
was refined for these eight atoms while refining x. The geometry of the two groups was 
restrained to be equivalent throughout the refinement process. An estimate for the site 
occupancy factors for O3 and O3a, which are the carbonyl oxygen atoms for these two 
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groups, were used from an earlier refinement. In this manner, the site occupancy for the 
major component consisting of atoms, C34, C35, O4 and C36 refined to 63(2)%. At this 
point in the refinement, there remained some fairly large peaks in the difference electron 
density map near the carbonyl oxygen atoms. These two big peaks were included in the 
refinement model to account for the position of the carbonyl oxygen atom. A refinement 
constraint was applied to the site occupancy factors for O3, O3a, O3b and O3c to sum to 
1 using the SUMP instruction. The isotropic displacement parameters for the four atoms 
were refined using a single free variable in the final refinement model. 
 
7.7.6 X-ray Experimental for Compound 87 
Crystals grew as dark blue prisms by vapor diffusion of hexanes into a solution of 
macrocycle 87 in chloroform. The data crystal was had approximate dimensions; 0.13 x 
0.06 x 0.04 mm. The data were collected on a Rigaku AFC12 diffractometer with a 
Saturn 724+ CCD using a graphite monochromator with MoKa radiation (l = 0.71073Å). 
A total of 714 frames of data were collected using w-scans with a scan range of 0.5° and 
a counting time of 70 seconds per frame. The data were collected at 100 K using a 
Rigaku XStream low temperature device. 
The hydrogen atoms on the pyrrole nitrogen atoms and the water molecule were 
observed in a ΔF map and refined with isotropic displacement parameters.   
One of the ethyl ester moieties was disordered. The disorder involved a rotation 
about the C46-C47 bond. The disorder was modeled by assigning the variable x to the 
site occupancy factors of one component of the disorder composed of atoms O1, O2, 
C48, C49 and C50. The variable 1-x) was assigned to the site occupancy factors of the 
alternate component composed of atoms, O1a, O2a, C48a, C49a and C50a. The geometry 
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of these two components was restrained to be comparable throughout the refinement. A 
common isotropic displacement parameter was refined for the atoms of the two groups. 
In this way, the major component of the disorder, O1, O2, C48, C49 and C50, had a site 
occupancy factor of 78(%). The atoms of the major component were refined 
anisotropically while restraining their displacement parameters to be approximately 
isotropic. The atoms of the minor component were refined isotropically.   
 
7.7.7 X-ray Experimental for Compound 97 
Crystals grew as black plates by vapor diffusion of pentane into a chloroform 
solution of the complex.  The data crystal had approximate dimensions; 0.36 x 0.24 x 
0.12 mm.  The data were collected on a Rigaku AFC12 diffractometer with a Saturn 724+ 
CCD using a graphite monochromator with MoKα radiation (λ = 0.71075Å).  A total of 
1884 frames of data were collected using ω-scans with a scan range of 0.5° and a 
counting time of 23 seconds per frame.  The data were collected at 100 K using a Rigaku 
XStream low temperature device.   
What appeared to be three molecules of chloroform were disordered around a 
crystallographic inversion center at 0, 0, ½.  The disorder could not be modeled 
satisfactorily.  Therefore, the utility Squeeze25 was used to remove the effects of the 
solvent disorder from the structure factors. 
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Appendix: X-ray Crystallographic Data 
 
All crystals for X-ray crystallographic analyses described in this appendix were 
grown by the author. All crystal X-ray diffraction structures were solved and refined by 
Dr. Vincent Lynch of the Department of Chemistry and Biochemistry at The University 
of Texas at Austin. All structures have been deposited with the Cambridge 
Crystallographic Data Centre (CCDC) and can be obtained from that source by quoting 
the CCDC numbers given here. Relevant data tables for each structure as provided by 
Dr. Lynch follow. 
 
Table A1:  Crystallographic data and refinement for compound 60. 
 
CCDC Number 790736 
Empirical formula  C74 H100 Bi2 N12 O21 
Formula weight  1911.62 
Temperature  100(2) K 
Wavelength  0.71069 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 10.9258(8) Å a= 75.646(3)°. 
 b = 12.9230(10) Å b= 74.471(3)°. 
 c = 15.3223(15) Å g = 88.263(2)°. 
Volume 2017.9(3) Å3 
Z 1 
Density (calculated) 1.573 Mg/m3 
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Absorption coefficient 4.432 mm-1 
F(000) 962 
Crystal size 0.18 x 0.13 x 0.04 mm 
Theta range for data collection 3.08 to 27.48°. 
Index ranges -14<=h<=12, -10<=k<=16, -19<=l<=19 
Reflections collected 16942 
Independent reflections 9198 [R(int) = 0.0405] 
Completeness to theta = 27.48° 99.4 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.84 and 0.66 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 9198 / 41 / 479 
Goodness-of-fit on F2 1.094 
Final R indices [I>2sigma(I)] R1 = 0.0479, wR2 = 0.1288 
R indices (all data) R1 = 0.0557, wR2 = 0.1341 
Largest diff. peak and hole 1.893 and -2.670 e.Å-3 
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Figure A1:  View of the Bi coordination to the macrocycle in complex 60 showing 
the atom labeling scheme. Displacement ellipsoids are scaled to the 
50% probability level. Note that this structure shows only one 
individual texaphyrin subunit viewed form the top (ancillary ligands 
omitted). The complete structure is shown in Figure A2. 
 
Figure A2:  View of the dimer present in complex 60. Displacement ellipsoids are 
scaled to the 50% probability level. The oxygen atom bridging the two 
Bi-cations resides on the crystallographic inversion center at ½, ½, O. 
The distance between the rings defined by the five nitrogen atoms of the 
macrocycle is 3.433(5) Å. 
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Table A2:  Crystallographic data and refinement for compound 67. 
 
CCDC Number 859294 
Empirical formula  C37 H48 Gd N7 O12 
Formula weight  940.07 
Temperature  123(2) K 
Wavelength  0.71069 Å 
Crystal system  Monoclinic 
Space group  P21/c 
 
Unit cell dimensions a = 15.3250(10) Å a= 90°. 
 b = 11.5950(8) Å b= 99.592(2)°. 
 c = 21.5387(15) Å g = 90°. 
Volume 3773.8(4) Å3 
Z 4 
Density (calculated) 1.655 Mg/m3 
Absorption coefficient 1.832 mm-1 
F(000) 1916 
Crystal size 0.23 x 0.07 x 0.07 mm 
Theta range for data collection 2.00 to 25.00°. 
Index ranges -18<=h<=18, -13<=k<=12, -25<=l<=25 
Reflections collected 11918 
Independent reflections 6623 [R(int) = 0.0816] 
Completeness to theta = 25.00° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00 and 0.869 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6623 / 1 / 523 
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Goodness-of-fit on F2 1.171 
Final R indices [I>2sigma(I)] R1 = 0.0537, wR2 = 0.0838 
R indices (all data) R1 = 0.1176, wR2 = 0.1031 
Largest diff. peak and hole 1.759 and -0.791 e.Å-3 
 
 
 
 
 
                                      
Figure A3:  Top view of the GdTx complex 67 (after ligand exchange) showing 
a partial atom labeling scheme. Displacement ellipsoids are scaled 
to the 50% probability level. The hydrogen atoms were omitted for 
clarity. 
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Figure A4:  Side view of the GdTx complex 67 (after ligand exchange) showing 
a partial atom labeling scheme. Displacement ellipsoids are scaled 
to the 50% probability level. The hydrogen atoms have been omitted 
for clarity. 
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Table A3: Crystallographic data and refinement for compound 83.     Empirical formula  C53 H53 N5 O9 
 
CCDC Number 907308 
Empirical formula  C50 H47 N5 O8 
Formula weight  904.00 
Temperature  153(2) K 
Wavelength  0.71070 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 10.9910(6) Å a= 65.252(2)°. 
 b = 14.2970(8) Å b= 79.553(3)°. 
 c = 16.8010(9) Å g = 86.157(2)°. 
Volume 2357.7(2) Å3 
Z 2 
Density (calculated) 1.273 Mg/m3 
Absorption coefficient 0.088 mm-1 
F(000) 956 
Crystal size 0.08 x 0.08 x 0.03 mm 
Theta range for data collection 1.57 to 24.98°. 
Index ranges -13<=h<=12, -16<=k<=16, -19<=l<=19 
Reflections collected 14703 
Independent reflections 8152 [R(int) = 0.0761] 
Completeness to theta = 24.98° 98.6 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 8152 / 373 / 638 
Goodness-of-fit on F2 1.045 
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Final R indices [I>2sigma(I)] R1 = 0.0650, wR2 = 0.1048 
R indices (all data) R1 = 0.1913, wR2 = 0.1230 
Largest diff. peak and hole 0.251 and -0.229 e.Å-3 
  
 
             
Figure A5:   View of 83 showing a partial atom labeling scheme.  Displacement 
ellipsoids are scaled to the 30% probability level.  
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Table A4: Crystallographic data and refinement for compound 86. 
 
CCDC Number 907306 
Empirical formula  C45 H52 Cl3 N5 O8 
Formula weight  897.27 
Temperature  153(2) K 
Wavelength  0.71075 Å 
Crystal system  Trilcinic 
Space group  P-1 
Unit cell dimensions a = 13.5265(14) Å a= 69.862(3)°. 
 b = 14.2344(15) Å b= 63.191(2)°. 
 c = 14.841(2) Å g = 64.576(3)°. 
Volume 2262.8(5) Å3 
Z 2 
Density (calculated) 1.317 Mg/m3 
Absorption coefficient 0.260 mm-1 
F(000) 944 
Crystal size 0.35 x 0.35 x 0.14 mm 
Theta range for data collection 3.00 to 27.48°. 
Index ranges -17<=h<=17, -18<=k<=18, -19<=l<=19 
Reflections collected 27878 
Independent reflections 10344 [R(int) = 0.0526] 
Completeness to theta = 27.48° 99.5 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00 and 0.705 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 10344 / 516 / 605 
Goodness-of-fit on F2 1.021 
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Final R indices [I>2sigma(I)] R1 = 0.0581, wR2 = 0.1298 
R indices (all data) R1 = 0.0973, wR2 = 0.1517 
Largest diff. peak and hole 0.347 and -0.408 e.Å-3 
 
 
 
           
            
            
    
 
 
 
 
 
 
Figure A6: View of 86 showing the atom labeling scheme.  Displacement ellipsoids are 
scaled to the 50% probability level.  Only the major component of the 
disordered ester group is shown.  Most hydrogen atoms have been omitted 
for clarity. 
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Table A5: Crystallographic data and refinement for compound 87. 
 
CCDC Number 907307 
Empirical formula  C51 H52 Cl3 N7 O5 
Formula weight  949.35 
Temperature  100(2) K 
Wavelength  0.71069 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 11.2987(13) Å a= 111.979(3)°. 
 b = 13.8007(15) Å b= 97.304(3)°. 
 c = 16.639(2) Å g = 101.968(2)°. 
Volume 2292.9(5) Å3 
Z 2 
Density (calculated) 1.375 Mg/m3 
Absorption coefficient 0.258 mm-1 
F(000) 996 
Crystal size 0.13 x 0.06 x 0.04 mm 
Theta range for data collection 3.02 to 27.48°. 
Index ranges -14<=h<=14, -17<=k<=16, -19<=l<=21 
Reflections collected 18829 
Independent reflections 10172 [R(int) = 0.0479] 
Completeness to theta = 27.48° 96.7 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 10172 / 7 / 645 
Goodness-of-fit on F2 1.001 
Final R indices [I>2sigma(I)] R1 = 0.0642, wR2 = 0.1376 
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R indices (all data) R1 = 0.1147, wR2 = 0.1674 
Largest diff. peak and hole 0.395 and -0.544 e.Å-3 
 
 
 
Figure A7:  View of 87 showing the atom labeling scheme.  Displacement ellipsoids are 
scaled to the 50% probability level.  The minor component of the disordered 
ethyl acetate moiety is shown as open circles.  Most hydrogen atoms have 
been omitted for clarity.  The dashed lines are indicative of H-bonding 
interactions. 
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Table A6: Crystallographic data and refinement for compound 103. 
 
CCDC Number  889353 
Empirical formula  C66 H27 Cl5 F15 N6 
Formula weight  1366.19 
Temperature  100(2) K 
Wavelength  0.71075 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 7.3095(9) Å α= 88.785(3)°. 
 b = 19.203(2) Å β= 82.718(2)°. 
 c = 21.986(2) Å γ = 89.498(2)°. 
Volume 3060.4(6) Å3 
Z 2 
Density (calculated) 1.483 Mg/m3 
Absorption coefficient 0.330 mm-1 
F(000) 1370 
Crystal size 0.36 x 0.24 x 0.12 mm 
Theta range for data collection 3.00 to 27.48°. 
Index ranges -9<=h<=9, -24<=k<=24, 0<=l<=28 
Reflections collected 62427 
Independent reflections 13819 [R(int) = 0.154] 
Completeness to theta = 27.48° 98.2 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00 and 0.483 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 13819 / 0 / 766 
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Goodness-of-fit on F2 1.557 
Final R indices [I>2sigma(I)] R1 = 0.1173, wR2 = 0.2723 
R indices (all data) R1 = 0.1557, wR2 = 0.2849 
Largest diff. peak and hole 0.557 and -0.481 e.Å-3 
 
                    
Figure A8:  View of the chloride complex in 103 showing the atom labeling scheme.  
Displacement ellipsoids are scaled to the 50% probability level.  
 
 
 
 
 
 
 174 
Comprehensive Bibliography 
 
• Podsypanina, K.; Du, Y. C.; Jechlinger, M.; Beverly, L. J.; Hambardzumyan, D.; 
Varmus, H. Science 2008, 321, 1841-1844. 
• Croce, C. M. N. Engl.. J. Med. 2008, 358, 502-511. 
• Loeb, K. R.; Loeb, L. A. Carcinogenesis 2000, 21, 379-385.  
• Merlo, L. M., Pepper, J. W.; Reid, B. J.; Maley, C. C. Nat. Rev. Cancer 2006, 6, 924-
935. 
• Maruyama, K. In Drug Delivery System, CAS 1999, Vol. 14, 433-447. 
• Shayan, R.; Achen, M. G.; Stacker, S. A. Carcinogenesis 2006, 27, 1729-1738. 
• Kunar, V.; Abbas, A. K.; Fausto, N.; Robbins, S. L.; Cotran, R. S. Robbins and Cotran 
pathologic basis of disease, 7th ed., Elsevier Saunders, Philadelphia, 2005.  
• Briasoulis, E.; Pavlidis, N. Oncologist 1997, 2, 142-152.  
• American Cancer Society, Cancer Facts and Figures 2010, American Cancer Society, 
Atlanta 2010. 
• Spalding, A. C.; Lawrence, T. S. Cancer Investigation 2006, 24, 444-456. 
• Von Sonntag, C. In The Chemical Basis of Radiation Biology, Taylor and Francis, 
London 1987.  
• Feldmeier, J. J. In Radiation Oncology, G. R. Weiss, Ed., Appleton & Lange, Norwalk 
1993, 74-88. 
• Petry, E. Biochim. Z. 1923, 135, 353-383. 
• Thomlinson, R. H.; Gray, L. H. British Journal of Cancer 1955, 9, 539-549. 
• Otto, S. E. In Pocket guide to oncology nursing, Mosby-Year Book, Inc., St. Louis 
1995. 
 175 
• Gates, R. A.; Fink, R. M. In Oncology nursing secrets, Hanley and Belfus, Inc., 
Philadelphia 1997. 
• Longley, D. B.; Harkin, D. P.; Johnston, P. G. Nat. Rev. Cancer 2003, 3, 330-338. 
• Thomas, D. M.; Zalcberg, J. R. Clin. Exp. Pharmacol. Physiol. 1998, 25, 887-895. 
• Cerqueira, N. M. F. S. A.; Fernandes, P. A.; Ramos, M. J. Chemistry: A European 
Journal 2007, 13, 8507-8515.  
• Guo, Z.; Sadler, P. J. Angew. Chem. Int. Ed. 1999, 38, 1512-1531. 
• Turchi, J. J.; Henkels, K. M.; Hermanson, I. L.; Patrick, S. M. J. Inorg. Biochem. 
1999, 77, 83-87. 
• Rixe, O.; Ortuzar, W.; Alvarez, M.; Parker, R.; Reed, E. Biochem. Pharmacol. 1996, 
52, 1855-1865. 
• De Gramont, A.; Figer, A.; Seymour, M.; Homerin, M.; Hmissi, A. J. Clin. Oncol. 
2000, 18, 2938-2947. 
• Natarajan, G. et al. Biochem. Pharmacol. 1999, 58, 1625-1629.  
• Jiang, X.; Pandey, R. K.; Smith, K. M. Tetrahedron Letters 1995, 36, 365-368. 
• Ghiggino, K. P.; Bennett, L. E.; Henderson, R. W. Photochemistry and Photobiology 
1988, 47, 65-72. 
• Derat, E.; Cohen, S.; Shaik, S.; Altun, A.; Thies, W. J. Am. Chem. Soc. 2005, 127, 
13611-136121. 
• Benfrey, O. T.; Morris, P. J. T. Eds. Robert Burns Woodward Artist and Architect in 
the World of Molecules, Chemical Heritage Foundation, Philadelphia 2001, 256-277, 
302-242. 
• Alberts, B.; Johnson, A.; Lewis, J.; Raff, M.; Roberts, K.; Walter, P. In Molecular 
Biology of the Cell, 4th Ed., Gardland Science, New York 2002. 
 176 
• Sanchez-Alcazar, J. A.; Khodjakov, A.; Schneider, E. Cancer Research 2001, 61, 
1038-1044. 
• Kalka, K.; Merk, H.; Mukhtar, H. J. Am. Acad. Dermatol. 2000, 42, 389-413. 
• Luksiene, Z.; Juzenas, R.; Moan, J. Cancer Letters 2006, 235, 40-47. 
• Hausmann, W. Biochem. Z. 1909, 14, 275-278. 
• Schwartz, S.; Absolon, K.; Vermund, H. Univ. Minnesota Med. Bull. 1955, 27, 7-13.  
• Schwartz, S.; Keprios, M.; Modelevsky, G.; Freyholtz, H.; Walters, R.; Larson, L. In 
M. Doss (Ed.), Diagnosis and Therapy of Porphyrins and Lead Intoxication, Springer, 
Berlin 1978. 
• Sternberg, E. D.; Dolphin, D. Tetrahedron 1998, 54, 4151-4202. 
• Pandey, R. K.; Sihiau, F.-Y.; Dougherty, T. J.; Smith, K. M. Tetrahedron 1991, 47, 
9571-9584. 
• Lou, Y.; Chang, C. K.; Kessel, D. Photochem. and Photobiol. 1996, 63, 528-534. 
• Dougherty, T. J.; Gomer, C. J.; Henderson, B. W.; Jori, G.; Kessel, D.; Korbelik, M.; 
Moan, J.; Peng, Q. J. Nat. Cancer Inst. 1998, 90, 889-905. 
• Pandey, R. K.; Zheng, G. In Porphyrin Handbook 2000, 6, 157-230. 
• Zhao, F.-Y.; Zhang, K.-H.; Huang, H.-N.; Sun, K.-H.; Ling, Q.-B.; Xu, B. Lasers Med. 
Sci. 1986, 1, 253-256. 
• Chen, D. Y. Treat. Laser 1985, 5, 137. 
• Bellnier, D. A.; Dougherty, T. J. Int. J. Radiat. Biol. 1986, 50, 659-664. 
• Moan, J.; Pettersen, E. O. Int. J. Radiat. Biol. 1981, 40, 107-109. 
• O´Hara, J.; Douple, E. B.; Abrams, M. J.; Picker, D. J.; Giandomenico, C. M.; 
Vollano, J. F. Int. J. Radiat. Oncol. Biol. Phys. 1989, 16, 1049-1052.  
• James, B. R.; Meng, G. G.; Posakony, J. J.; Ravensbergen, J. A.; Ware, C. J.; Skov, K. 
A. Metal-Based Drugs 1996, 3, 85-89. 
 177 
• Ali, H.; van Lier, J. E., Chem. Rev. 1999, 99, 2379-2450. 
• Han, F. X. G.; Wheelhouse, R. T.; Hurley, L. H. J. Am. Chem. Soc. 1999, 121, 3561-
3570. 
• Yuasa, M.; Oyaizu, K.; Horiuchi, A.; Ogata, A.; Hatsugai, T.; Yamaguchi, A.; 
Kawakami, H. Mol. Pharmaceutics 2004, 5, 387-389. 
• Rudat, V.; Stadler, P.; Becker, A.; Vanselow, B.; Dietz, A. Strahlenther. Onkol. 2001, 
177, 462-468. 
• Brizel, D. M.; Dodge, R. K.; Clough, R. W.; Dewhirst, M. W. Radiother. Oncol. 1999, 
53, 113-117. 
• Fyles, A. W.; Milosevic, M.; Pintilie, M.; Syed, A.; Hill, R. P. Radiother. Oncol. 2000, 
57, 13-19. 
• Bauer, V. J.; Clive, D. L. J.; Dolphin, D.; Paine III, J. B.; Harris, F. L.; King, M. M.; 
Loder, J.; Wang, S.-W. C.; Woodward, R. B. J. Am. Chem. Soc. 1983, 105, 6429-
6436. 
• Kral, V.; Davis, J.; Andrievsky, A.; Kralova, J.; Synytsya, A.; Pouckova, P.; Sessler, J. 
L. J. Med. Chem. 2002, 45, 1073-1078. 
• Wang, Z.; Lecane, P.; Thiemann, P.; Fan, A.; Cortez, C.; Ma, X.; Tonev, D.; Miles, 
D.; Lin, A.; Hemmi, G.; Naumovski, L.; Miller, R. A.; Magda, D.; Cho, D.-G.; 
Sessler, J. L.; Pike, B. L.; Yeligar, S. M.; Karaman, M. W.; Hacia, J. G. Mol. Cancer 
2007, 6, 9-20. 
• Roitman, L.; Ehrenberg, B.; Nitzan, Y.; Kral, V.; Sessler, J. L. Photochem. Photobiol. 
1994, 60, 421-426. 
• van Gemert, M. G. C.; Welch, A. J.; Amin, A. P. Lasers Surg. Med. 1986, 6, 76-83. 
• Wan, S.; Parrish, J. R.; Anderson, R. R.; Madden, M. Photochem Photobiol. 1981, 34, 
679-681. 
 178 
• Eichler, J.; Knop, J.; Lenz, H. Radiat. Environ, Biophys. 1977, 14, 239-242. 
• Parmeswaran, D.; Pushpan, S. K.; Srinivasan, A.; Ravi, K. M.; Chandrashekar, T. K.; 
Ganesan, S. Photochem. Photobiol. 2003, 78, 487-495. 
• Sessler, J. L.; Miller, R. A. Biochem. Pharmacol. 2000, 59, 733-739. 
• Mehta, M. P.; Shapiro, W. R.; Phan, S. C.; Gervais, R.; Carrie, C.; Chabot, P.; 
Patchell, R. A.; Glantz, M. J.; Recht, L.; Langer, C.; Sur, R. K.; Roa, W. H.; Mahe, M. 
A.; Fortin, A.; Nieder, C.; Meyers, C. A.; Smith, J. A.; Miller, R. A.; Renschler, M. F. 
Int. J. Radiat. Oncol. Biol. Phys. 2009, 73, 1069-1076. 
• Patel, H.; Mick, R.; Finlay, J.; Zhu, T. C.; Rickter, E.; Cengel, K. A.; Malkowicz, S. 
B.; Hahn, S. M.; Busch, T. M. Clin. Cancer Res. 2008, 14, 4869-4876. 
• Sessler, J. L.; Hemmi, G.; Mody, T. D.; Murai, T.; Burrell, A.; Young, S. W. Acc. 
Chem. Res. 1994, 27, 43-50.   
• Magda, D.; Lepp, C.; Gerasimchuk, N.; Lee, I.; Sessler, J. L.; Lin, A.; Biaglow, J.; 
Miller, R. A. Int. J. Radiat. Biol. Oncol. Phys. 2001, 51, 1025-1036. 
• Sessler, J. L.; Tvermoes, N. A.; Guldi, D. M.; Hug, G. L.; Mody, T. D.; Magda, D. 
J. Phys. Chem. B 2001, 105, 1452-1457.  
• Rockwell, S.; Donnelly, E. T.; Liu, Y.; Tang, L.-Q. Int. J. Radiat. Oncol. Biol. Phys. 
2002, 54, 536. 
• Young, S. W.; Sidhu, M. K.; Qing, F. Invest. Radiol. 1994, 29, 330-338. 
• Rosenthal, D. I.; Nurenberg, P.; Becerra, C. R.; Frenkel, E. P.; Carbonne, D. P.; Lum, 
B. L.; Miller, R.; Engel, J.; Young, S.; Miles, D.; Renschler, M. F. Clin. Cancer Res. 
1999, 5, 739-745. 
• Carde, P.; Timmerman, R.; Mehta, M. P.; Koprowski, C. D.; Ford, J.; Tishler, R. B.; 
Miles, D.; Miller, R. A.; Renschler, M. F. J. Clin. Oncol. 2001, 19, 2074-2083. 
 179 
• Viala, J.; Vanel, D.; Meingau, P.; Lartigau, E.; Carde, P.; Renschler, M. F. Radiology 
1999, 3, 755-759. 
• Miller, R. A.; Woodburn, K.; Fan, Q.; Renschler, M. F.; Sessler, J. L.; Koutcher, J. A. 
Int. J. Radiation Oncology Biol. Phys. 1999, 45, 981-989. 
• Mehta, M. P.; Shapiro, W. R.; Glantz, M. J.; Patchell, R. A.; Weitzner, M. A.; Meyers, 
C. A.; Schultz, C. J.; Roa, W. H.; Leibenhout, M.; Ford, J.; Curran, W.; Phan, S.; 
Smith, J. A.; Miller, R. A.; Renschler, M. F. J. Clin. Oncol. 2002, 20, 3445-3453. 
• Sessler, J. L.; Burrel, A. K. Top. Curr. Chem. 1991, 161, 177. 
• Acholla, F. V.; Mertes, K. B. Tetrahedron Lett. 1984, 25, 3269-3270.  
• Acholla, F. V.; Takusagawa, F.; Mertes, K. B. J. Am. Chem. Soc. 1985, 107, 6902-
6908. 
• Curtis, N. F. Coord. Chem. Rev. 1968, 3, 3-47. 
• Sessler, J. L.; Johnson, M. R.; Lynch, V. J. Org. Chem. 1987, 52, 4394-4397. 
• Sessler, J. L.; Hemmi, G. W.; Mody, T. D.; Murai, T.; Burrell, A. Acc. Chem. Res. 
1994, 27, 43-50. 
• Mody, T. D.; Sessler, J. L. In Supramolecular Materials and Technologies, Reinhoudt 
DN (ed) Wiley: Chichester 1999, Vol. 4, 245-299. 
• Mody, T. D.; Fu, L.; Sessler, J. L. In Progress Inorganic Chemistry, Karlin KJ (ed) 
Wiley: Chichester 2001, Vol. 49, 551. 
• Sessler, J. L.; Mody, T. D.; Hemmi, G. W.; Lynch, V. Inorg. Chem. 1993, 32, 3175-
3187. 
• Sessler, J. L.; Tvermoes, N. A.; Guldi, D. M.; Mody, T. D. Phys. Chem. 1999, 103, 
787-794. 
• Mody, T. D.; Sessler, J. L. J. Porphy. Phthalocy. 2001, 5, 134-142. 
• Clezy, P. S.; Liepa, A. J. Aust. J. Chem. 1972, 25, 1979-1990. 
 180 
• Jasat, A.; Dolphin, D. Chem. Rev. 1997, 97, 2267-2340. 
• Sessler, J. L.; Murai, T.; Lynch, V.; Cyr, M. J. Am. Chem. Soc. 1988, 110, 5586-5588.  
• Sessler, J. L.; Murai, T.; Lynch, V. Inorg. Chem. 1989, 28, 1333-1341. 
• Sessler, J. L.; Johnson, M. R.; Lynch, V.; Murai, T. J. Coord. Chem. 1988, 18, 99-104. 
• Cotton, F. A.; Wilkinson, G. In Advanced Inorganic Chemistry, John Wiley: New 
York 1980, 4th ed., pp 589, 982. 
• Maiya, B. G.; Mallouk, T. E.; Hemmi, G. W.; Sessler, J. L. Inorg. Chem. 1990, 29, 
3738-3745. 
• Sessler, J. L.; Mody, T. D.; Ramasamy, R.; Sherry, A. D. New J. Chem. 1992, 16, 541-
544. 
• Sessler, J. L.; Dow, W. C.; O’Connor, D.; Harriman, A.; Hemmi, G. W.; Mody, T. D.; 
Miller, R. A.; Qing, F.; Springs, S.; Woodburn, K. J. Alloys and Compounds 1997, 
249, 146-152. 
• Harriman, A.; Majya, B. G.; Murai, T. D.; Hemmi, G. W.; Sessler, J. L.; Mallouk, T. 
E. J. Chem. Soc., Chem. Commun. 1989, 314-316. 
• Hemmi, G. W. Dissertation (Ph.D.), The University of Texas at Austin 1992, 41-43. 
• Baxter, G. F. Chem. Ber. 1992, 28, 445-448. 
• Kozak, R. W.; Waldmann, T. A.; Atcher, R. W.; Gansow, O. A. Trends Biotechnol. 
1985, 4, 259-264. 
• Kumar, K.; Magerstädt, M.; Gansow, O. A. J. Am. Chem. Soc., Chem. Commun. 1989, 
145-146. 
• Hancock, R. D.; Cukrowski, I.; Baloyi, J.; Mashishi, J. J. Chem. Soc., Dalton Trans. 
1993, 2895-2899.  
• Luckay, R.; Reibenspies, J. H.; Hancock, R. D. J. Chem. Soc., Chem. Commun. 1995, 
2365-2366. 
 181 
• Hancock, R. D.; Maumela, H.; de Sousa, A. S. Coord. Chem. Rev. 1996, 148, 315-347. 
• Wullens, H.; Devillers, M.; Tinant, B.; Declercq, J.-P. J. Chem. Soc., Dalton Trans. 
1996, 2023-2029. 
• Brechbiel, M. W.; Pippin, C. G.; McMurry, T. J.; Milenic, D.; Roselli, M.; Colcher, 
D.; Gansow, O. A. J. Chem. Soc., Chem. Commun. 1991, 1169-1170. 
• Treibs, A. Justus Liebigs Ann. Chem. 1969, 728, 115-148. 
• Buchler, J. W.; Lay, K. L. Inorg. Nucl. Chem. Lett. 1974, 10, 297-300. 
• Barbour, J.; Belcher, W. J.; Brothers, P. J.; Rickard, C. E. F.; Ware, D. C. Inorg. 
Chem. 1992, 31, 746-754. 
• Michaudet, L.; Fasseur, D.; Guilard, R.; Ou, Z.; Kadish, K. M.; Dahoui, S.; Lecomte, 
C. J. Porphyrins Phthalocyanins 2000, 4, 261-270. 
• Chacko, G.-P.; Hambright, P. Inorg. Chem. 1994, 33, 5595-5597. 
• Boitrel, B.; Breede, M.; Brothers, P. J.; Hodgson, M.; Michaudet, L.; Rickard, C. E. F.; 
Al Salim, N. Dalton Trans. 2003, 1803-1807. 
• Halime, Z.; Lachkar, M.; Furet, E.; Halet, J.-F.; Boitrel, B. Inorg. Chem. 2006, 45, 
10661-10669. 
• Halime, Z.; Lachkar, M.; Roisnel, R.; Furet, E.; Halet, J.-F.; Boitrel, B. Angew. Chem. 
Int. Ed. 2007, 46, 5120-5124. 46, 5120-5124. 
• Barkigia, K. M.; Fajer, J.; Adler, A. D.; Williams, G. J. B. Inorg. Chem. 1980, 19, 
2057-2061. 
• Sayer, P.; Gouterman, M.; Connell, C. R. Acc. Chem. Res. 1982, 15, 73-79. 
• Arambula, J. F.; Sessler, J. L.; Fountain, M. E.; Wei, W.; Magda, D.; Siddik, Z. H. 
Dalton Trans. 2009, 48, 10834–10840. 
 182 
• Magda, D.; Sessler, J. L.; Gerasimchuk, N.; Miller, R. A. In Medicinal Inorganic 
Chemistry, Sessler, J. L.; Doctrow, S.; McMurry, T.; Lippard, S. J. Eds. American 
Chemical Society Symposium Series 903, Oxford University Press, 2005. 
• Evens, A. M.; Lecane, P.; Magda, D.; Prachand, S.; Singhal, S.; Nelson, J.; Miller, R. 
A.; Gartenhaus, R. B.; Gordon, L. I. Blood, 2005, 105, 1265–1273. 
• Lauffer, R. E. Chem. Rev. 1987, 87, 901-927. 
• Na, H. B.; Song, I. C.; Hyeon, T. Adv. Mater. 2009, 21, 2133-2148.  
• Arbab, A. S.; Liu, W.; Frank, J. A. Expert Rev. Med. Devices 2006, 3, 427-439. 
• Jun, Y.-w.; Lee, J.-H.; Cheon, J. Angew. Chem., Int. Ed. 2008, 47, 5122-5135. 
• Caravan, P. Chem. Soc. Rev. 2006, 35, 512-523. 
• Bulte, D. L.; Kraitchman, W. M. NMR Biomed. 2004, 17, 484-499. 
• Massoud, T. F.; Gambhir, S. S. Gene. Dev. 2003, 17, 545-580 
• Nahrendorf, M.; Zhang, H.; Hembrador, S.; Panizzi, P.; Sosnovik, D. E.; Aikawa, E.; 
Libby, P.; Swirski, F. K.; Weissleder, R. Circulation 2008, 117, 379-387. 
• Cheon, J.; Lee, J.-H. Acc. Chem. Res. 2008, 41, 1630-1640. 
• Gao, J. H.; Gu, H. W.; Xu, B. Acc. Chem. Res. 2009, 42, 1097-1107. 
• Mosley, M.; Donnan, G. Stroke 2004, 35, 2632-2634.  
• Choi, J.-s.; Lee, J.-H.; Shin, T.-H.; Song, H.-T.; Kim, E. Y.; Cheon, J. J. Am. Chem. 
Soc. 2010, 132, 11015-11017.  
• Raison, C. L.; Miller, A. H. Mol. Psychiatry 2012, 1–23, and references therein. 
• Kluger, M. J. In Fever: Its Biology, Evolution, and Function, Princeton University 
Press, Princeton 1979. 
• Su, Y.; Wei, X.; Peng, F.; Zhong, Y.; Lu, Y.; Su, S.; Xu, T.; Lee, S.-T.; He, Y. Nano 
Lett. 2012, 12, 1845-1850. 
 183 
• Barreto, J. A.; O’Malley, W.; Kubeil, M.; Graham, B.; Stephan, H.; Spiccia, L. Adv. 
Mater. 2011, 23, H18-H40. 
• Kuo, W.-S.; Chang, C.-N.; Chang, Y.-T.; Yang, M.-H.; Chien, Y.-H.; Chen, S.-J.; 
Yeh, C.-S. Angew. Chem., Int. Ed. 2010, 49, 2711-2715. 
• Hu, K.-W.; Liu, T.-M.; Chung, K.-Y.; Huang, K.-S.; Hsieh, C.-T.; Sun, C.-K.; Yeh, 
C.-S. J. Am. Chem. Soc. 2009, 131, 14186-14187. 
• Fortin, J.-P.; Wilhelm, C.; Servais, J.; Ménager, C.; Bacri, J.-C.; Gazeau, F. J. Am. 
Chem. Soc. 2007, 129, 2628-2635. 
• Hiraoka, M.; Nagata, Y.; Mitsumori, M.; Sakamoto, M.; Masunaga, S. AIP Conf. 
Proc. 2004, 716, 102-105. 
• Ito, A.; Shinkai, M.; Honda, H.; Kobayashi, T. J. Biosci. Bioeng. 2005, 100, 1-11.  
• Colombo, M.; Carregal-Romero, S.; Casula, M. F.; Gutiérrez, L.; Morales, M. P.; 
Böhm, I. B.; Heverhagen, J. T.; Prosperi, D.; Parak, W. J. Chem. Soc. Rev. 2012, 41, 
4306-4334. 
• Noh, S.-h.; Na, W.; Jang, J.-t.; Lee, J.-H.; Lee, E. J.; Moon, S. H.; Lim, Y.; Shin, J.-S.; 
Cheon, J. Nano Lett. 2012, 12, 3716-3721. 
• Bae, K. H.; Park, M.; Do, M. J.; Lee, N.; Ryu, J. H.; Kim, G. W.; Kim, C.; Park, T. G.; 
Hyeon, T. ACS Nano 2012, 6, 5266-5273. 
• Guardia, P.; Di Corato, R.; Lartigue, L.; Wilhelm, C.; Espinosa, A.; Garcia-
Hernandez, M.; Gazeau, F.; Manna, L.; Pellegrino, T. ACS Nano 2012, 6, 3080-3091. 
• Lartigue, L.; Innocenti, C.; Kalaivani, T.; Awwad, A.; del Mar Sanchez Duque, M.; 
Guari, Y.; Larionova, J.; Guerin, C.; Montero, J.-L. G.; Barragan-Montero, V.; Arosio, 
P.; Lascialfari, A.; Gatteschi, D.; Sangregorio, C. J. Am. Chem. Soc. 2011, 133, 10459-
10472. 
 184 
• Lee, J.-H.; Jang, J.-t.; Choi, J.-s.; Moon, S. H.; Noh, S.-h.; Kim, J.-w.; Kim, J.-G.; 
Kim, I. S.; Park, K. I.; Cheon, J. Nature Nanotechnol. 2011, 6, 418-422. 
• Ho, D.; Sun, X.-L.; Sun, S.-H. Acc. Chem. Res. 2011, 44, 875-882. 
• Yoo, D.; Lee, J.-H.; Shin, T.-H.; Cheon, J. Acc. Chem. Res. 2011, 44, 863-874. 
• Cole, A. J.; Yang, V. C.; David, A. E. Trends Biotechnol. 2011, 29, 323-332. 
• Riehemann, K.; Schneider, S. W.; Luger, T. A.; Godin, B.; Ferraro, M.; Fuchs, H. 
Angew. Chem., Int. Ed. 2009, 48, 872-897. 
• Shi, D.; Cho, H. S.; Chen, Y.; Xu, H.; Gu, H.; Lian, J.; Wang, W.; Liu, G.; Huth, C.; 
Wang, L.; Ewing, R. C.; Budko, S.; Pauletti, G. M.; Dong, Z. Adv. Mater. 2009, 21, 
2170-2173. 
• Sonvico, F.; Mornet, S.; Vasseur, S.; Dubernet, C.; Jaillard, D.; Degrouard, J.; 
Hoebeke, J.; Duguet, E.; Colombo, P.; Couvreur, P. Bioconjugate Chem. 2005, 16, 
1181-1188.   
• O’Neill, K. L.; Fairbairn, D. W.; Smith, M. J.; Poe, B. S. Apoptosis 1998, 3, 369-375. 
• Harmon, B. V.; Corder, A. M.; Collins, R. J.; Gobé, G. C.; Allen, J.; Allan, D. J. Kerr, 
J. F. R. Int. J. Radiat. Biol. 1990, 58, 845-858. 
• Kanduc, D.; Mittelman, A.; Serpico, R.; Sinigaglia, E.; Sinha, A. A.; Natale, C.; 
Santaroce, R.; Di Corcia, M. G.; Lucchese, A.; Dini, L.; Pani, P.; Santacroce, S.; 
Simone, S.; Bucci, R.; Farber, E. Int. J. Oncol. 2002, 21, 165-170. 
• Golstein, P.; Kroemer, G. Trends Biochem. Sci. 2007, 32, 37-43. 
• Bonfil, R. D.; Bustuoabad, O. D.; Ruggiero, R. A.; Meiss, R. P.; Pasqualini, C. D. 
Clin. Expl. Metastasis 1998, 6, 121-129. 
• Beckham, J. T.; Wilmink, G. J.; Opalenik, S. R.; Mackanos, M. A.; Abraham, A. A.; 
Takahashi, K.; Contag, C. H.; Takahashi, T.; Jansen, E. D. Laser Surg. Med. 2010, 42, 
752-765. 
 185 
• Huang, L.; Mivechi, N. F.; Moskophidis, D. Mol. Cell. Biol. 2001, 21, 8575-8591.  
• Nollen, E. A. A.; Brunsting, J. F.; Roelofsen, H.; Weber, L. A.; Kampinga, H. H. Mol. 
Cell. Biol. 1999, 19, 2069-2079. 
• Van der Zee, J. Ann. Oncol. 2002, 13, 1173-1184. 
• Fajardo, L. F. Cancer Res. 1984, 44, 4826-4835. 
• Wei, W.-H.; Fountain, M.; Magda, D.; Wang, Z.; Lecane, P.; Mesfin, M.; Miles, D.; 
Sessler, J. L. Org. Biomol. Chem. 2005, 3, 3290-3296. 
• Wondrak, G. T. Antioxid. Redox Signaling 2009, 11, 3013–3069. 
• Yokoyama, M. J. Exp. Clin. Med. 2011, 3, 151-158. 
• Oerlemans, C.; Bult, W.; Bos, M.; Storm, G.; Nijsen, J. F. W.; Hennik, W. E. Pharm. 
Res. 2010, 27, 2569-2589. 
• Kedar, U.; Phutane, P.; Shidhaye, S.; Kadm, V. Nanomed.: Nanotech., Biology and 
Medicine 2010, 6, 714-729. 
• Kim, S.; Shi, Y.; Kim, J. Y.; Chen, K. P. & J.-X. Expert Opin. Drug Deliv. 2010, 7, 
49-62.  
• Shiraishi, K.; Kawano, K.; Maitani, Y.; Yokoyama, M. J. Controlled Release 2010, 
148, 160-167. 
• Li, J.; Huo, M.; Wang, J.; Zhou, J.; Mohammad, J. M. Zhang, Y.; Zhu, Q.; Waddad, Z. 
Y.; Zhang, Q. Biomaterials 2012, 33, 2310-2320. 
• Lee, H.; Hoang, B. Fonge, H.; Reilly, R.; Allen, C. Pharmaceutical Research 2010, 
27, 2343-2355. 
• Kim, T.; Chen, Y.; Mount, C.; Gambotz, W.; Li, X.; Pun, S. Pharm. Res. 2010, 27, 
1900-1913. 
• Jia, Z.; Wong, L.; Davis, T. P.; Bulmus, V. Biomacromolecules 2008, 9, 3106-3113. 
 186 
• Yang, X.; Grailer, J. J.; Pilla, S.; Steebe, D. A.; Dong, S. Bioconjugate Chem. 2010, 
21, 496-504. 
• Li, Y.; Xiao, W.; Xiao, K.; Berti, L.; Luo, J.; Tseng, H. P.; Fung, G.; Lam, K. S. 
Angew. Chem., Int. Ed. 2012, 51, 2864-2869. 
• Cannan, R. K.; Kibrick, A. J. Am. Chem. Soc. 1938, 60, 2314-2320. 
• Rios-Doria, J.; Carie, A.; Costich, T.; Burke, B.; Skaff, H.; Panicucci, R.; Sill, K. J. 
Drug Delivery 2012, Article ID 951741, 1-8. 
• Sun, T.-M.; Du, J.-Z.; Yao, Y.-D.; Mao, C. Q.; Dou, S.; Huang, S. Y.; Zhang, P. Z.; 
Leong, K. W.; Song, E. W.; Wang, J. ACS Nano 2011, 5, 1483-1494. 
• Koo, H.; Huh, M.; Sun, I.-C.; Yuk, S. H.; Choi, K.; Kim, K.; Kwon, I. C. Acc. Chem. 
Res. 2011, 44, 1018-1028. 
• Tang, N.; Dy, G.; Wang, N.; Liu, C.; Hang, H.; Liang, W. J. Natl. Cancer Inst. 2007, 
99, 1004-1015. 
• Christina, A.; Massey, K. A.; Schnitzer, J. E. Interdisciplinary Reviews: Nanomedicine 
and Nanobiotechnology 2011, 3, 421-437. 
• Kessinger, C.; Khemtong, C.; Togao, O.; Tajahashi, M.; Sumer, B.; Gao, J. Experim. 
Biol. Med. 2010, 235, 957-965. 
• Poon, Z.; Lee, J.; Huang, S.; Prevost, R.; Hammond, P. Nanomedicine 2010, 7, 201-
209. 
• Lee, H.; Fonge, H.; Hoang, B.; Reilly, R.; Allen, C. Mol. Pharm. 2010, 7, 1195-1208. 
• Hu, J.; Qian, Y.; Wang, X.; Liu, W.; Liu, S. Langmuir 2012, 28, 2073-2082. 
• Liu, T.; Liu, X.; Qian, Y.; Hu, X.; Liu, S. Biomaterials 2012, 33, 2521-2531. 
• Xiong, X.-B.; Lavasanifar, A. ACS Nano 2011, 5, 5202-5213. 
• Yang, R.; Meng, F.; Ma, S.; Huang, F.; Liu, H.; Zhong, Z. Biomacromolecules 2011, 
12, 3047-3055.  
 187 
• Siegrist W.; Solca, F.; Stutz S.; Giuffrè, L.; Carrel, S.; Girard, J.; Eberle, A. N. Cancer 
Res. 1989, 49, 6352-6358. 
• Cai, M.; Varga, E. V.; Stankova, M.; Mayorov, A.; Perry, J. W.; Yamamura, H. I.; 
Trivedi, D.; Hruby, V. J. Chem. Biol. Drug Des. 2006, 68, 183-193. 
• Mayorov, A. V.; Han, S. Y.; Cai, M.; Hammer, M. R.; Trivedi, D.; Hruby, V. J. Chem. 
Biol. Drug Design 2006, 67, 329-335. 
• Koikov, L. N.; Ebertino, F. H.; Solinsky, M. G. Bioorg. Med. Chem. Lett. 2003, 13, 
2647-2650.  
• Chen, J.; Giblin, M. F.; Wang, N.; Jurisson, S. S.; Quinn, T. P. Nucl. Med. Biol. 1999, 
26, 687-693. 
• Sawyer, T.; Sanfilippo, P.; Hruby, V.; Engel, M. H.; Heward, C. B.; Burnett, J. B.; 
Hadley, M. E. Procl. Natl. Acad. Sci. USA 1980, 77, 5754-5758. 
• Chen, J.; Cheng, Z.; Hoffman, T. J.; Jurisson, S. S.; Quinn, T. P. Cancer Res. 2000, 
60, 5649-5658. 
• Cai, M.; Mayorov, A. V.; Cabello, C.; Stankova, M.; Trivedi, D.; Hruby, V. J. J. Med. 
Chem. 2005, 48, 1839-1848. 
• Handl, H. L.; Vagner, J.; Yamamura, H. I.; Hruby, V. J.; Gillies, R. J. Anal. Biochem. 
2004, 330, 242-250. 
• Yang, Y.; Hruby, V. J.; Chen, M.; Crasto, C.; Cai, M.; Harmon, C. M. Biochemistry 
2009, 48, 9775-9784. 
• Rodrigues, A. R.; Pignatelli, D.; Almeida, H.; Gouveiaa, A. M. J. Mol. Cell. 
Endocrinol. 2009, 303, 74-81. 
• Webb, T. R.; Clark, A. J. L. J. Mol. Endocrinol. 2009, 24, 475-484. 
• Van der Ploeg, L. H. T.; Martin, W. J.; Howard, A. D.; Nargund, R. P.; Austin, C. P.; 
Guan, X.; Drisko, J.; Cashen, D.; Sebhat, I.; Patchett, A. A.; Figueroa, D. J.; DiLella, 
 188 
A. G.; Connolly, B. M.; Weinberg, D. H.; Tan, C. P.; Palysha, O. C.; Pong, S.-S.; 
MacNeil, T.; Rosenblum, C.; Vongs, A.; Tang, R.; Yu, H.; Sailer, A. W.; Fong, T. M.; 
Huang, C.; Tota, M. R.; Chang, R. S.; Stearns, R.; Tamvakopoulos, C.; Christ, G.; 
Drazen, D. L.; Spar, B. D.; Nelson, R. J.; MacIntyre, D. E. PNAS 2002, 99, 11381-
11386. 
• Hall, J. E.; da Silva, A. A.; do Carmo, J. M.; Dubinion, J.; Hamza, S.; Munusmy, S.; 
Smith, G.; Stec, D. E. J. Biol. Chem. 2010, 285, 17271-17276.  
• Jun, D.-J.; Na, K.-Y.; Kim, W.; Kwak, D.; Kwon, E. J.; Yoon, J. H.; Yea, K.; Lee, H.; 
Kim, J.; Suh, P. G.; Ryu, S. H.; Kim, K. T. J. Mol. Endocrinol. 2010, 44, 225-236. 
• Barkey, N. M.; Tafreshi, N. K.; Josan, J. S.; De Silva, C. R.; Sill, K. N.; Hruby, V. J.; 
Gillies, R. J.; Morse, D. L.; Vagner, J. J. Med. Chem. 2011, 54, 8078-8084. 
• Ehrlich, J.; Bogert, M. T. J. Org. Chem. 1947, 12, 522-534. 
• Sessler J. L.; Weghorn, S. J. In Expanded, Contracted & Isomeric Porphyrins, 
Elsevier Oxford, 1997, Vol. 15. 
• Bauer, V. J.; Clive, D. L. J.; Dolphin, D.; Paine III, J. B.; Harris, F. L.; King, M. M.; 
Loder, J.; Wang, S.-W. C.; Woodward, R. B. J. Am. Chem. Soc. 1983, 105, 6429-
6436. 
• Burell, A. K.; Sessler, J. L.; Cyr, M. J.; McGhee, E.; Ibers, J. A. Angew. Chem. Int. Ed. 
Eng. 1991, 30, 91-93. 
• Sessler, J. L.; Gebauer, A.; Hoehner, M. C.; Lynch, V. Chem. Commun. 1998, 17, 
1835-1836. 
• Yan, Y. K.; Melchart, M.; Habtemariam, A.; Sadler, P. J. Chem. Commun. 2005, 38, 
4764-4776. 
• Ang, W. H.; Dyson, P. J. Eur. J. Inorg. Chem. 2006, 20, 4003-4018. 
 189 
• Hartinger, C. G.; Zorbas-Seifried, S.; Jakupec, M. A.; Kynast, B.; Zorbas, H.; Kepper, 
B. K. J. Inorg. Biochem. 2006, 100, 891-904. 
• Barton, J. K.; Danishefsky, A.; Goldberg, J. J. Am. Chem. Soc. 1984, 106, 2172-2176. 
• Lincoln, P.; Nordén, B. J. Phys. Chem. B 1998, 102, 9583-9594. 
• Hiort, C.; Linoln, P.; Nordén, B. J. Am. Chem. Soc. 1993, 115, 3448-3454. 
• Nordell, P.; Westerlund, F.; Wilhelmsson, L. M.; Nordén, B.; Lincoln, P. Angew. 
Chem. Int. Ed. 2007, 46, 2203-2206. 
• Chen, T. F.; Liu, Y. N.; Zheng, W. J.; Liu, J.; Wong, Y. S. Inorg. Chem. 2010, 49, 
6366-6368. 
• Sessler, J. L.; Cyr, M. J.; Lynch, V. M.; McGhee, E.; Ibers, J. A. J. Am. Chem. Soc. 
1990, 112, 2810-2813. 
• Lash, T. D.; Lin, Y.; Novak, B. H.; Parikh, M. D. Tetrahedron 2005, 61, 11601-11614. 
• Cyr, M. J., Ph.D. Dissertation, The University of Texas at Austin, 1991. 
• Smith, G. F.; Cagle, F. Wm. J. Org. Chem. 1947, 12, 781-784. 
• Schmuck, C.; Rupprecht, D.; Urban, C.; Walden, N. Synthesis 2006, 1, 89-96. 
• Lightner, D. A.; McDonagh, A. F. Acc. Chem. Res. 1984, 17, 417-424. 
• Smith, K. M.; Pandey, R. K. J. Heterocycl. Chem. 1983, 20, 1383-1388. 
• Johnson, A. W.; Kay, I. T.; Markham, E.; Price, R.; Shaw, K. B. J. Chem. Soc. 1959, 
3416-3424. 
• Sullivan, B. P.; Salmon, D. J.; Meyer, T. J. Inorg. Chem. 1978, 17, 3334-3341.  
• Lim, J. M.; Yoon, Z. S.; Shin, J.-Y.; Kim, K. S.; Yoon, M.-C.; Kim, D. Chem. 
Commun. 2009, 261-273. 
• Yoon, Z. S.; Cho, D.-G.; Kim, K. S.; Sessler, J. L.; Kim, D. J. Am. Chem. Soc. 2008, 
130, 6930-6931. 
• Mori, S.; Osuka, A. J. Am. Chem. Soc. 2005, 127, 8030-8031. 
 190 
• Cho, S.; Yoon, Z. S.; Kim, K. S.; Yoon, M.-C.; Cho, D.-G.; Sessler, J. L.; Kim, D. J. 
Phys. Chem. Lett. 2010, 1, 895-900. 
• Sessler, J. L.; Weghorn, S. J.; Morishima, T.; Rosingana, M.; Lynch, V.; Lee, V. J. 
Am. Chem. Soc. 1992, 114, 8306-8307.  
• Sessler, J. L.; Weghorn, S. J.; Morishima, T.; Rosingana, M.; Lynch, V.; Lee, V. J. 
Am. Chem. Soc. 1992, 114, 8306-8307. 
• Setsune, J.; Katakami, Y.; Iizuka, N. J. Am. Chem. Soc. 1999, 121, 8957-8958. 
• Panda, P. K.; Kang, Y.-J.; Lee, C.-H. Angew. Chem. Int. Ed. 2005, 44, 4053-4055. 
• Kobe, K.; Herman, L. J. Ind. Eng. Chem. 1950, 42, 352-356. 
• Berlin, A.; Bradamante, S.; Ferraccioli, R.; Pagani, G. A.; Sannicolò, F. J. Chem. Soc., 
Chem. Commun. 1987, 15, 1176-1177. 
• Yoon, M.-C.; Cho, S.; Suzuki, M.; Osuka, A.; Kim, D. J. Am. Chem. Soc. 2009, 131, 
7360-7367. 
• Yoon, Z. S.; Kwon, J. H.; Yoon, M.-C.; Koh, M. K.; Noh, S. B.; Sesler, J. L.; Lee, J. 
T.; Seidel, D.; Aguilar, A.; Shimizu, S.; Suzuki, M.; Osuka, A.; Kim, D. J. Am. Chem. 
Soc. 2006, 128, 14128-14134. 
• Mori, S.; Kim, K.. S.; Yoon, Z. S.; Noh, S. B.; Kim, D.; Osuka, A. J. Am. Chem. Soc. 
2007, 129, 11344-11345. 
• Sessler, J. L.; Seidel, D. Angew. Chem. Int. Ed. 2003, 42, 5134-5175. 
• Saito, S.; Osuka, A. Angew. Chem. Int. Ed. 2011, 50, 4342-4373. 
• Osuka, A.; Saito, S. Chem. Commun., 2011, 47, 4330-4339; and the references therein. 
• Hannah, S.; Lynch, V.; Guldi, D. M.; Gerasimchuk, N.; Mac Donald, C. L. B.; Magda, 
D.; Sessler, J. L. J. Am. Chem. Soc. 2002, 124, 8416-8427. 
• Sessler, J. L.; Hemmi, G. H.; Mody, T. D. PCT Int. Appl. 1993, WO 9314093 A1 
19939722. 
 191 
• Sessler, J. L.; Mody, T. D.; Hemmi, G. W.; Kral, V. U.S. 1995, US5457183 A 
19951010. 
• Mosmann, T. J. Immunol. Methods 1983, 65, 55-63. 
• Lee, J.-H.; Huh, Y.-M.; Jun, Y.-w.; Seo, J.-w.; Jang, J.-t.; Song, H.-T.; Kim, S.; Cho, 
E.-J.; Yoon, H.-G.; Suh, J.-S.; Cheon, J. Nature Medicine 2007, 13, 95–99.  
• Yi, D. K.; Lee, S. S.; Papaefthymiou, G. C.; Ying, J. Y. Chem. Mater. 2006, 18, 614–
619. 
• CrystalClear Version 1.40 2008, Rigaku Americas Corportion, The Woodlands, TX, 
USA. 
• SIR97 1999, A program for crystal structure solution. Altomare, A.; Burla, M.C.; 
Camalli, M.; Cascarano, G.L.; Giacovazzo, C.; Guagliardi, A.; Moliterni, A. G. G.; 
Polidori, G.; Spagna, R. J. Appl. Cryst. 1999, 32, 115-119. 
• Sheldrick, G. M. SHELXL97 1994, Program for the Refinement of Crystal Structures, 
University of Göttingen, Germany. 
• In International Tables for X-ray Crystallography 1992, Vol. C, Tables 4.2.6.8 and 
6.1.1.4, A. J. C. Wilson, editor, Boston: Kluwer Academic Press. 
• Sheldrick, G. M., SHELXTL/PC (Version 5.03) 1994, Siemens Analytical X-ray 
Instruments, Inc., Madison, Wisconsin, USA. 
• Sluis, P. v. d.; Spek, A. L. Acta Cryst. 1990, A46, 194-201.  
 
 
 
